

IOM Research Project: P937/3

May 2011

Health, socio-economic and environmental aspects of possible amendments to the EU Directive on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Trichloroethylene

Authors:

JW Cherrie, M Gorman Ng, A Sleeuwenhoek, A Shafrir, M van Tongeren (IOM) R Mistry, O Warwick, C Corden (AMEC Environment & Infrastructure UK Ltd) L Rushton (Imperial College, MRC-HPA Centre for Environemnt and Health) S Hutchings (Imperial College)

Other project team members:

O Warwick and M-H Bouhier (AMEC Environment & Infrastructure UK Ltd), T Kaupinnen and P Heikkila (Finnish Institute of Occupational Health), H Kromhout (IRAS, University of Utrecht), L Levy (IEH, Cranfield University)



CONTENTS

| SUMN | MARY | 1 |
|-------------------|--|---------------------------------|
| 1 | PROBLEM DEFINITION | 3 |
| 1.1 1.2 1.3 | Outline of the investigation OELs/exposure control Description of different uses 1.3.1 Manufacture 1.3.2 Uses | 3 3 4 4 5 |
| 1.4 | Risks to Human Health 1.4.1 Introduction 1.4.2 Summary of the available epidemiological literature on risk 1.4.3 Choice of risk estimates to assess health impact | 6 |
| 2 | BASELINE SCENARIOS | 8 |
| 2.1 2.2 2.3 | Structure of the sector Prevalence of Trichloroethylene exposure in EU Level of exposure to trichloroethylene 2.3.1 Estimation of exposure levels 2.3.2 Development of metal degreasing machines 2.3.3 Temporal change in exposure | 8 11 15 15 17 21 |
| 2.4 | Health Impact from Current Exposures 2.4.1 Background data 2.4.2 Exposed numbers and exposure levels 2.4.3 Forecast cancer numbers 2.4.4 Results | 22 22 23 23 |
| 2.5 | Possible Costs Associated with not Modifying the Directtive 2.5.1 Health impacts – possible costs under the baseline scenario | 24 24 |
| 3 | POLICY OPTIONS | 31 |
| 3.1 | Description of measures 3.1.1 Existing exposure controls in the sector 3.1.2 Additional actions needed to comply with a Community-wide OEL | 31 31 33 |
| 3.2 | Level of protection achieved (OELs) | 33 |
| 4 | ANALYSIS OF IMPACTS | 35 |
| 4.1 | Health Impacts from changes to the EU Directive 4.1.1 Health information 4.1.2 Monetised health benefits | 35 35 45 |
| 4.2 | ECONOMIC IMPACTS 4.2.1 Operating costs and conduct of business 4.2.2 Impact on innovation and research 4.2.3 Macroeconomic impact | 53 53 59 60 |
| 4.3 | Social impacts 4.3.1 Employment and labour markets 4.3.2 Changes in end products | 60 60 61 |
| 4.4 | Environmental impacts | 61 |
| 5 | COMPARISON OF OPTIONS | 62 |



| 6 | CONCLUSIONS | 68 |
|------------|--|----------|
| 7 | REFERENCES | 70 |
| 8 | APPENDIX | 71 |
| 8.1 | Estimated number of employees in each industry group – Member state breakdown – males and females | 71 |
| 8.2 8.3 | summary of occupational exposure data for trichloroethylene Estimated deaths and registrations in the EU from Kidney and Liver | |
| 8.4 | cancer and NHL Supplementary tables - Costs under the baseline scenario | 78 86 |
| 8.5 | Health benefits – Intervention scenarios | 91 |
| 8.6 | VALUING Health benefits – Intervention scenarios | 143 |
| 8.7 | Health benefits using different discount rates | 151 |



SUMMARY

Workplace exposure to trichloroethylene (TCE) is associated with increased risks of Kidney cancer, liver and biliary cancer and non-Hodgkin's Lymphoma (NHL). TCE has been classified as a group 2a carcinogen (Probably carcinogenic to humans) carcinogen by IARC and as a Category 2 carcinogen in the EU under the classification and labelling legislation¹. This report considers the likely health, socioeconomic and environmental impacts associated with possible changes to the Carcinogens Directive, in particular, the establishment of an EU-wide OEL for TCE of 10 ppm or 50 ppm (50 or 273 mg/m³).

The main use of TCE is as an intermediate for the synthesis of CFC substitutes (75%), in metal cleaning and in the adhesives industry. Its use in metal cleaning has declined sharply and its use in the adhesives industry is very small. TCE consumption in solvent applications is expected be about a quarter of 1996 levels by the end of 2010. This is largely due to implementation of the Solvents Emissions Directive. The annual production of TCE in the EU is well under 100,000 ktonnes.

We estimate that in 2006 approximately 74,000 workers in the EU were potentially exposed to TCE with most exposed workers being involved in the manufacture of fabricated metal products including machinery and transport equipment or the manufacture of furniture. In these industries, about 28% of workers are exposed to more than 10 ppm and about 2% are exposed are to more than 50 ppm. The estimated overall weighted geometric mean (GM) exposure across all countries and industries is 4.6 ppm with a GSD of 3.7.

We estimate that in 2010 in the EU there will be about 34 deaths from liver cancer and a similar number of registrations that might be attributable to past exposure to TCE. which corresponds to about 0.071% of all liver cancer deaths amongst the exposed workers. There will also be about 13 deaths from kidney cancer and about 31 registrations, accounting for 0.046% of all kidney cancer deaths amongst the exposed workers. There will be about 12 deaths from NHL and 28 registrations accounting for 0.054% of all NHL deaths amongst exposed workers. If no specific actions are taken to reduce exposure to TCE, based on the assumption that current employment and exposure levels are maintained, the predicted numbers of cancer deaths in 2060 attributable to TCE would be 21, 15 and 7 for cancers of the liver and kidney and NHL respectively. The corresponding numbers of registrations are 18, 29 and 15. The relative reduction in incidence differs for each of the cancers because of differences in the trends of background incidence (the incidence of kidney cancer is increasing as is the incidence of liver cancer to a lesser degree) and also to differences in the period of latency between exposure and the onset of disease. The predicted Years of Life Lost (YLLs) and Disability Adjusted Life Years (DALYs) are expected to decrease for all three cancers from a combined 866 YLLs and 904 DALYs in 2010 falling to 515 YLLs and 544 DALYs in 2060.

The introduction of an OEL of 50 ppm is not predicted to lead to any significant health benefit relative to the baseline scenario. The impact would be to reduce the number of



Page 1 of 154

¹ Available at: http://monographs.iarc.fr/ENG/Classification/ClassificationsAlphaOrder.pdf

liver cancer deaths and registrations in 2060 attributable to TCE from current levels to 25 and 22 respectively, the number of kidney cancer deaths and registrations to 15 and 30 respectively and the number of NHL deaths and registrations to 10 and 20 respectively. The predicted loss of life expectancy attributable to these cancers in 2060 would be 603 YLLs and 636 DALYs.

The introduction of an OEL of 10 ppm is predicted to reduce the number of liver cancer deaths and registrations in 2060 attributable to TCE from current levels to 10 and 9 respectively, the number of kidney cancer deaths and registrations to 14 and 27 respectively and the number of NHL deaths and registrations to 4 and 8 respectively. The predicted loss of life expectancy attributable to these cancers in 2060 would be 328 YLLs and 353 DALYs.

The total net health benefits from setting an OEL at 10 ppm are estimated to be between €1,118m and €430m for the period of 2010-2069, whereas there would be no significant health benefit in setting an OEL of 50 ppm.

Given that the current GM exposure to TCE is 4.6 ppm, it is anticipated that the majority of employers will be able to comply with an OEL of 50ppm (with around 4% of workers potentially affected above this OEL). There may be more workers affected with an OEL of 10 ppm (with around 28% of workers potentially affected above this OEL).

However, since under the Solvents Emissions Directive (SED) those firms using solvents that are covered by the SED (i.e. not just TCE) above 1 tonne per year are required to install and use a closed system. This is also reinforced by a voluntary industry agreement (Charter for the safe use of Trichloroethylene in metal cleaning) whereby TCE will not be sold to those without an installed closed system. Therefore it is possible that the main costs of compliance with an OEL (i.e. the use of closed systems) may already have been incurred by industries affected.

Given the interactions with the SED, it is difficult to provide a good estimate of the number of firms affected, but it is possible to examine costs per firm affected. The capital cost of installing closed systems (estimated to be between €58k-135k per enterprise, which is appropriately €6k per year).

Therefore the cost to comply with an OEL of 10 ppm (or 50ppm) is unlikely to be significant for large businesses but for SMEs, the majority of affected enterprises, it could represent a substantial proportion of their operating surplus, which could potentially lead to some business closures. Many businesses, however, may be able to switch to use of an alternative substance or pass on the additional costs by charging more for their products. The macroeconomic, social and environmental impacts of introducing an OEL of 10 ppm are not predicted to be significant (relative to the baseline scenario).



1 PROBLEM DEFINITION

1.1 OUTLINE OF THE INVESTIGATION

Workplace exposure to trichloroethylene (TCE) is associated with increased risks of Kidney cancer, liver and biliary cancer and non-Hodgkin's Lymphoma (NHL). TCE has been classified as a group 2a carcinogen (Probably carcinogenic to humans) carcinogen by IARC and as a Category 2 carcinogen in the EU under the classification and labelling legislation². TCE is therefore already regulated as a carcinogen throughout the EU.

The key objectives of the present study are to the to identify the technical feasibility and the socioeconomic, health and environmental impacts associated with the establishment of an EU-wide OEL for TCE of 10 ppm or 50 ppm (50 or 273 mg/m³).

1.2 OELS/EXPOSURE CONTROL

Existing national occupational exposure limits (OELs) in EU Member States are presented in Table 1.1. OELs from countries outside the EU are also presented for information. An OEL of 50 ppm (Time Weighted Average (TWA)) can be considered as the most common value across the EU and beyond. As can be seen in Table 1.1, the 8 hour TWA OELs vary from around 10 ppm to 100 ppm.

Table 1.1 Occupational Exposure Limits in Various Member States and selected countries outside the EU

| Country | OEL (TWA) [1] | STEL ^[2] |
|-----------------|--------------------------------------|------------------------------|
| Austria | 50 ppm | 250 ppm |
| Belgium | 50 ppm | 100 ppm |
| Denmark | 10 ppm | 20 ppm |
| France | 75 ppm | 200 ppm |
| Germany | 30 ppm | 120 ppm |
| Hungary | 270 <i>mg/m</i> ³ [50ppm] | 540 <i>mg/m</i> ³ |
| Italy | 50 ppm | 100 ppm |
| The Netherlands | 35 ppm | 100 ppm |
| Poland | 50 <i>mg/m³</i> [9.3ppm] | 400 mg/m ³ |
| Spain | 50 ppm | 100 ppm |
| Sweden | 10 ppm | 25 ppm |
| United Kingdom | 100 ppm | 150 ppm |
| Canada – Quebec | 50 ppm | 200 ppm |
| Japan | 50 ppm | - |
| Switzerland | 50 ppm | 100 ppm |
| USA - OSHA | 100 ppm | 200 ppm |

^[1] OEL (TWA): Occupational Exposure Limit (Time Weighted Average): 8 hours per day.



Page 3 of 154

^[2] STEL: Short Term Exposure Limit (15 minutes).

² Available at: http://monographs.iarc.fr/ENG/Classification/ClassificationsAlphaOrder.pdf

Source: http://www.dguv.de/bgia/en/gestis/limit_values/index.jsp, RRS (Defra 2005) and http://www.eurochlor.org/qandatrienglish

In 2008 the Scientific Committee for OELs (SCOEL) issued a recommendation for an OEL on trichloroethylene at a level of 10 ppm TWA and 30 ppm STEL. This recommendation was submitted to a public consultation. These values can be met by the use of closed surface cleaning equipment (von Grote, 2003). Communication with stakeholders has indicated that one of the major TCE producers in Europe and its affiliated companies has introduced an internal exposure limit of 5 ppm.

For the purposes of this report we have chosen 10 and 50 ppm (50 and 273 mg/m³) as "typical" OELs.

1.3 DESCRIPTION OF DIFFERENT USES

1.3.1 Manufacture

There are three processes that can be used to manufacture trichloroethylene: oxychlorination of ethylene, ethylene dichloride or other chlorinated C2-hydrocarbons; non-catalytic chlorination of ethylene dichloride or other chlorinated C2 hydrocarbons and catalytic hydrogenation of perchloroethylene.

The risk assessment report (RAR)³ for TCE indicated that there were four producers in the early 2000s, and that the production capacity at a typical plant ranges from 1,000 to 50,000 tonnes per year. According to the environmental risk assessment strategy (RSS) for TCE⁴, one producer stopped production of trichloroethylene in 2006. Stakeholder information indicates that a further manufacturer ceased production in 2009. Although there are currently only two companies in the EU manufacturing TCE, there are other companies who act as suppliers in the EU.

Stakeholders have indicated that total TCE production in Europe reduced by more than 50% between 1985 and 2007 and will have been further reduced due to the closure of a manufacturing plant in 2009. The environmental risk reduction strategy indicates that EU production was around 100,000 tonnes in 2003⁴. Table 1.2 below provides details of the sales of trichloroethylene for use as a solvent (i.e. not as an intermediate) in Western Europe between 1996 and 2004.

Table 1.2 Sales for Trichloroethylene manufactured in Western Europe for use as a solvent

| Year | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 |
|------------|------|------|------|------|------|------|------|------|------|
| Sales (kt) | 101 | 93 | 85 | 79 | 74 | 63 | 52 | 38 | 33 |

³ EU Risk Assessment Report on Trichloroethylene. Vol 31, 2004. Publication EUR 21057 EN. Available at: http://ecb.jrc.ec.europa.eu/documents/Existing-Chemicals/RISK ASSESSMENT/REPORT/trichloroethylenereport018.pdf



Page 4 of 154

⁴ DEFRA (2005) Risk Reduction Strategy and Analysis of the Advantages and Drawbacks for Tetrachlorotheylene. Available at:

http://www.defra.gov.uk/environment/quality/chemicals/documents/report-tetra060203.pdf

1.3.2 Uses

According to the environmental RRS, trichloroethylene is mainly used as an intermediate for the synthesis of CFC substitutes, in metal cleaning and in the adhesives industry. The change in the relative importance of each use over the period 1996 to 2003 is detailed in Table 1.3 below. Note that this table includes trichloroethylene imported into Europe as well as that which is manufactured in the EU.

Table 1.3 Uses of Trichloroethylene sold into the EU Market in 1996 and 2003

| Use | Percentage of Sales, 1996 | Percentage of Sales, 2003 |
|---------------------------------------|-------------------------------|------------------------------|
| Metal degreasing in vapour degreasers | 52% | 28% |
| Adhesives | 6% | 3% |
| Consumer uses | 4% | 0% |
| Others | 2% | 2% |
| Feedstock (intermediate) | 37% | 67% |
| Total | 100% (approx. 122,000 tonnes) | 100% (approx. 96,000 tonnes) |

Table 1.3 shows that use of trichloroethylene in adhesives and in other uses are comparatively low. Consumer use is no longer permitted because of the classification of trichloroethylene as a Category 2 carcinogen⁵ under Directive 67/548/EEC.

More recent stakeholder information (2010) indicates that approximately 75% of total TCE production is used in intermediate applications. TCE use as a solvent continues to decline and in 2007 solvent use accounted for approximately 25% of TCE production in the EU. Additional reductions in the use of TCE in solvent applications and a shift towards intermediate use are anticipated due to ongoing substitution of TCE by alternative products and technologies and the conversion to closed systems in surface cleaning to minimise solvent emissions and therefore reduce solvent consumption. These trends are the result of stringent requirements under the Solvents Emissions Directive (SED), anticipation of REACH and a voluntary industry commitment through the European Chlorinated Solvent Association (ESCA)⁶. The SED and the voluntary commitment are driving companies to use TCE for surface cleaning only in closed systems. REACH will reinforce the use of closed systems as the only registered use for surface cleaning. By the end of 2010 TCE consumption in solvent applications is expected to drop an additional 50% from 2007 levels.

Other minor uses of TCE include the production and use of adhesives containing TCE, ceramic production, wool scouring, asphalt testing, as a heat transfer fluid and in the production of some pharmaceutical products.



Page 5 of 154

⁵ Category 1 and 2 carcinogens and mutagens are prohibited from consumer use according to the REACH regulation (Annex XVII)

⁶ Available at: http://www.eurochlor.org/upload/documents/document282.pdf

The introduction of a Community-wide OEL for trichloroethylene could potentially have implications for the following life-cycle stages:

- Production of trichloroethylene;
- · Use in metal degreasing;
- · Use in adhesives;
- Use as a feedstock/intermediate; and
- Other uses.

Based on the results of the RAR⁷, use in metal degreasing was considered to be of most concern regarding exposure of workers to trichloroethylene. Given this and the significantly greater use in this sector than in other sectors, metal degreasing is the focus for the assessment of impacts.

Also as set in the exposure assessments in Section 2, there is not expected to be a need to assess other uses other than metal degreasing as these uses (e.g. intermediates, adhesives) are already well controlled and deemed low risk. Therefore there are not expected to be benefits of introducing an OEL for uses other than metal degreasing.

1.4 RISKS TO HUMAN HEALTH

1.4.1 Introduction

Short term exposure to high concentrations of TCE may cause headaches, lung irritation, dizziness, poor coordination and difficulty concentrating. Longer periods of exposure may cause nerve, kidney and liver damage. Three types of cancer have been identified due to long periods of exposure to trichloroethylene:

- Liver and biliary cancer;
- Kidney cancer; and
- Non-Hodgkin's lymphoma.

1.4.2 Summary of the available epidemiological literature on risk

A large number of cohort and case-control studies have evaluated the association between TCE exposure in occupations involving use of TCE as a dry cleaning agent and as a metal degreasant (in aerospace, cardboard and other industries) and incidence of and/or mortality from kidney and liver cancers and non-Hodgkin's lymphoma (NHL). The risk estimates obtained through case-control studies are generally higher than the risks from cohort studies. There is often no adjustment for confounders such as smoking, alcohol consumption and other lifestyle factors. Many of



⁷ EU Risk Assessment Report on Trichloroethylene. Vol 31, 2004. Publication EUR 21057 EN. Available at: http://ecb.jrc.ec.europa.eu/documents/Existing- Chemicals/RISK ASSESSMENT/REPORT/trichloroethylenereport018.pdf

the studies also have difficulty in separating TCE exposure from exposures to other organic solvents including tetrachloroethylene.

Wartenberg et al. (2000) evaluate many of these studies, including 20 cohort and 40 case-control studies, dividing the cohort studies into three tiers based on the specificity of the exposure information. Tier 1 studies were those which provide the best characterisation of TCE exposure through the use of biomarkers and job-exposure matrices, Tier II studies included those that evaluated mortality in cohorts using job titles and other general information to assess TCE exposure and Tier III were those relating to dry cleaning and laundry workers, where exposures were assessed on job title only. The combined risk of kidney cancer was elevated in Tier 1 studies for incidence (Standardised Incidence Rate (SIR) = 1.7, 95% CI 1.1, 2.7) and mortality (Standardised Mortality Rate (SMR) = 1.2, 95% CI 0.8, 1.7) despite the lack of association reported by the authors of most of the individual studies. The SIR for Tier II studies was 3.7 (95% CI 1.7, 8.1) based on only 1 study. The Tier III incidence was 0.9 (95% CI 0.7, 1.2) and mortality was 2.3 (95%CI 1.5, 3.5). Across the Tier 1 studies, for primary liver cancer an average SIR of 1.9 (95%CI=1.0, 3.4) and an average SMR of 1.7 (95%CI=0.2, 16.2) were obtained. For liver and biliary tract cancer combined, a SIR of 1.1 (95% CI 0.3, 4.8) and SMR of 1.1 (95% CI 0.7, 1.7) was reported. The combined results for Tier II studies was a relative risk for primary liver cancer of 2.0 (95% CI 1.3, 3.3) and, for liver and biliary tract cancer combined, an RR of 1.3 (95% CI, 1.0, 1.8). Tier III studies gave more ambiguous findings with increased incidence of primary liver cancer (average RR = 3.3, 95% CI 1.6, 6.90) and liver and biliary tract cancer combined (RR = 1.8, 95% CI 1.1, 2.9) but no increased mortality for liver and biliary cancer combined (RR = 0.7, 95% CI of 0.4, 1.3). Evidence of excess incidence for NHL was also found in the Tier 1 studies (SMR=1.5, 95%CI=0.9, 2.3) and Tier III studies (SIR=1.4, 95% CI 0.8, 2.6) but not for Tier II studies (SIR=0.9 (95% CI 0.6, 1.4).

In another meta-analysis reported by Alexander et al (2007), incidence of and mortality from liver cancer in workers exposed to TCE was assessed across 14 occupational cohort studies. Ecologic studies of TCE in drinking water and studies of dry cleaners and laundry workers (included as Tier III studies in Wartenberg et al (2000)) were excluded due to exposure assessment limitations and use of proportional mortality rates (PMR) that limits the ability to make causal links. In contrast to the meta-analysis from Wartenberg et al., (2000), studies were divided into 2 Groups, although Group I studies were again those that provided the most accurate estimate of TCE exposure through biomonitoring. For liver and biliary tract cancer, the combined summary relative-risk estimate (SRRE) for all 15 studies was slightly elevated (RR=1.08; 95% CI, 0.91, 1.29). For Group I studies only (n=9) the combined SRRE was reported as 1.14 (95% CI, 0.93, 1.39) with five studies reporting an elevated SRRE (1.37, 95% CI 1.04, 1.79) for primary liver cancer and four studies for biliary tract cancer (SRRE = 1.35, 95% CI 1.03, 1.78). For the Group II studies, the combined SRREs for primary liver cancer and liver and biliary tract cancer were not elevated (0.87, 95% CI 0.55, 1.38). In the TCE-exposed sub-cohort of Group I studies, a combined SRRE of 1.30 (95% CI of 1.09, 1.55) was reported for liver and biliary tract cancer; this was slightly stronger but less precise for primary liver cancer only (SRRE=1.41, 95% CI 1.06, 1.87).

A more recent meta-analysis regarding NHL of 14 cohort and four case-control studies of workers exposed to TCE estimated a summary RR of 1.29 (95%CI=1.00, 1.66) from the cohort studies that had more detailed information on TCE-exposure (Mandel *et al*,



2006). For the studies (n=7) that identified a specific TCE-exposed sub-cohort the SRR was 1.59 (95%CI=1.21-2.08). No significant dose-response relationship was found.

A study of dry cleaners found an elevated risk for kidney cancer of 1.41 (0.46, 3.30) (Ruder *et al.*, 2001).

1.4.3 Choice of risk estimates to assess health impact

Not all of the studies of workers potentially exposed to TCE give estimates for the three cancer sites (kidney, liver and biliary and NHL) and there is a wide variation in the risk estimates from individual studies. In addition because the inclusion criteria vary between the meta-analyses the summary measures also vary. For this reason a pragmatic choice of risk estimates has been selected to ensure that there is consistent gradation in risk estimates across the high, medium and low exposure categories as follows: Kidney cancer: high 1.7 (95% CI 1.1, 2.7) (Wartenberg et al. 2000), medium (1.41 95%CI 0.46, 3.30) (Ruder et al.), low 1.3 (95%CI 0.9, 1.7) (Wartenberg et al. 2000), liver cancer estimate), medium 1.8 (95%CI 1.1,2.9) (Wartenberg et al. 2000), low 0.9 (95%CI 0.5,1.9) (Wartenberg et al. 2000); NHL: high 1.5 (95%CI 0.9,2.3) (Wartenberg et al. 2000), medium 1.4 (95%CI 0.7,2.8) (Wartenberg et al. 2000), low 0.9 (95%CI 0.6, 1.4) (Wartenberg et al. 2000).

2 BASELINE SCENARIOS

2.1 STRUCTURE OF THE SECTOR

The introduction of an OEL for trichloroethylene within firms using the substance for metal degreasing could have significant implications for this use because of the possible risks of exposure within metal degreasing and the amount of trichloroethylene that is used in this process.

According to the environmental RRS⁸, the metal finishing sector (understood to encompass metal degreasing, metal coating, metal plating, etc.) in the UK comprises a large number of small companies, with a high proportion having fewer than 20 workers. In addition, the surface cleaning sector, also covering a wide range of operations, is generally not well defined, with companies having very different sizes.

Consultation with ECSA indicated that the structure of the metal degreasing sector was unknown to them.

Data from Eurostat indicates that in 2006 there were some 141,858 enterprises engaged in 'treatment and coating of metals', within the 'manufacture of fabricated metal products, except machinery and equipment' (NACE code DJ 28.51)⁹. The



Page 8 of 154

⁸ DEFRA (2005) Risk Reduction Strategy and Analysis of the Advantages and Drawbacks for Tetrachlorotheylene. Available at:

http://www.defra.gov.uk/environment/quality/chemicals/documents/report-tetra060203.pdf

Available at: http://epp.eurostat.ec.europa.eu/

Eurostat data is broken down by member state and the data for 2006 is presented in Table 2.1.

It is recognised that this NACE code does not exclusively refer to the metal degreasing sector, but it is considered likely to be the most representative data available. The treatment and coating of metals includes:

- · plating and anodising of metals;
- · heat treatment of metals;
- · deburring, sandblasting, tumbling, cleaning of metals;
- · colouring, engraving of metals;
- · non-metallic coating of metals;
- · plasticising, enamelling, lacquering etc; and
- · hardening and buffing of metals.

This code excludes:

- activities of farriers;
- · printing onto metals;
- · metal coating of plastics;
- · rolling precious metals onto base metals or other metals; and
- · 'while-you-wait' engraving services.



Table 2.1 Enterprises in the EU engaged in treatment and coating of metals, within the manufacture of fabricated metal products, except machinery and equipment

| Member State | Number of Enterprises 2006 |
|------------------------------------|--|
| Austria | 740 |
| Belgium | 2,582 |
| Bulgaria | 1,337 |
| Cyprus | 136 |
| Czech Republic | 8,436 |
| Denmark | 2,795 |
| Estonia | 230 |
| Finland | 1,909 |
| France | 12,472 |
| Germany | 14,975 |
| Greece | 1,784 |
| Hungary | 4,104 |
| Ireland | 98 |
| Italy | 33,121 |
| Latvia | 149 |
| Lithuania | 179 |
| Luxembourg | 69 |
| Malta | No data |
| Netherlands | 3,890 |
| Poland | 14,831 |
| Portugal | 4,834 |
| Romania | 900 |
| Slovakia | 524 |
| Slovenia | 2,032 |
| Spain | 8,774 |
| Sweden | 7,136 |
| United Kingdom | 13,821 |
| EU27 | 141,858 |
| Source: Eurostat classification of | of economic activities - NACE Rev.1.1: DJ 285 - Treatment of |

Source: Eurostat classification of economic activities - NACE Rev.1.1: DJ 285 - Treatment of coating of metals; general mechanical engineering. Number of Enterprises

On the basis of the Eurostat data there are a significant number of firms ("enterprises") active in the metals cleaning sector. The Eurostat data cannot tell us whether these firms use trichloroethylene; however, since trichloroethylene is an effective and widely used solvent for the cleaning of metals, as a worst case it could be assumed that all of the enterprises use trichloroethylene.



Member States with the largest number of firms are Italy, Germany, Poland, UK and France each with greater than 12,000 firms and accounting for 89,220 of the 143,196 in the EU 27 + Norway (c 62% of the total). Spain, Czech Republic, Sweden, Portugal and Hungary each have more than 4,000 firms accounting for 33,284 firms (c.23% of the total); Netherlands, Denmark, Belgium, Slovenia, Finland, Greece, Norway and Bulgaria each have more than 1,000 firms accounting for 17,667 firms (12% of the total). The remaining Member States with fewer that 1,000 firms make up 3,025 firms (2% of the total).

Eurostat also provides data on the financial measures for this activity group which are useful for the later analysis in this section. As mentioned above Eurostat data are not available on the use of particular products or substances for a specific activity.

2.2 PREVALENCE OF TRICHLOROETHYLENE EXPOSURE IN EU

The prevalence of exposure to TCE was estimated based on the Finnish CAREX estimate of 2007, The Spanish CAREX estimate of 2004 and the Italian CAREX estimate of 2000 – 2003 (Mirabelli and Kauppinen, 2005). The proportion of workers in each industry who are exposed was taken from each of these three CAREX estimate and the average proportion exposed across all three countries calculated for each industry.

The number of workers employed in each industry in 2006 was, where possible, obtained from the EUROSTAT database¹⁰, which provides numbers exposed at the level of two or three digit NACE code. If information from 2006 was unavailable, it was substituted with information from 2005 or recorded as being unavailable. Where the numbers of workers employed is not available from the EUROSTAT database, this information was obtained form the Labour Force Survey¹¹. The Labour Force Survey only provides information at NACE section level, which incorporates a number of two digit NACE codes. The number of exposed workers in each industry in each country, including Finland, Spain and Italy, was estimated by multiplying the number of workers employed in each industry in each country in 2006 by the average proportion of exposed workers.

Several of the low exposure industries from the 1975 classification (Table 2.3 below) no longer have any TCE exposure according to the CAREX updates. These industries are NACE 15, 16, 18, 19 and 26. It appears likely that TCE has been replaced by alternative solvents in these industries since the mid 1990's. We have assumed that workers in industries in which exposures have historically been attributed to dry cleaning work (NACE 17, 92, 93, and 95) do not currently have any exposure. Beginning in the 1950s TCE was replaced by tetrachloroethylene in dry cleaning and there is no longer any use of TCE in dry cleaning in the EU12. The Finnish 2007 CAREX update has attributed some exposure to TCE to use in dry cleaning but we



¹⁰ Available at: http://epp.eurostat.ec.europa.eu/
Available at: http://epp.eurostat.ec.europa.eu/

¹² EU Risk Assessment Report on Trichloroethylene. Vol 31, 2004. Publication EUR 21057 EN. Available at: http://ecb.irc.ec.europa.eu/documents/Existing-Chemicals/RISK ASSESSMENT/REPORT/trichloroethylenereport018.pdf

could not find any evidence of a resurgence in TCE use in the dry cleaning industry and industries in which exposures would have been attributed to dry cleaning were assumed to have no exposure to TCE. Exposures in NACE O (Other community, social and personal service activities) are to workers in the sewage and refuse disposal industry.

The estimated exposure prevalence for the EU member states based on 2006 employment data is shown in Table 2.2. It is estimated that approximately 74,000 workers in the EU are potentially exposed to TCE.

The estimated number of male and female employees in each industry group in each EU member state is also shown in Appendix 8.1. These estimates were obtained by applying the average male to female employee ratio for the industry group for each country to the total number of employees. Male to female employee ratios were calculated with data from the Labour Force Survey. Managers, salespeople and office clerks were excluded from these calculations as they were assumed to be unexposed.



 Table 2.2 Number of workers exposed to trichloroethylene by country and NACE code

| | NAC | E cod | е | | | | | | | | | | | | |
|----------------|-----|-------|------|------|-------|------|------------|------|-------|------|-------|-----|------|------|-------|
| Country | 21 | 22 | 24 | 25 | 28 | 29 | 30 | 31 | 34 | 35 | 36 | 73 | 80 | 0 | Total |
| Austria | 5 | 5 | 48 | 53 | 215 | 187 | 6 | 28 | 169 | 58 | 506 | 5 | 22 | 125 | 1432 |
| Belgium | 4 | 7 | 124 | 51 | 204 | 101 | 5 | 18 | 240 | 48 | 274 | 6 | 37 | 103 | 1222 |
| Bulgaria | 3 | 3 | 46 | 45 | 125 | 161 | 11 | 22 | 14 | 58 | 397 | 0 | 21 | 86 | 994 |
| Cyprus | 0 | 0 | 3 | 2 | 11 | 2 | 0 | 0 | 1 | 1 | 28 | 0 | 2 | 12 | 65 |
| Czech Republic | 6 | 9 | 74 | 161 | 501 | 376 | 57 | 116 | 574 | 111 | 775 | 6 | 28 | 110 | 2902 |
| Denmark | 2 | 7 | 53 | 39 | 142 | 144 | 6 | 24 | 33 | 40 | 298 | 6 | 21 | 109 | 925 |
| Estonia | 1 | 1 | 5 | 10 | 39 | 13 | 2 | 6 | 11 | 15 | 137 | 0 | 6 | 23 | 268 |
| Finland | 32 | 6 | 32 | 29 | 138 | 134 | 2 | 18 | 34 | 55 | 156 | 6 | 50 | 140 | 832 |
| France | 24 | 38 | 489 | 439 | 1288 | 703 | 43 | 151 | 1365 | 757 | 1637 | 38 | 176 | 736 | 7884 |
| Germany | 43 | 73 | 814 | 720 | 2367 | 2430 | 216 | 519 | 4286 | 711 | 2665 | 85 | 206 | 1330 | 16463 |
| Greece | 2 | 6 | 32 | 22 | 121 | 52 | $NK^{[1]}$ | 8 | 15 | 71 | NK | 8 | 30 | 87 | 455 |
| Hungary | 5 | 7 | 57 | 78 | 224 | 158 | 49 | 69 | 261 | 41 | 358 | 6 | 31 | 110 | 1454 |
| Ireland | 1 | 3 | 44 | 19 | 39 | 27 | 71 | 8 | 20 | 19 | NK | 2 | 13 | 67 | 332 |
| Italy | 0 | 33 | 355 | 382 | 2123 | 1305 | 81 | 185 | 847 | 553 | 3336 | 0 | 0 | 0 | 9200 |
| Latvia | 0 | 2 | 8 | 9 | 29 | 17 | 1 | 4 | 6 | 28 | 163 | 1 | 9 | 34 | 310 |
| Lithuania | 1 | 2 | 11 | 18 | 55 | 25 | 2 | 7 | 6 | 37 | 329 | 1 | 13 | 43 | 550 |
| Luxembourg | NK | NK | 2 | 12 | 13 | 5 | 0 | NK | NK | NK | 3 | NK | 1 | 4 | 41 |
| Malta | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | 1 | 4 | 5 |
| Netherlands | 7 | 16 | 113 | 62 | 295 | 206 | 29 | 17 | 115 | 128 | 424 | 30 | 53 | 198 | 1695 |
| Poland | 13 | 19 | 192 | 286 | 833 | 477 | 35 | 107 | 613 | 363 | 2372 | 4 | 112 | 359 | 5786 |
| Portugal | 4 | 7 | NK | 49 | 265 | 110 | NK | 25 | NK | 54 | 663 | 1 | 31 | 98 | 1306 |
| Romania | 5 | 7 | 87 | 89 | 308 | 238 | 24 | 84 | 319 | 308 | 1225 | 21 | 41 | 163 | 2919 |
| Slovakia | 2 | 2 | 23 | 40 | 104 | 104 | 8 | 46 | 148 | 37 | 202 | 4 | 16 | 53 | 789 |
| Slovenia | 2 | 2 | 25 | 26 | 102 | 62 | 4 | 15 | 45 | 14 | 172 | 2 | 7 | 27 | 506 |
| Spain | 0 | 31 | 248 | 228 | 1127 | 445 | 27 | 88 | 807 | 296 | 1975 | 13 | 105 | 630 | 6021 |
| Sweden | 12 | 10 | 77 | 54 | 255 | 270 | 24 | 25 | 438 | 113 | 545 | NK | 48 | 154 | 2025 |
| United Kingdom | 22 | 66 | 381 | 396 | 998 | 640 | 139 | 125 | 910 | 751 | 1935 | 93 | 251 | 989 | 7695 |
| Total | 196 | 364 | 3343 | 3320 | 11924 | 8393 | 840 | 1713 | 11277 | 4666 | 20577 | 337 | 1331 | 5791 | 74073 |

^[1] NK=Not Known



Classification of Industries by Exposure Level

Industries in which exposure to TCE occurred in approximately 1975 have been classified as high, medium, low or background exposure based on an evaluation of the peer-reviewed literature, information from industry and expert judgement. The industries, grouped by NACE code, were identified from the CAREX data and stakeholder information. The exposure classification by industry is presented in Table 2.3.

Table 2.3 Classification of industries by exposure level in 1975

| Industry | NACE (rev 1.1) | Classification |
|--|-------------------|----------------|
| Beverage industries | 15 | Low |
| Tobacco industry | 16 | Low |
| Manufacture of textiles | 17 | Low |
| Manufacture of wearing apparel, except footwear | 18 | Medium |
| Manufacture of leather and products of leather or of its substitutes | 19 | Low |
| Manufacture of pulp, paper and paper products | 21 | Low |
| Printing, publishing and reproduction of recorded media | 22 | Medium |
| Manufacture of chemicals and chemical products | 24 | Medium |
| Manufacture of rubber and plastic products | 25 | Medium |
| Manufacture of glass and other glass products | 26.1 | Low |
| Manufacture of other non-metallic mineral products | 26 | Low |
| Manufacture of fabricated metal products, except machinery and equipment | 28 | High |
| Manufacture of machinery except electrical | 29 | High |
| Manufacture of office machinery and computers | 30 | Medium |
| Manufacture of electrical machinery, apparatus, appliances and supplies | 31 | Medium |
| Manufacture of transport equipment | 34 | High |
| Manufacture of other transport equipment | 35 | High |
| Manufacture of furniture: manufacturing nec | 36 | Medium |
| Research and scientific institutes | 73 | Low |
| Education services | 80 | Low |



| Industry | NACE | (rev | Classification |
|--|------|------|----------------|
| | 1.1) |) | |
| Sanitary and similar services | 90 | | Low |
| Recreational and cultural services | 92 | | Low |
| Personal and household services | 93 | | Medium |
| Private households with employed persons | 95 | | Medium |

2.3 LEVEL OF EXPOSURE TO TRICHLOROETHYLENE

2.3.1 Estimation of exposure levels

The available scientific literature was reviewed for occupational personal exposure data for trichloroethylene. Only exposure information from 1980 onwards was considered. No exposure data for TCE was available for recent years. The main sources of exposure information were as follows. The RAR presents occupational exposures incurred during manufacturing of TCE and its use as an intermediate in the UK over the period 1991-1994. A paper published in the US, which looked at the causes of exposure to trichloroethylene in US industry, carried out a systematic literature review and reported TCE exposure measurements by industry (Bakke *et al.*, 2007). A study of the exposure of Danish workers in industry over the period 1947 – 1989 was reported by Raaschou-Nielsen *et al* (2002). A study into the reduction of occupational exposure to perchloroethylene and trichloroethylene over the last 30 years summarises TCE exposure measurements associated with degreasing from 1942 until 2000 (von Grote *et al*, 2003). Finally, a study of shoe manufacturing in Northern Portugal reports TCE measurements in the finishing department.

Information was extracted from the RAR and papers and is reported in Table 2.4 below by NACE code. A fuller description of the data and source is given in the in Appendix 8.2.



¹³ EU Risk Assessment Report on Trichloroethylene. Vol 31, 2004. Publication EUR 21057 EN. Available at: http://ecb.jrc.ec.europa.eu/documents/Existing- Chemicals/RISK ASSESSMENT/REPORT/trichloroethylenereport018.pdf

 Table 2.4 Summary of occupational exposure data for trichloroethylene

| NACE | E Description Country Exposure | | | | | | e (ppn | 1) | |
|----------|---|---------------|--------------------|------------|-------|------------|--------|------------|-----|
| | • | • | Year(s) | No. | Min | Max | ΑM | ́GМ | GSD |
| 19.3 | Shoe manufacturing | Portugal | 1999 | 100 | | | | 18 | 27 |
| | | | 1999 | 80 | | | | 18 | 20 |
| 00 | Deletie e | Dammadı | 1999 | 150 | | | 0.0 | 33 | 69 |
| 22 24 | Printing Manufacture of | Denmark UK | 1980-89 | 12 | | 49 | 6.3 | 3.5 | 2.9 |
| 24 | chemicals | UK | 1991-94 | 584 | | 49 | | 0.6 | |
| | (Manufacture of TCE) | LIIZ | 1001 04 | 171 | | 120 | | 0.5 | |
| | | UK UK | 1991-94 1991-94 | 171 837 | | 128 128 | | 0.5 0.6 | |
| | | UK | 1991-94 | 298 | | 590 | | 1.3 | |
| 24 | Manufacture of | UK | 1991-94 | 162 | | 11.5 | 0.2 | 1.3 | |
| 24 | chemicals (TCE used as intermediate) | OK | 1991-94 | 102 | | 11.5 | 0.2 | | |
| | | UK | 1991-94 | 7 | | 1.5 | 0.3 | | |
| | | UK | 1991-94 | 57 | | 1.6 | 0.2 | | |
| | | UK | 1991-94 | 34 | | 2.7 | 0.2 | | |
| 28, 29 | Manufacture of fabricated metal products | Denmark | 1980-89 | 371 | | | 13.0 | 5.0 | 4.5 |
| 28 | Manufacture of | UK | 1988 | 29 | | | 5.1 | | |
| | fabricated metal products, except | | | | | | | | |
| | machinery and equipment | | | | | | | | |
| 29 | Manufacture of | US | 1984 | 18 | 0.3 | 26 | 85 | 22 | 6.9 |
| | machinery and equipment nec | | | | | | | | |
| | • • | US | 1984 | 12 | 2.2 | 274 | 86 | 30 | 8.4 |
| | | US | 1990 | 2 | 4.5 | 5.2 | 4.9 | | |
| | | US | 1986 | 3 | 107 | 137 | 120 | 120 | 1.1 |
| | | US | 1986 | 18 | 20 | 89 | 38 | 36 | 1.3 |
| | | US | 1980 | 1 | 0.6 | | | | |
| 30 | Manufacture of electrical and optical equipment | US | 1980 | 28 | 0.1 | 27 | 2.7 | 0.7 | 4.6 |
| | equipment | US | 1980 | 49 | 0.038 | 40 | 2.5 | 0.7 | 4.6 |
| | | US | 1993 | 4 | 0.04 | 0.04 | | | |
| 31 | Manufacture of | US | 1990 | 6 | 0.01 | 11 | 4.1 | 1 | 14 |
| | electrical equipment and apparatus nec | | - | - | - | | | | |
| 32 | Manufacture of radio, television and | Denmark | 1980-89 | 24 | | | 7.8 | 0.7 | 7.3 |
| | communication equipment and | | | | | | | | |
| 0.4 | apparatus | | 4000 | _ | | | c = | | |
| 34 | Manufacture of motor vehicles, trailers and | US | 1982 | 2 | 0.3 | 1.1 | 0.7 | | |
| 35/3 | semi-trailers Manufacture of | US | 1982 | 1 | 4.1 | | | | |



| NACE | Description | Country | | | E | cposur | sure (ppm) | | | |
|------|---|---------|---------|-----|-----|--------|------------|-----|-----|--|
| | | | Year(s) | No. | Min | Max | AM | GM | GSD | |
| | transport equipment | | | | | | | | | |
| | | US | 1982 | 29 | 0.2 | 39 | 5.7 | 2.2 | 4 | |
| 36.2 | Manufacture of jewellery and related articles | US | 1988 | 8 | 15 | 33 | 25 | 24 | 1.3 | |
| 93 | Dry-cleaning shops | Denmark | 1980-89 | 2 | | | 4.1 | 2.0 | 6.2 | |

2.3.2 Development of metal degreasing machines

There are five types of metal degreasing machines progressing from type I machines which are highly emissive open-top machines developed in the early 1950s, to type V machines which are closed-loop one-working chamber machines with closed loop drying and recycling systems with refrigeration cooling, developed in the late 1980s. In Germany, Austria and Switzerland conversion to closed systems (Type V), regardless of the volume of TCE used has already taken place (stakeholder information). A summary of occupational exposure data for the use of TCE in degreasing is shown in Table 2.5.

Table 2.5 Summary of occupational exposure data for trichloroethylene for degreasing

| | | | | Exposure (ppm) | | | | | | | | |
|---------|---------|-----|--------|----------------|------|------|-----|-----------|-----------|--|--|--|
| Country | Year(s) | No. | Min | Max | AM | GM | GSD | 90th %ile | 95th %ile | | | |
| US | 1980 | 1 | 0.6 | | | | | | | | | |
| US | 1981 | 2 | 0.8 | 1.7 | 1.2 | | | | | | | |
| US | 1982 | 2 | 0.3 | 1.1 | 0.7 | | | | | | | |
| US | 1982 | 1 | 4.1 | | | | | | | | | |
| US | 1982 | 29 | 0.2 | 39 | 5.7 | 2.2 | 4 | | | | | |
| US | 1983 | 4 | <0.004 | 25 | 7.8 | 0.2 | 136 | | | | | |
| US | 1983 | 4 | <0.004 | 25 | 7.8 | 0.2 | 136 | | | | | |
| US | 1984 | 18 | 0.3 | 26 | 85 | 22 | 6.9 | | | | | |
| US | 1984 | 12 | 2.2 | 274 | 86 | 30 | 8.4 | | | | | |
| US | 1986 | 3 | 107 | 137 | 120 | 120 | 1.1 | | | | | |
| US | 1986 | 18 | 20 | 89 | 38 | 36 | 1.3 | | | | | |
| UK | 1988 | 29 | | | 5.1 | | | | | | | |
| US | 1988 | 8 | 15 | 33 | 25 | 24 | 1.3 | | | | | |
| US | 1990 | 2 | 4.5 | 5.2 | 4.9 | | | | | | | |
| US | 1990 | 6 | 0.01 | 11 | 4.1 | 1 | 14 | | | | | |
| Denmark | 1980-89 | 371 | | | 13.0 | 5.0 | 4.5 | | | | | |
| Denmark | 1980-89 | 24 | | | 7.8 | 0.7 | 7.3 | | | | | |
| Denmark | 1980-89 | 45 | | | 32.6 | 11.2 | 6.4 | | | | | |
| Denmark | 1980-89 | 23 | | | 0.9 | 0.6 | 2.4 | | | | | |
| Denmark | 1980-89 | 371 | | | 13 | | | | | | | |
| Denmark | 1980-89 | 45 | | | 32.6 | 11.2 | 6.4 | | | | | |
| Denmark | 1980-89 | 23 | | | 0.9 | 0.6 | 2.4 | | | | | |
| Germany | 1990-95 | 14 | | | 7.6 | | | 56.3 | 109.6 | | | |
| Germany | 1990-95 | 23 | | | 4.1 | | | 52.2 | 104.8 | | | |
| Germany | 1990-95 | 159 | | | 10 | | | 44.3 | 67.4 | | | |



| | | | | | | Expos | ure (ppn | 1) | |
|-----------|---------------------|-----|-----|-----|---------------------|-------|----------|-----------|-----------|
| Country | Year(s) | No. | Min | Max | AM | GM | GSD | 90th %ile | 95th %ile |
| Germany | 1990-95 | 30 | | | 44.6 ^[1] | | | 131.7 | 168.9 |
| Australia | 1997 ^[2] | 5 | | | 8.8 | | | | |

^[1] Median

Stakeholder information indicates that the introduction of automated closed systems and solvent substitution has resulted in the estimated exposure dropping to below 10 ppm.

The RAR gives the following data (from monitoring or modelling) as exposure estimates used for the purposes of risk characterisation (Table 2.6).

Table 2.6 Exposure estimates from the EU RAR¹⁴

| Description | Source | 8 hr TWA (ppm) | Short term |
|---------------------------------------|------------------------|---------------------------|---|
| Manufacturing and recycling | Industry | 10 | Short term peaks - potential for high peaks - cannot quantify |
| Metal degreasing | HSE/published/industry | 50 | 500 |
| Adhesives (manufacture) – with LEV | EASE | 10-20 | |
| Adhesives (manufacture) - without LEV | EASE | 100-400 | |
| Adhesives (use) | N/A | Wide use, quantifiable | controls uncertain - not |
| Manufacture of HCFC 133a and HFC 134a | Industry | 11.5 | |

However, it is well known that the EASE model¹⁵ overestimates exposure (Creely *et al*, 2005) and values estimated using it should be treated with caution.

Exposure estimates for various occupational groups are provided by the Finnish Job-Exposure Matrix (FINJEM) which is a database which summarises data from the Finnish occupational exposure measurements supplemented by professional judgement (Kauppinen, 2001). The FINJEM exposure estimates are arithmetic rather than geometric means. All occupational groups for which there was an exposure (occupations in smelting, metallurgical and foundry work not elsewhere classified (nec) turners, toolmakers and machine-tool setters, machine and engine mechanics, metal plating and coating work, assemblers and other machine and metalware occupations, electronics and telecommunications workmen, electrical and electronic equipment assemblers) are estimated to have an exposure of 5 ppm since 1985. FINJEM



Page 18 of 154

^[2] No date given, year of publication reported

¹⁴ EU Risk Assessment Report on Trichloroethylene. Vol 31, 2004. Publication EUR 21057 EN. Available at: http://ecb.jrc.ec.europa.eu/documents/Existing-chemicals/RISK ASSESSMENT/REPORT/trichloroethylenereport018.pdf

¹⁵ Estimation and Assessment of Substance Exposure model can be used to predict workplace exposures.

estimates that exposures in the rubber industry have been at or near 0 ppm since 1984 indicating that exposures in the rubber industry are now at low to background levels.

Due to the limited availability of exposure data for TCE it is not feasible to determine whether there are systematic differences in exposure between countries within the EU.

We have selected exposure measurements from the data presented in Table 2.4, Table 2.5 and Table 2.6 that are expected to be most representative of EU TCE exposure levels for each medium and high exposure industry in 2010. These are summarised in Table 2.7. Several of the industries that were classified as medium or high exposure based on 1975 exposure levels are no longer considered medium to high exposure due to decreased usage of TCE. NACE 17, 18, 25, 93 and 95 are no longer considered medium exposure industries and current typical exposure levels for these industries were not identified. In the past, exposures in NACE 17, 18, 93 and 95 occurred due to the use of TCE in dry cleaning but TCE has now been replaced by other solvents including tetrachloroethylene in this application. Exposure to TCE in NACE 25 (Manufacture of rubber and plastic products) has occurred due to the use of rubber adhesives that contain TCE. This use is infrequent and average exposure levels are now expected to be low.

The only available exposure estimate for the printing industry (NACE 22) is from a Danish study in the 1980s. Creely *et al.*, (2007) analysed temporal trends in exposure in 38 published datasets of long-term trends in aerosol exposure and found that, over time, exposures typically reduced by 5 to 10% per year. The median decrease in exposure level seen by Creely *et al.*, (2007) was 7% per year. We have assumed that the estimated GM of 3.5 ppm for the printing industry is relevant to 1985 and we have estimated a 2010 exposure level of 0.6 ppm based on an estimated decrease in exposure of 7% per year. We have assumed that the GSD has remained constant at 2.9.

For the chemical manufacturing industry (NACE 24) an exposure estimate from the early 1990's based on 837 workers in both process operation and maintenance tasks at a UK chemical manufacturing plant has been selected as the most representative estimate. We have assumed that the estimated GM of 0.6 ppm is relevant to 1992 exposure levels and we have estimated a 2010 exposure level of 0.2 ppm based on an estimated decrease in exposure of 7% per year. No estimated GSD was available and we have assumed a GSD of 3 as occupational exposure data is typically log normally distributed with GSDs typically around 3.

In industries in which exposure arises due to the use of TCE in metal degreasing (NACE 28, 29, 30, 31, 34, 35 and 36), German exposure measurements from the 1990s are likely to be representative of current exposure levels across the EU. Following the implementation of the German emission legislation 2.BImSchV in 1986 (and a revision in 1990), type V closed system metal degreasing machines have been required in Germany since the early 1990s. Stakeholder information has indicated that by the beginning of 2011 type V closed system metal degreasing machines will be in use across the EU and exposures levels across the EU will be similar to those seen in Germany since the 1990s. The average exposure level from 159 measurements taken in Germany between 1990 and 1995 was 10 ppm. The GM or GSD are not available. A GSD of 3 was assumed. To estimate the GM from the arithmetic mean of 10 ppm



exposure distributions were simulated with Monte Carlo simulation in @Risk using different geometric means. Ten thousand data points were generated per simulation. A distribution with a GM of 5.5 ppm and a GSD of 3 was found to have an arithmetic mean of 10 ppm. We have selected 5.5 ppm as a reasonable estimate of GM exposure during metal degreasing in the EU.

Table 2.7 Estimated current 2010 trichloroethylene levels for medium and high exposure industries

| NACE Code | Industry | Estimated Geometric Mean (ppm) | Estimated Geometric Standard Deviation |
|--------------|--|--------------------------------------|---|
| 22 | Printing, publishing and reproduction of recorded media | 0.6 | 2.9 |
| 24 | Manufacture of chemicals and chemical products | 0.2 | 3 |
| 28 | Manufacture of fabricated metal products, except machinery and equipment | 5.5 | 3 |
| 29 | Manufacture of machinery except electrical | 5.5 | 3 |
| 30 | Manufacture of office machinery and computers | 5.5 | 3 |
| 31 | Manufacture of electrical machinery, apparatus, appliances and supplies | 5.5 | 3 |
| 34 | Manufacture of transport equipment | 5.5 | 3 |
| 35 | Manufacture of other transport equipment | 5.5 | 3 |
| 36 | Manufacture of furniture; manufacturing nec | 5.5 | 3 |

We have assumed that the exposures presented for high exposure groups in Table 2.3 are typical of exposures throughout the EU. The overall weighted GM and GSD was estimated across all medium high exposure industries across the EU using @Risk © (Palisade Corporation, New York). Exposures were simulated using the GM and GSD for each industry. The number of values each country contributed was weighted according to the number of workers exposed in that industry.

The estimated overall weighted GM exposure across all countries and industries is 4.6 with a GSD of 3.7

The exposure distribution for the EU was simulated using Monte Carlo simulation. The distributions for each high exposure industry were based on the GMs and GSDs presented in Table 2.7 and the overall distribution across all industries was based on a GM of 4.6 and a GSD of 3.7. The percentage of workers who are expected to be exposed above the typical OEL (10 ppm and 50 ppm) was estimated with the simulated distributions (Table 2.8).



Table 2.8 Estimated percentage of workers exposed above the typical EU OELs (10 and 50 ppm)

| Industry | | Estimated percentage of workers exposed above 10 ppm (%) | Estimated percentage of workers exposed above 50 ppm (%) |
|----------|--|--|--|
| 22 | Printing, publishing and reproduction of recorded media | <1 | 0 |
| 24 | Manufacture of chemicals and chemical products | <1 | 0 |
| 28 | Manufacture of fabricated metal products, except machinery and equipment | 29 | 2 |
| 29 | Manufacture of machinery except electrical | 29 | 2 |
| 30 | Manufacture of office machinery and computers | 29 | 2 |
| 31 | Manufacture of electrical machinery, apparatus, appliances and supplies | 29 | 2 |
| 34 | Manufacture of transport equipment | 29 | 2 |
| 35 | Manufacture of other transport equipment | 29 | 2 |
| 36 | Manufacture of furniture; manufacturing nec | 29 | 2 |
| OVERALI | (All high exposure industries) | 28 | 4 |

2.3.3 Temporal change in exposure

The available scientific literature was reviewed for historic TCE occupational exposure data. Although the results of numerous studies have been reported in the literature (see summary Tables 5, 6 and A2), only one study has looked at the average annual decrease in exposure. Raaschou-Nielsen *et al.*, (2002) demonstrated an average annual decrease in TCE exposure of 4% from 1947 to 1964 and 15% between 1964 and 1989. Since the conversion to closed systems is mostly complete, it is likely that the annual decrease since 1989 has been less than 15%. For current exposures, a percentage decline in exposure of 7% has been assumed based on the findings of the Creely *et al* (2007) study mentioned above.

Von Grote *et al.*, (2003) has shown that in Germany the combined effect of technological innovation and stricter legislation led to significantly reduced airborne concentrations of TCE. The authors concluded that with the long-term near-range concentration for type Va (closed machines, without vacuum technology) was below 5 ppm and that for type Vb machines (closed machines, with vacuum technology) was below 2 ppm. It is expected that at the start of 2011, once the SED and voluntary industry commitment are fully implemented, similar levels can be achieved in other EU countries.



2.4 HEALTH IMPACT FROM CURRENT EXPOSURES

2.4.1 Background data

The occupational cancers associated with trichloroethylene exposure are shown in Table 2.9, along with a summary of the information used in the health impact assessment.

Table 2.9 Occupational cancers associated with exposure to trichloroethylene

| Cancer site | Liver and | Liver and biliary tract | | Kidney | | | |
|--|--------------|--------------------------------------|-----------------|------------------|--------------|------------------|--|
| ICD-10 code | C22 | | C64 | | C82-C85 | | |
| IARC group for | 2A | | 2A | 2A | | 2A | |
| carcinogen | | | | | | | |
| Strength of evidence | Suggestiv | re | Suggestiv | re | Suggestive | | |
| for cancer site [1] | | | | | | | |
| Latency assumption | 10-50 yrs | | 10-50 yrs | | 0-20 yrs | | |
| Source of forecast numbers - deaths | Eurostat, | 2006 | Eurostat, | 2006 | Eurostat, 20 | 006 | |
| Source of forecast numbers - registrations | GLOBOC | AN ¹⁶ , 2002 | GLOBOC | AN, 2002 | GLOBOCA | N, 2002 | |
| Exposure levels | Relative | Source of | Relative | Source of | Relative | Source of | |
| , | Risk (RR) | RR | Risk (RR) | RR | Risk (RR) | RR | |
| "High" | ì.9 (1- | Wartenberg | ì.7 (1.1- | Wartenberg | 1.5 (0.9- | Wartenberg | |
| Ü | 3.4) | et al. (2000), liver cancer estimate | 2.7)` | et al. (2000) | 2.3) | et al. (2000) | |
| "Medium" | 1.8 (1.1- | Wartenberg | 1.41 | Ruder et al. | 1.4 (0.7- | Wartenberg | |
| | 2.9) | et al. (2000) | (0.46- 3.30) | (2001) | 2.8) | et al. (2000) | |
| "Low" | 0.9 (0.5- | Wartenberg | 1.3 (0.9- | Wartenberg | 0.9 (0.6- | Wartenberg | |
| | 1.9) (set | et al. (2000) | 1.7) | et al. | 1.4) (set | et al. | |
| 111 5 | to 1) | | | (2000) | to 1) | (2000) | |

^[1] Based on Siemiatycki et al, 2004

2.4.2 Exposed numbers and exposure levels

Industry sectors, their NACE codes and classifications to High/Medium/Low/Background exposure as applicable for the mid 1970's are given in Table 2.3 in the previous section on the exposure. The estimated average exposure level (GM) and measure of variability (GSD) across NACE industries used are 4.6 ppm and a geometric standard deviation of 3.7 in 2010.

We present data for a "baseline" trend scenario which for all industries assumes a 7% annual decline in exposure levels and standard change in employed numbers up to the 2021-30 estimation interval and constant levels thereafter.



¹⁶ IARC, GLOBOCAN database, available at: http://www-dep.iarc.fr/globocan/database.htm

2.4.3 Forecast cancer numbers

Separate estimates for total numbers of deaths for kidney and liver cancer by age band are available from EUROSTAT for the 27 countries of the EU, for 2006. Deaths for NHL were estimated by applying deaths from NHL (ICD10 codes C82-C85) for Great Britain (2005) as a proportion of deaths from ICD10 codes C81-C96 to the C81-C96 data by country from Eurostat. Total numbers of registrations are available for all three cancers from GLOBOCAN for 2002. The forecast numbers of deaths and registrations by country used to estimate attributable numbers are in Appendix 8.3.

2.4.4 Results

The cancer deaths and registrations attributed to occupational exposure to trichloroethylene for the baseline scenario are presented per year for the target years given and are based on the working age cohort of currently (2006) exposed workers. Attributable fractions and numbers of deaths and registrations, and Years of Life Lost (YLLs), Years Lived with Disability (YLDs) and Disability Adjusted Life Years (DALYs), are estimated.

As the exposure data suggests that exposure declines over time, a dynamic baseline scenario has been used.

A summary of the results for liver cancer, kidney cancer and non-Hodgkin's lymphoma for the total EU is in Table 2.10 below.

Table 2.10 Results for the baseline forecast scenario, total EU (27 countries), men plus women

| Scenario | All scenar | ios | | (trend) sc ent and ex to 2021-30, o | | |
|----------------------------|------------|---------|---------|---|---------|---------|
| EU Total | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Numbers ever exposed | 291,882 | 299,942 | 310,620 | 315,914 | 319,370 | 321,932 |
| Proportion of the | 0.081% | 0.079% | 0.080% | 0.080% | 0.081% | 0.084% |
| population exposed | | | | | | |
| Liver cancer | | | | | | |
| Attributable Fraction | 0.071% | 0.066% | 0.058% | 0.047% | 0.035% | 0.025% |
| Attributable deaths | 34 | 37 | 38 | 35 | 28 | 21 |
| Attributable registrations | 34 | 36 | 37 | 33 | 25 | 18 |
| 'Avoided' cancers | | | | | | |
| YLLs | 481 | 509 | 506 | 437 | 331 | 243 |
| DALYs | 490 | 519 | 516 | 445 | 338 | 247 |
| Kidney cancer | | | | | | _ |
| Attributable Fraction | 0.046% | 0.042% | 0.038% | 0.034% | 0.031% | 0.030% |
| Attributable deaths | 13 | 14 | 14 | 15 | 15 | 15 |
| Attributable registrations | 31 | 32 | 33 | 32 | 30 | 29 |
| 'Avoided' cancers | | | | | | |
| YLLs | 189 | 196 | 196 | 188 | 179 | 174 |
| DALYs | 216 | 224 | 223 | 215 | 205 | 198 |



| Scenario | All scenar | ios | employme | nt and ex | enario (1) xposure lev constant the | |
|--|------------|---------|----------|-----------|---|---------|
| EU Total | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| NHL | | | | | | _ |
| Numbers ever exposed | 213,655 | 216,910 | 220,378 | 221,459 | 221,459 | 221,459 |
| Proportion of the population exposed | 0.054% | 0.053% | 0.054% | 0.055% | 0.057% | 0.059% |
| Attributable Fraction | 0.042% | 0.033% | 0.023% | 0.016% | 0.017% | 0.017% |
| Attributable deaths | 12 | 10 | 8 | 6 | 7 | 7 |
| Attributable registrations 'Avoided' cancers | 28 | 24 | 19 | 14 | 15 | 15 |
| YLLs | 196 | 167 | 127 | 92 | 96 | 98 |
| DALYs | 198 | 169 | 129 | 94 | 97 | 99 |

The attributable deaths in the EU 2010 from previous trichloroethylene exposures were relatively small: 34 for liver cancer, 13 for kidney cancer and 12 for NHL. The estimated deaths and cancer registrations decrease steadily over the following 50 years for liver cancer and NHL so that by 2060 there are only 21 liver cancer deaths and 7 NHL deaths from trichloroethylene exposure predicted to occur. The estimated deaths from kidney cancer remain fairly constant over the 50 years with 15 deaths expected to occur in 2060. The corresponding estimated attributable fraction for all three cancers are expected to decrease between 2010 and 2060, with expected decreases from 0.07% in 2010 to 0.03% in 2060 for liver cancer, 0.05% in 2010 to 0.03% in 2060 for kidney cancer and 0.04% in 2010 to 0.02% in 2060 for NHL. DALYs also are predicted to decrease over the 50 year period – from 490 years for liver cancer in 2010 to 247 years in 2060, 216 years in 2010 to 198 years in 2060 for kidney cancer and 198 years in 2010 to 99 years in 2060 for NHL.

2.5 POSSIBLE COSTS ASSOCIATED WITH NOT MODIFYING THE DIRECTTIVE

2.5.1 Health impacts – possible costs under the baseline scenario

Introduction

The health data (cancer registrations and Years of Life Lost - 'YLL') for the baseline in which there are no further modifications to the Carcinogens Directive are shown in section 2.4 of this report. These data show that there are predicted to be a significant number of cancer registrations and YLLs from liver, kidney and non-hodgkins lymphoma (NHL) resulting from predicted future exposure to trichloroethylene. There is predicted to be a decline in registrations and YLLs over time as a result of predicted exposure reduction owing to implementation of existing and ongoing risk management measures across the EU.

Method in brief

Using the health data (cancer registrations and YLL), it is possible to monetise the costs under the baseline by estimating the:



- Life years lost This is calculated by using the YLL and multiplying this by a valuation of the Value of Life Year Lost (VLYL). This gives a value for the time (in years) lost as a result of premature death.
- Cost of Illness (COI) –This is a monetary cost of the time spent with cancer.
 In this study, a unit COI estimate is multiplied by the number of cancer registrations, give a total value for COI. (COI is often the main market-based approach in relation to health impact¹⁷). COI includes the direct and indirect costs of cancer but not the intangible costs (see below).
- Willingness to Pay (WTP) to avoid cancer WTP in this study is used as an
 alternative method (high cost scenario) based on publically available, peer
 reviewed studies on what people would be willing to pay to avoid having
 cancer. This includes various intangible costs (such as disfigurement,
 functional limitations, pain and fear) and includes the costs associated with
 life years lost.

The cost variables used in this study are presented in Table 2.11 in 2010 prices. For the purposes of this study, valuations are increased by 2% each year in the future in part to present costs in real terms (i.e. adjusting for inflation in prices) and to reflect the increasing value society attaches to its health (as economic growth typically increases over a long period of time)¹⁸.

Table 2.11 Summary of cost variables used in this study (€2010 prices)

| Cost/benefit elements | Low scenario | High scenario |
|---|------------------------------|-------------------------------|
| VLYL - Each year lost | € 50,393 | € 0 (note 1) |
| COI or WTP - Unit cost (per cancer | € 49,302 (COI) | € 1,793,776 (WTP) |
| registration) | | |
| (Note 1) – By using WTP (€1.8m) in the high scenario inste | ead of COI, the WTP can i | nclude the costs of premature |
| death and therefore there was a risk of double counting ben | efits if VLYL costs were inc | luded. |

All costs and benefits over time in this study are discounted using a 4% discount rate as recommended by the European Commission's Impact Guidelines¹⁹. In order to assess the effect that discounting has on the results ('sensitivity analysis), we have also presented estimates that take into consideration a declining discount rate for impacts occurring after 30 years and no discounting.

The health data shown in section 2.4 are 'snap-shots' (i.e. an estimation for the initial year of a ten year period) of the number of cancer registrations, deaths, YLLs in future years at 10 year intervals. In calculating the costs associated with these effects, each 'snap-shot' result is multiplied by 10 in order to derive an estimate for the whole assessment time period (for example, 2020 results are multiplied by 10 to give results over the period 2020-2029). This assumes that each snap-shot year is representative of the following 10 years.



Page 25 of 154

¹⁷ Source: European Chemicals Agency: http://echa.europa.eu/

This is consistent with some other European Commission studies and is standard practice for air quality under the Clean Air for Europe (CAFE) programme.

¹⁹ European Commission impact Assessment Guidelines (Jan 2009) http://ec.europa.eu/governance/impact/commission_guidelines/docs/iag_2009_en.pdf

The method to valuing health benefits is explained in more detail in the method paper titled "Valuing health benefits – Method paper".

Results

The health costs under the baseline scenario are presented in Table 2.12. Health-related costs are predicted to decline over time and are predominately the result of historical exposure. As set out in Section 2.4, the numbers of cancer registrations and YLLs are estimated to decline over time, accounted for by risk management measures (RMMs) already implemented during trichloroethylene manufacture and end use over the past 10-20 years. These include, for example, increased prevalence of enclosed cleaning systems, replacement of use in textile ("dry") cleaning and other small uses.

The introduction of an EU-wide OEL is not expected to have a significant impact in the short term given that the largest Member States already have a national OEL in place (although the stringency of the OELs varies by Member State). Table 2.12 sets out the ranges of health costs for each representative decade. The ranges are based on the high and low cost scenarios (see Table 2.11). The results are also illustrated in Figure 2.1.


Table 2.12 Health costs – baseline scenario – 2010 to 2070 (Present Value – 2010 €m prices)

| 86 to 291 | 68 to 228 | 50 to 172 | 37 to 133 | 26 to 103 | 105 to 1,287 |
|-----------------|----------------------|--|--|--|---|
| 282 to 993 | 224 to 792 | 164 to 596 | 118 to 455 | 85 to 347 | 1,210 to 4,370 |
| 368 to 1,284 | 292 to 1,020 | 214 to 767 | 155 to 589 | 111 to 450 | 1,582 to 5,657 |
|) | 282 to 993 368 to | 282 to 993 224 to 792 368 to 292 to | 282 to 993 224 to 792 164 to 596 368 to 292 to 214 to 767 | 282 to 993 224 to 792 164 to 596 118 to 455 368 to 292 to 214 to 767 155 to 589 | 282 to 993 224 to 792 164 to 596 118 to 455 85 to 347 368 to 292 to 214 to 767 155 to 589 111 to 450 |

⁻ All costs are presented in present value using a discount rate of 4%. The low range is based on low estimates for costs of illness and life years lost. The upper range of costs relate to WTP estimates to avoid having cancer, which include intangible costs associated with having cancer.



⁻ Totals may not match to sums of females and male costs due to underlying small differences in raw data and rounding to whole number



Time periods




Figure 2.1 Health costs – baseline scenario – 2010 to 2070 (Present Value – 2010 €m prices)

These costs will affect Member States differently depending upon the overall number of workers within affected industry groups, existing RMMs and the proportion of males and females within these groups. Figure 2.2 shows that France, Germany and Italy are predicted to have relatively high health costs. The industrial sectors estimated to be most affected under the baseline are the sectors manufacturing metal products, transport equipment and furniture (all assumed to relate to use of the substance in metal degreasing). There are also notable impacts in the manufacture of motor vehicles and manufacture of machinery. This is shown in Figure 2.3.

Detailed tables are included in the Appendix 8.4.







Figure 2.2 Total health costs – baseline scenario – By Member State (Present Value – 2010 €m prices)

Member State








Figure 2.3 Total health costs – baseline scenario – by industry group (Present Value – 2010 €m prices)²⁰




²⁰ Charts exclude industries for which zero costs are estimated.

In order to present all socio-economic costs and benefits consistently in present value terms, all future costs and benefits have been discounted. The primary approach was to apply the European Commission IA recommended 4% discount rate. Since most health impacts occur over a long period of time relative to costs, the impacts of discounting are significant.

In Figure 2.4, the effects of different discount rates on the overall results are shown, indicating that the impacts of discounting become more pronounced the further in the future that the impact occurs.

Health costs - baseline scenario - Effect of using different discount rates - Low cost scenario



Health costs - baseline scenario - Effect of using different discount rates - High cost scneario




Figure 2.4 Impacts of discounting



3 POLICY OPTIONS

3.1 DESCRIPTION OF MEASURES

3.1.1 Existing exposure controls in the sector

The solvent emissions directive

The use of trichloroethylene (and of other solvents²¹) in metal degreasing is regulated by the solvent emissions directive (SED)²². The objective of the SED is to reduce the direct and indirect effects on the environment and on human health of emissions (mainly to air) of volatile organic compounds.

According to the environmental risk reduction strategy for trichloroethylene (RRS)²³, the main measure available to reduce emissions of trichloroethylene, to below the emission limits imposed by the SED, is to implement closed systems for degreasing where open systems were in place. Indeed, the review of available documentation, as well as consultation with ECSA (the main EU trade association representing the substance) for this report did not identify specific technical measures that could be used to achieve compliance with OELs, other than the use of closed systems.

Although the emission limits set out in the SED are environmental targets, it is anticipated they are still of relevance for OELs. These emission limits have to be complied with at a site level in terms of emissions in waste gases (as opposed to a workshop/process level) whereas OELs have to be complied with in the direct environment of the process, i.e. in each hall or workshop where a process involving trichloroethylene is carried out.

The emission limit values under the SED are 2 mg/m³ where the mass flow is over 10g/h and 20 mg/m³ where the mass flow is less than 10g/h. These correspond to around 3.7ppm and 0.4ppm, respectively. These are lower than the most common OEL (50ppm 8-hour TWA) and also lower than the value of 10ppm proposed by the SCOEL.

With regard to the use of trichloroethylene in the surface cleaning sector, different options are set out in the directive that would apply to this use:

- For consumption of the solvent (in this case trichloroethylene) above 1 tonne per annum, compliance with emission limits.
- Application of a 'reduction scheme', in which emissions of the solvent (in this case trichloroethylene) can be reduced by other means, but achieving

http://www.defra.gov.uk/environment/quality/chemicals/documents/report-tetra060203.pdf



²¹ Volatile organic compound (VOC) and organic solvent are defined in Council Directive 1999/13/EC

²² Council Directive 1999/13/EC of 11 March 1999 on the limitation of emissions of volatile organic compounds due to the use of organic solvents in certain activities and installations.
²³ DEFRA (2005) Risk Reduction Strategy and Analysis of the Advantages and Drawbacks for Tetrachlorotheylene. Available at:

an equivalent level of emission to that which would have been achieved if the emission limits were applied.

Given the classification of trichloroethylene as 'may cause cancer' (R45), the SED also requires that use should be substituted within 'the shortest possible time' 24, 25.

Table 3.1 summarises the main requirements of the SED for trichloroethylene in the metal degreasing sector.

Table 3.1 Main Requirements of SED that apply to trichloroethylene used in surface cleaning

| Requirement | Details for Trichloroethylene |
|-------------------------------|--|
| Threshold for inclusion | 1 tonne per year |
| Emission limits (waste gases) | 2 mg/Nm ³ |
| | (20 mg/Nm ³ where mass flow < 10g/h) |
| Substitution of solvents | Substitute trichloroethylene within the "shortest possible time" |

Consultation with metal degreasing companies was undertaken for the environmental RRS for trichloroethylene²⁶. From this consultation three possible routes to comply with the above requirements were suggested:

- 1. substitution with alternative solvents that are not classified as CMRs;
- 2. reducing solvent consumption to below 1 t/yr to fall out of the scope of the Directive; or
- 3. reducing emissions to below the 2 mg/m³ level.

The first two compliance options were considered to be the preferred options across the sector. This may partly explains the sharp decrease in the overall sales of trichloroethylene as a solvent over recent years (see Table 1.2).

Whilst the SED does not specify averaging periods for the limit values for emissions to air in the workplace, an emission limit of 20 mg/m³ is equivalent to less than 5 ppm, half of the OEL recommended by the SCOEL and well below most of the national OELs presented in Table 1.1. During communication with ECSA for this study, they did not



²⁴ This also applies to substances labelled R46 (may cause heritable genetic damage), R49 (may cause cancer by inhalation), R60 (may impair fertility) and R61 (may cause harm to the unborn child).

unborn child).

25 According to Article 7(1) of the Directive: "The Commission shall ensure that an exchange of information between Member States and the activities concerned on the use of organic substances and their potential substitutes takes place. It shall consider the questions of: fitness for use, potential effects on human health and occupational exposure in particular; potential effects on the environment, and the economic consequences, in particular, the costs and benefits of the options available, with a view to providing guidance on the use of substances and techniques which have the least potential effects on air, water, soil, ecosystems and human health. Following the exchange of information, the Commission shall publish guidance for each activity."

²⁶ DEFRA (2005) Risk Reduction Strategy and Analysis of the Advantages and Drawbacks for Tetrachlorotheylene. Available at:

http://www.defra.gov.uk/environment/quality/chemicals/documents/report-tetra060203.pdf

indicate specific additional risk reduction measures would be used to comply with a national OEL. It is assumed that when compliance with the SED emission limit values is met through use of closed degreasing systems that this, in general, also allows the national OELs to be met²⁷.

3.1.2 Additional actions needed to comply with a Community-wide OEL

The requirements of the SED for metal degreasing and the ECSA charter (the latter applicable from the end of 2010) would be expected to be sufficient to allow an EU - wide OEL to be met, if set at the most commonly applied adopted value of 50 ppm 8-hour TWA. However, there may be some metal cleaning installations that fall outside the scope of the SED and which do not apply closed systems that allow an OEL of 10 ppm (as proposed by the SCOEL) to be met. It is assumed that such companies would be required to implement closed systems in order to comply with such an OEL or to use alternative cleaning solvents to trichloroethylene.

3.2 LEVEL OF PROTECTION ACHIEVED (OELS)

Companies covered by the solvent emissions directive

We have not gathered detailed data on compliance with national OELs for trichloroethylene. In the absence of this we have assumed that the use of enclosed vapour degreasing allows industry to comply with existing national OELs. This seems to be corroborated through consultation with ECSA (Personal Communication for this study) who did not identify the use of equipment other than closed systems to specifically reduce exposure of workers.

Companies not covered by the solvent emissions directive

For companies using less than 1 tonne of trichloroethylene per year, there is no requirement under the SED to comply with emission limit values or to substitute trichloroethylene. Nevertheless, OELs still apply to such companies (as does the obligation under Article 4 of the Carcinogens Directive to replace the substance where technically feasible). As stated above, the use of closed degreasing systems is understood to be the main means of complying with the SED emission limit values and assumed also to allow compliance with national OELs. We assume therefore that closed vapour degreasing systems would be required by companies that do not have to comply with SED in order to comply with a Community-wide OEL for trichloroethylene.

In practice, it may be the case that companies using trichloroethylene for metal degreasing will already use closed vapour degreasing systems, or will do so in the near future. This results in part from to the recent introduction of an industry agreement, signed by all European manufacturers of trichloroethylene. This 'Charter for the safe use of Trichloroethylene in metal cleaning' commits the signatories to phase out sales of trichloroethylene for open metal-cleaning systems by 31 December 2010²⁸. According to the charter, only end-users customers that have signed, as a pre-



Page 33 of 154

²⁷ Personal communication with ECSA, July 2009.

²⁸Available at: http://www.eurochlor.org/qandatrienglish (accessed August 2009) and personal communication with ECSA, July 2009

condition of purchase, a declaration of conformity stating that they use trichloroethylene in closed systems²⁹, will be permitted to purchase trichloroethylene from European suppliers.

Conclusions on existing exposure controls

It appears that using trichloroethylene in closed vapour degreasing systems is the main risk reduction measure available to the metal degreasing sector. The application of the SED has promoted the use of vapour degreasing systems in order to comply with the emission limits set in the Directive, for those companies consuming over 1 tonne of trichloroethylene per year. We understand (from limited consultation) that these closed systems also allow reduction of emissions to the workplace to levels that are below the national OELs.

For companies outside of the scope of the SED because of their low trichloroethylene consumption, closed systems seem likely to be implemented in Europe as a result of the voluntary industry agreement (Charter for the safe use of Trichloroethylene in metal cleaning). This agreement is expected to be implemented such that sales of trichloroethylene for open metal-cleaning systems will be phased out by the end of 2010.

It is also worth noting that users of trichloroethylene can be subject to the SED even with a low consumption of trichloroethylene (below 1 tonne per annum) where they also consume other solvents that are subject to the SED, with a total consumption of solvents above 1 tonne per annum. Therefore, it is understood that there would be some companies complying with the SED (and therefore potentially implementing a closed vapour degreasing system) even where consumption of trichloroethylene is below 1 tonne per annum.

Assuming that the above requirements for implementation of closed systems apply, the only cases where introduction of an EU-wide OEL would be expected to lead to additional requirements (after 2011) would be:

- Where users of trichloroethylene in metal degreasing purchase the substance from suppliers that are not signatories to the ECSA charter (e.g. those which purchase from manufacturers outside the EU).
- If some of the closed systems are less effective than others, they may only allow certain national OELs to be met (e.g. 50ppm 8h TWA). It is assumed



²⁹ Closed systems as defined in European Standard EN 12921-4 (Machines for surface cleaning and pretreatment of industrial items using liquids or vapours - Part 4: Safety of machines using halogenated solvents), including: (1) Sealed Systems (Type I) in which there is no direct connection between any volume containing a halogenated solvent and the outside environment during normal operation. (2) Collection Chamber Systems (Type Ia) which consist of a collection chamber and one or more process chambers with doors, one door sealing the collection chamber from the process chamber(s), the other from the outside environment. (3) Single Chamber Systems (Type Ib) which consist of a chamber which is used for both processing items and collecting halogenated solvent vapours for recovery. (4) Enclosed Systems (Type II) which consist of a chamber which is used for both processing items and collecting halogenated solvent vapours for recovery.

that less effective systems may not necessarily allow a more stringent OEL (e.g. 10ppm 8h TWA) to be met.

4 ANALYSIS OF IMPACTS

4.1 HEALTH IMPACTS FROM CHANGES TO THE EU DIRECTIVE

4.1.1 Health information

We present data for two "intervention" scenarios as described in Table 4.1 below, compared to the baseline trend scenario described in section 2.4.1.

For trichloroethylene, OELs of 10 and 50 ppm (50 and 273 mg/m³) are to be tested. Kidney and liver cancer and NHL numbers will therefore be estimated given full compliance³⁰ to these OELs. Baseline for all industries assumes a 7% annual decline in exposure levels based on the estimate for NACE 22 printing industries (Creely *et al.*, 2007) and standard change in employed numbers up to the 2021-30 estimation interval and constant levels thereafter.

Table 4.1 Baseline and intervention scenarios

| Carcinogen Intervention scenarios ^[1] | Trichloroethylene | | | | | |
|---|--|--|--|--|--|--|
| Baseline (trend) scenario (1) | Linear employment and exposure level trends assumed to 2021-30, constant thereafter. | | | | | |
| Intervention scenario (2) | Full compliance for OEL = 50 ppm (273 mg/m ³) | | | | | |
| Intervention scenario (3) | Full compliance for OEL = 10 ppm (50 mg/m ³) | | | | | |

^[1] All intervention scenarios are estimated as change to (1) the baseline scenario

Results for the baseline scenario (1) and intervention scenarios (2) and (3) compared to the baseline scenario are in Figure 4.1 (for attributable registrations), Figure 4.2 (for attributable fractions) and Figure 4.3 (for DALYs) for liver cancer, Figure 4.4, Figure 4.5 and Figure 4.6 for kidney cancer and Figure 4.7, Figure 4.8 and Figure 4.9 for NHL for men plus women for the total EU (27 countries). A summary of the results for kidney and liver cancer and NHL for the total EU is in Table 4.2 below. Due to cancer latency, no effect is seen from interventions in 2010 until 2030.

Introducing full compliance with the trial OELs in 2010 will avoid cancers occurring but only from 2040 onwards for kidney and liver cancers (Figure 4.1 and Figure 4.2 for liver cancer and Figure 4.4 and Figure 4.5 for kidney cancer), and from 2020 onwards for NHL (Figure 4.7 and Figure 4.8). Introducing the higher OEL (50 ppm) in 2010 has no impact on reducing attributable cancers compared to assuming a continuing 7% downward trend in exposure levels to 2021-30 (Figure 4.1, Figure 4.4 and Figure 4.7 suggest more cancers result than under the baseline scenario; this is because we assume 99% rather than 100% compliance to the OEL, with approaching 100% compliance attributable numbers are as for the baseline, see Table 4.2). Introducing



³⁰ Full compliance is assumed in the intervention scenarios; however, due to modelling restrictions full compliance is modelled as 99% compliance.

the OEL of 10 ppm would avoid 10 liver and 2 kidney cancers by 2060 and 12 cases of NHL by 2030 (earlier due to its shorter latency; 'avoided' NHLs are lower from 2040 as the effect of the continuing baseline 7% decline in exposure levels has more effect).




Figure 4.1 Results for intervention scenarios compared to the baseline trend scenario (1) – Occupation Attributable cancer registrations, Liver cancer, men plus women

Figure 4.1 shows the numbers of registrations for liver cancer attributable to trichloroethylene exposure are expected to decrease for all four scenarios over the next 50 years.






Figure 4.2 Occupation Attributable Fractions, Liver cancer

Figure 4.2 shows that in addition to the number of liver cancer registrations the attributable fraction also decreases over the period up to 2060. By 2060 it is predicted that less than 0.04% of all liver cancer could be attributed to trichloroethylene, regardless of which scenario is followed.






Figure 4.3 Occupation Attributable DALYs, Liver cancer

Additionally, the estimated DALYs are predicted to decrease from just under 500 years in 2010 to less than 300 years in 2060 for all three scenarios (Figure 4.3).

Data for kidney cancer follows a similar pattern to that for liver cancer and these data are shown in Figure 4.4, Figure 4.5 and Figure 4.6.






Figure 4.4 Results for intervention scenarios compared to the baseline trend scenario (1) – Occupation Attributable cancer registrations, Kidney cancer, men plus women




Figure 4.5 Occupation Attributable Fractions, Kidney cancer






Figure 4.6 Occupation Attributable DALYs, Kidney cancer

Data for NHL follow a different pattern to that for liver and kidney cancer. These data are shown in Figure 4.7, Figure 4.8 and Figure 4.9.




Figure 4.7 Results for intervention scenarios compared to the baseline trend scenario (1) – Occupation Attributable cancer registrations, NHL, men plus women



Figure 4.7 shows that the number of attributable registrations for NHL is expected to decrease between 2010 and 2030 and then increase slightly from 2040 to 2060 for all three scenarios. The attributable fractions and DALYs in Figure 4.8 and Figure 4.9, respectively, show the same pattern as the attributable registrations for NHL.




Figure 4.8 Occupation Attributable Fractions, NHL




Figure 4.9 Occupation Attributable DALYs, NHL



Table 4.2 summarises the data shown in the previous figures. The data for the first two time periods (2010, 2020) are identical for all scenarios, and then the data for the two interventions are shown in the next two groups of four columns (2030-2060). Attributable deaths for all three types of cancer decrease from 59 deaths in 2010 to 51 deaths in 2060 for scenario 2 (full compliance with OEL of 50 ppm) and 28 deaths in 2060 for scenario 3 (full compliance with OEL of 10 ppm).

In Table 8.5.1 in Appendix 8.5 are the estimated proportions exposed above the OELs to be tested, as estimated under the baseline trend scenario (1). Under the alternative change scenarios they behave as determined by the scenarios.

Full results are given in Appendix 8.5 for men plus women by country and by industry. Estimates of numbers of cancer registrations 'avoided' in each of the forecast target years from 2030 onwards relative to the baseline scenario can be obtained by subtraction. Data for men and women separately, and by industry within country, are available in supplementary spreadsheets (*TCE Report data.xls*), if required.



Table 4.2 Results for the intervention scenarios, total EU (27 countries), men plus women

| Scenario | All scena | arios | | n scenario (2 pm (273 mg/ | | pliance for | | n scenario (pm (50 mg/n | 3) - Full com | pliance for |
|------------------------------------|-----------|-------------|---------|------------------------------|---------|-------------|------------------------|-----------------------------|---------------|-------------|
| EU Total | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Numbers ever | 291,882 | 299,942 | 310,620 | 315,914 | 319,370 | 321,932 | 310,620 | 315,914 | 319,370 | 321,932 |
| exposed | | | | | | | | | | |
| Proportion of the | 0.081% | 0.079% | 0.080% | 0.080% | 0.081% | 0.084% | 0.080% | 0.080% | 0.081% | 0.084% |
| population | | | | | | | | | | |
| exposed | | | | | | | | | | |
| Liver cancer | | | | | | | | | | |
| Attributable | 0.071% | 0.066% | 0.058% | 0.046% | 0.035% | 0.030% | 0.058% | 0.043% | 0.024% | 0.012% |
| Fraction | 0.4 | 07 | 00 | 0.5 | 00 | 0.5 | 00 | 20 | 40 | 40 |
| Attributable deaths | 34 | 37 | 38 | 35 | 28 | 25 | 38 | 32 | 19 | 10 |
| Attributable | 34 | 36 | 37 | 32 | 26 | 22 | 37 | 30 | 17 | 9 |
| registrations 'Avoided' cancers | | | 0 | 0 | 0 | 0 | 0 | 3 | 8 | 10 |
| YLLs | 481 | E 00 | 506 | 433 | 338 | 288 | 504 | 397 | o 227 | 112 |
| DALYs | _ | 509 519 | 515 | 433 441 | 345 | 200 294 | 50 4 514 | 397 405 | 232 | 112 |
| | 490 | 519 | 515 | 44 1 | 345 | 294 | 514 | 405 | 232 | 114 |
| Kidney cancer Attributable | 0.046% | 0.042% | 0.038% | 0.034% | 0.031% | 0.031% | 0.038% | 0.033% | 0.030% | 0.028% |
| Fraction | 0.046% | 0.042% | 0.038% | 0.034% | 0.031% | 0.031% | 0.038% | 0.033% | 0.030% | 0.028% |
| Attributable deaths | 13 | 14 | 14 | 15 | 15 | 15 | 14 | 14 | 14 | 14 |
| Attributable deaths | 31 | 32 | 33 | 31 | 30 | 30 | 33 | 31 | 29 | 27 |
| registrations | 31 | 52 | 33 | 31 | 30 | 30 | 33 | 31 | 20 | 21 |
| 'Avoided' cancers | | | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| YLLs | 189 | 196 | 196 | 187 | 180 | 178 | 196 | 184 | 170 | 162 |
| DALYs | 216 | 224 | 223 | 214 | 205 | 203 | 223 | 210 | 194 | 185 |
| NHL | | | | | | | | | | |
| Numbers ever | 213,655 | 216,910 | 220,378 | 221,459 | 221,459 | 221,459 | 220,378 | 221,459 | 221,459 | 221,459 |
| exposed | , | _::,::: | , | , | , | , | , | , | ,, | , |
| Proportion of the | 0.054% | 0.053% | 0.054% | 0.055% | 0.057% | 0.059% | 0.054% | 0.055% | 0.057% | 0.059% |
| , population | | | | | | | | | | |
| exposed | | | | | | | | | | |
| Attributable | 0.042% | 0.032% | 0.022% | 0.023% | 0.024% | 0.025% | 0.009% | 0.009% | 0.009% | 0.010% |



| Scenario | All scena | arios | | n scenario (pm (273 mg/ | | pliance for | | n scenario (pm (50 mg/n | 3) - Full com n³) | pliance for |
|----------------------------|-----------|-------|------|-----------------------------|------|-------------|------|-----------------------------|----------------------|-------------|
| EU Total | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Fraction | | | | | | | | | | |
| Attributable deaths | 12 | 10 | 8 | 9 | 10 | 11 | 3 | 4 | 4 | 4 |
| Attributable registrations | 28 | 24 | 18 | 19 | 20 | 21 | 7 | 8 | 8 | 8 |
| 'Avoided' cancers | | | 1 | 0 | 0 | 0 | 12 | 6 | 7 | 7 |
| YLLs | 196 | 165 | 120 | 128 | 134 | 137 | 47 | 50 | 53 | 54 |
| DALYs | 198 | 167 | 122 | 130 | 136 | 139 | 48 | 51 | 53 | 54 |



4.1.2 Monetised health benefits

The possible health benefits (i.e. avoided healthcare costs and effects of having cancer) for the introduction of an EU-wide OEL at 50 ppm and 10 ppm are shown in Table 4.3. The change in cancer impacts over the first 30 years (2010-2040) are predominately the result of chronic impacts from past (historical) exposure as well as short term acute impacts that are predicted to continue to occur in the future (these are relatively small).

There is estimated to be a greater benefit to introducing a more stringent OEL of 10 ppm. The impacts of introducing an OEL at 50 ppm are estimated to have no affect as there is already estimated to be a reduction below 50 ppm under the baseline scenario. The results are also illustrated in Figure 4.10.

Table 4.3 Health benefits of intervention over time (Present Value – 2010 €m prices)

| Costs by Gender (€m) | 2010-2019 | 2020- 2029 | 2030- 2039 | 2040-2049 | 2050-2059 | 2060-2069 | Totals |
|-------------------------------|--------------------|---------------|---------------|----------------|--------------|-----------|------------|
| Intervention | on option 2 - Intr | oduce OEL: | = 50ppm in 20 | 010, 1% remain | exposed abov | e limit | |
| Female | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 |
| Male | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 |
| Total | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 | 0 to 0 |
| Intervention | on option 3 - Intr | oduce OEL: | = 10ppm in 20 | 010, 1% remain | exposed abov | e limit | |
| Female | 0 to 0 | 1 to 7 | 7 to 31 | 5 to 19 | 8 to 25 | 7 to 23 | 28 to 105 |
| Male | 0 to 0 | 4 to 16 | 20 to 90 | 17 to 60 | 25 to 81 | 25 to 78 | 90 to 325 |
| Total | 0 to 0 | 5 to 23 | 27 to 121 | 22 to 79 | 33 to 106 | 32 to 101 | 118 to 430 |
| | | | | | | | |


Notes:



⁻ All costs are presented in present value using a discount rate of 4%

⁻ Totals may not match to sums of females and male costs due to underlying small differences in raw data and rounding to nearest million

Health benefits of introducing an EU OEL - Low cost scenario



Health benefits of introducing an EU OEL - High cost scenario




Figure 4.10 Health benefits over time of introducing an EU wide OEL (Present Value – 2010 €m prices)

These benefits will affect Member States differently depending upon the overall number of workers within affected industry groups, existing risk management measures (RMMs) and the proportion of males and females within these groups. The total benefits by Member State are shown in Figure 4.11 (low scenario) and Figure 4.12 (high scenario), where the Czech Republic, France, Germany, Italy, Poland, Spain and



the UK are predicted to particularly benefit from a possible 10pmm OEL assuming close to full compliance (99%) with the OEL³¹.

The monetised benefits of a revised OEL for trichloroethylene are likely to affect men more than women given the industrial sectors most exposed to trichloroethylene. The following industrial sectors related to metal degreasing are estimated to benefit from a revised OEL (and close to full compliance):

- Manufacture of fabricated metal products, except machinery and equipment (NACE 28).
- Manufacture of machinery except electrical (NACE 29).
- Manufacture of office machinery and computers (NACE 30).
- Manufacture of electrical machinery, apparatus, appliances and supplies (NACE 31).
- Manufacture of transport equipment (NACE 34).
- Manufacture of other transport equipment (NACE 35).
- Manufacture of furniture; manufacturing nec (not elsewhere classified) -(NACE 36).

This estimated health benefits in these sectors are shown in Figure 4.13 (low scenario) and Figure 4.14 (high scenario).

The Member State and industry groups that are predicted to benefit most from a revised OEL also vary at a gender level. This analysis is presented in the Appendix 8.6.



³¹ The assumption of full compliance is a standard assumption used in EU Impact Assessments.

Total Health benefits (2010 - 2070) of different OELs - By Member State - Low scost scenario




Figure 4.11 Total health benefits of introducing an EU wide OEL − By Member State − Low Scenario (Present Value − 2010 €m prices)



Total Health benefits (2010 - 2070) of different OELs - By Member State - High cost scenario




Figure 4.12 Total health benefits of introducing an EU wide OEL – By Member State – High Scenario (Present Value – 2010 €m prices)



Total health benefits (2010 - 2070) of different OEL levels - By Industry group - Low cost scenario




Figure 4.13 Total health benefits of introducing an EU wide OEL − By Industry Group − Low Scenario (Present Value − 2010 €m prices)



Total health benefits (2010 - 2070) of different OEL levels - By Industry group - High cost scenario




Figure 4.14 Total health benefits of introducing an EU wide OEL − By Industry Group − High Scenario (Present Value − 2010 €m prices)



As with the baseline scenario, in order to present all costs and benefits consistently in present value, it is necessary to discount all future costs and benefits. This was done using the IA guidelines recommended 4% discount rate. Since most health impacts occur over a long period of time relative to costs, the impacts of discounting are significant. As a means of sensitivity testing, different discount rates are also used. There are not expected to be any health benefits from the introduction of an OEL at 50ppm so there are no affects from the use of different discount rates. However, the overall impact of discounting can be seen in Figure 4.16 for introducing an OEL of 10ppm.

Detailed tables are included in the Appendix 8.7, with results presented using different discount rates.

Health benefits of Intervention option 2 - Low cost scenario € 1,000 Health benefits (€m) € 600 € 400 € 200 2010-2019 2020-2029 2030-2039 2040-2049 2050-2059 2060-2069 ■ No discount □ Using the EU IA guidance - 4% ■ Using a declining discount rate (4% going to 3%)

Figure 4.15 Impacts of discounting – Introducing an OEL of 10ppm



€ 1,000 € 800 € 600 € 400 € 200 € 0 2010-2019 2020-2029 2030-2039 2040-2049 2050-2059 2060-2069

Health benefits of Intervention option 2 - High cost scneario

Figure 4.16 Impacts of discounting – Introducing an OEL of 10ppm

A limitation is that the benefits of any RMMs undertaken post 2040 will not be included in this study, since the benefits of these measures to reduce occupational exposure in 2040-2070 are unlikely to be realised until after 2070 (due to the lag period) which is not estimated in this study.

4.2 ECONOMIC IMPACTS

4.2.1 Operating costs and conduct of business

Compliance costs

A regulatory impact assessment³² estimated the cost of compliance with the Solvent Emission Directive (SED) by using a closed vapour degreasing system. In particular, it estimated that the additional capital cost of a closed system for a small consumer of trichloroethylene (1-5 tonnes per annum (tpa)) as £30k (1999 prices). We consider this to be the most relevant (and recent) publicly available data source since it also considers net annual operating costs³³ (in which savings are estimated as a result of a more efficient consumption of trichloroethylene using a closed system and the cost of additional monitoring).

Table 4.4 shows the estimated cost of compliance using a closed system which has been updated into 2009 prices (€). The costs of meeting an OEL at 10 ppm for firms using less than 1 tpa of trichloroethylene are likely to be closer to the annualised costs



³² DETR (1999) Regulatory and Environmental Impact Assessment for the Implementation of the EC Solvent Emissions Directive

³³ Based on communications with closed system manufacturers (25/09/09) it is estimated that all machines require a full service once a year; twice if heavily used. The cost of a full service is estimated to be 1.5 man days for a technician.

shown for small firms (€6,384). To avoid giving a false sense of accuracy we estimate the costs are likely to be around €6k per year.

Table 4.4 Cost of compliance (closed system)

| | Small firm (1- 5 tpa) | Medium firm (5-10 tpa) | Large firm (>10 tpa) |
|--|--------------------------|---------------------------|-------------------------|
| Average Annualised Cost per firm (£ 1999 prices) | £3,300 | £5,200 | £6,500 |
| Average Annualised Cost per firm (€ 2009 prices) | €6,384 | €10,060 | €12,575 |

Source: (Regulatory Impact Assessment, Defra, 1999)

Note: Prices were converted from £ to € using a 1999 exchange rate of 1.52 -

http://www.ecb.int/stats/exchange/eurofxref/html/index.en.html

Prices were inflated from 1999 prices to 2009 prices using EuroStat Harmonised Index of Consumer Prices (HICP) -

http://epp.eurostat.ec.europa.eu/portal/page/portal/hicp/data/database

It is not possible to accurately estimate how many firms use less than 1 tpa of trichloroethylene, and therefore which may need to install a closed system. That is because we know little about trichloroethylene consumption at an installation/site level. This is further complicated since some firms may be using less than 1 tpa of trichloroethylene but may still be regulated under the SED as they may use other solvents that are covered by the SED with a combined tonnage totalling over 1 tpa. In Table 2.2 it was estimated that around 63,000 workers might have high expose to TCE. It was also estimated that around 4% of these workers may be exposed to TCE above an OEL of 50ppm and 28% of workers exposed above an OEL of 10ppm.

Using Eurostat data, on the average distribution of workers by employee size (e.g. 81% of firms are thought to employee between 1-9 workers), it is tentatively estimated (given the complicated interactions with the SED) that the number of firms requiring closed systems, could be around 400 for an OEL of 50ppm and around 3,000 firms for an OEL of 10ppm. This is shown below in Table 4.5.

Table 4.5 Number of firms potentially affected by a possible EU wide OEL

| Size of Enterprise by number of | Distribution (%) | Workers | affected | | Number of firms affected | |
|---------------------------------|---------------------|---------|----------|-------|--------------------------|--|
| employees: | | 10PPM | 50PPM | 10PPM | 50PPM | |
| Between 1 & 9 | 81% | 14,293 | 2,042 | 2,859 | 408 | |
| Between 10 & 19 | 11% | 1,999 | 286 | 133 | 19 | |
| Between 20 & 49 | 6% | 998 | 143 | 40 | 6 | |
| Between 50 and 250 | 2% | 356 | 51 | 2 | 0 | |
| Greater than 250 | 0.1% | 21 | 3 | 0 | 0 | |
| Total | | 17,667 | 2,524 | 3,034 | 433 | |

Based on an annualised cost of closed systems (€6k per firm) it is estimated that the total costs of compliance over the period 2010-69 could be up to €61m for an OEL of 50ppm and up to €428m for an OEL of 10ppm. This is shown in Table 4.6.



Table 4.6 Estimate of the total costs of closed systems (2010 € prices)

| Possible OEL | Estimate of the number of firms affected | Annual cost of compliance | Total annual cost (€m) | Total cost of compliance over the period 2010-69 (€m) |
|--------------|--|---------------------------|---------------------------|---|
| 10ppm | 3,034 | € 6,000 | € 18.2 | € 428 |
| 50ppm | 433 | € 6,000 | € 2.6 | € 61 |

Note: Total costs over the period 2010-69 have been discounted using a discount rate of 4%

Conduct of employers

If companies install closed systems, it is unlikely this will result in a need to increase regulation and monitoring the conduct of employees. In fact, the use of a closed system may result in less regulation of workers due to risks of exposure being easier to control. Obviously there should already be close monitoring of worker exposure given the classification of trichloroethylene.

Potential for closure of companies

For those metal degreasers already using a closed system and already subject to a national OEL (see Table 1.1) there are not expected to be any significant change in costs. For those firms already using a closed system, but not subject to a national OEL, the additional cost of monitoring, reporting and verifying compliance is not considered to be sufficiently high to result in firms closing down (see the administrative costs section below).

For those firms using less than 1 tpa that would need to install a closed system in order to meet an OEL of 10 ppm, there is a significant cost to consider. The estimated annualised cost of €6k per machine (which includes operating and monitoring costs plus capital costs apportioned over the lifetime of the closed system) is significant but may not necessarily trigger a decision to close production. However, the upfront capital cost (i.e. not annualised over its lifetime) of a closed system (every 10-15 years³⁴) is estimated to be in the region of €58k (2009 prices³⁵) to €135k³⁶. This is likely to be a significant cost for this sector which may potentially result in the closure of some companies. Based on communications with manufacturers, uptake of these smaller closed system units has not been as high as was previously estimated to occur as a result of the SED. It has also been suggested that some companies have closed rather than investing in a closed system.



³⁴ Based on communications with closed system manufacturers (25/09/09).

³⁵ Based on an estimate of £30k in 1999 prices from the Defra Regulatory impact assessment (1999)

This is based on cost estimates provided by manufacturers of closed systems during telephone interviews (25/09/09). The costs were estimated to be €95-135k based on the most popular size for users using less than 1tpa.

In order to be able to put the capital cost into perspective, it is useful to understand the profitability of firms in the metal degreasing sector as a means of understanding how significant the cost of compliance might be. Using the average annual operating surplus from Eurostat for the treatment and coatings of metals sector (DJ28.5) as a proxy for the metal degreasing sector we can compare the initial capital cost against the operating surplus to understand whether firms (on average) are likely to be able to afford to invest in a closed system or might instead opt to close the business or at least the metal degreasing elements of their business.

Table 4.7 shows the average operating surplus for firms with different numbers of employees. The average operating surplus increases with increasing number of employees (see Table 4.7). Table 4.7 also shows the percentage of capital cost (€58k for low cost and €135k for high cost) as a proportion of average operating surplus.

Table 4.7 Average operating surplus per enterprise size

| Size of Enterprise by | Average operating | Capital cost / operating surplus (%) | | |
|-----------------------|-------------------|--------------------------------------|----------------------|--|
| number of employees: | surplus | Low cost of capital | High cost of capital | |
| Between 1 and 9 | € 42,405 | 137% | 318% | |
| Between 10 and 19 | € 178,223 | 33% | 76% | |
| Between 20 and 49 | € 329,637 | 18% | 41% | |
| Between 50 and 250 | € 1,166,024 | 5% | 12% | |
| Greater than 250 | € 4,299,412 | 1% | 3% | |

Source: Eurostat classification of economic activities - NACE Rev.1.1: DJ 285 - Treatment of coating of metals; general mechanical engineering. Summary of average Operating Surplus (Euros) per enterprise by Size of Enterprise (number of Employees)

Note: Operating surplus is a measure of profitability of the enterprise prior to payment of interest and tax (i.e. pre-tax profit income).

As indicated in Table 4.7, the costs of capital as a percentage of annual profits are fairly small for those employing more than 250 people. However, the costs of capital as a percentage of annual profits are very significant for those employing fewer than 50 people. For those firms employing fewer than 10 people, the cost of capital is – on average – more than one year's profit. For affected small and medium sized enterprises (i.e. SMEs that do not have a closed system) it will potentially be very difficult to finance investing in a closed system using profits and, given the size of capital required, it may also be difficult for them to get access to finance from the market at a good interest rate. Therefore for affected SMEs, the costs could be considered high enough to force these companies to shut down. It is possible that some of these firms might be able to pass through additional costs by charging higher prices for their final products, especially because the OEL should be applied consistently across the EU. This should create a level playing field for firms across the EU and reduce competitiveness distortions created by differences in OELs across the EU.

Information from the environmental RRS³⁷ suggests that it may also be possible for some firms to substitute trichloroethylene in order to avoid the costs of a closed



³⁷ DEFRA (2005) Risk Reduction Strategy and Analysis of the Advantages and Drawbacks for Tetrachlorotheylene. Available at:

http://www.defra.gov.uk/environment/quality/chemicals/documents/report-tetra060203.pdf

system. Some possible substitutes include; tetrachloroethylene, n-propyl bromide, methylene chloride or bromochloromethane (though it is noted that some of these substances are now subject to increased regulatory controls and there may thus be other adverse effects associated with their use). It may also be possible to change the degreasing process although this is less likely. Trichloroethylene is principally used for hot vapor degreasing of metal components. This is only one of many methods employed to clean metal. Alternatives include other hydrocarbon solvents, aqueous formulations and water blasting or soft blasting (shot blasting using a relatively soft medium such as limestone) ³⁸.

Potential impacts for specific types of companies

Whilst the introduction of an EU-wide OEL for trichloroethylene would not specifically target companies of a particular size, it is considered likely that a greater proportion of those that do not already have closed systems in place that would allow such an OEL to be met are likely to be small companies, in particular those using less than 1 tonne per year. As indicated in Table 4.10, SMEs make up a large proportion of the treatment of coating of metal sector (NACE Code v1.1 DJ 28.5) although this does not necessarily mean only small firms would be affected (since large firms may only use small quantities).

Administrative costs to employers and public authorities

The following table (Table 4.8) describes the administrative burden to employers already subject to the Carcinogens Directive but will now incur costs of introducing an EU wide OEL on to Annex III.

Table 4.8 Administrative burdens to employers

| Ту | pe of administrative cost | Relevant article(s) | Type of cost | Significance |
|----|--|--|--|---------------------|
| 1. | Change in practice to use closed systems when using the substance. | 5 – Prevention and reduction of exposure | These costs are already estimated in the cost of compliance section - This will only affect those firms that do not have or use closed systems | Estimated elsewhere |



³⁸ Information from - Risk Reduction Strategy and Analysis of Advantages and Drawbacks for Trichloroethylene Defra (2005) (Report prepared by AMEC Environment & Infrastructure UK Ltd UK Ltd).

| Ту | pe of administrative cost | Relevant article(s) | Type of cost | Significance |
|---------------------------------|--|---|---|--------------|
| 2. | Develop/update health and safety and best practice guidance for: Minimising use and exposure to workers to the substance Redesign work processes and engineering controls to avoid/minimise release of carcinogens or mutagens Hygiene measures, in particular regular cleaning of floors, walls and other surfaces Information for workers Warnings and safety signs Drawing up plans to deal with emergencies likely to result in abnormally high exposure | 5 – Prevention and reduction of exposure 7 – Unforeseen exposure 8 – Foreseeable exposure 9 – Access to risk areas 10 – Hygiene and individual protection | Firms will already have been required to develop/update health and safety and best practice guidance. The guidance and procedures may be required to be updated as control measures may change in light of a more stringent OEL. Some firms may need to redesign work practices to minimise exposure to workers and the number of workers exposed. The costs of implementing controls on exposure (such as LEV or PPE) are already estimated in the costs of compliance section. | Low |
| 3.4. | Additional costs of training new and existing staff in line with requirements of the Directive Additional costs of making information available to | 11 – Information and training of workers 12 – | Firms will already have been required to ensure training and adequate aware of risks and control measures to | Low |
| 5. | employees Consultation with employees on compliance with the Directive | Information for workers 13 – Consultation and participation with workers | reduce/minimise exposure. Largely one-off cost if the revised OEL requires a change in control measures/working practice. | |

Note: Readers should consult the Directive for the official wording around specific requirements. This table provides only a summary of what are perceived to be the most significant administrative requirements of the Directive. Grading of the significance of impacts is subjective and is based on professional judgement.

The following table (Table 4.9) describes the administrative burden to competent authorities already enforcing the Carcinogens Directive but will now incur costs of introducing an EU wide OEL on to Annex III.



Table 4.9 Administrative burdens to Competent Authorities

| Ту | pe of administrative cost | Relevant article(s) | Type of cost | Significance |
|----|---|---|---|-----------------------------------|
| 1. | Communication with the Commission on provisions in national law to enforce the revised OEL. | 19 – Notifying the commission 20 – Repeal | Largely one-off cost of transposing the revised OEL into national law | Low - Medium (one-off cost) |
| 2. | Time and costs of implementing revised OEL into national law (consultation process) | | | |

Note: Readers should consult the Directive for the official wording around specific requirements. This table provides only a summary of what are perceived to be the most significant administrative requirements of the Directive. Grading of the significance of impacts is subjective and is based on professional judgement.

Third countries

There is not expected to be any significant impacts on countries outside of the EU. There are already national OELs in place in several Member States as well as regulation such as the SED and the voluntary industry agreement (Charter for the safe use of Trichloroethylene in metal cleaning) which affect all EU Member States, meaning that any firms using trichloroethylene above 1 tpa should already have closed systems in place. It is also possible for some firms to substitute trichloroethylene in order to avoid the costs of a closed system (for firms using less than 1 tpa).

However, given that the costs of installing a closed system are likely to be prohibitive for some smaller firms (based on the above comparison with average operating surplus); there is the potential that some products would cease to be produced in the EU. This production could potentially be relocated to third countries outside the EU.

An EU-wide OEL could, however, be expected to increase the dissemination of improved technologies and production methods. It is possible that increased sales (demand) could, in the long-run, bring down the overall cost of closed systems with manufacturers of closed systems able to benefit from economies of scale in production and better R&D developments in closed systems once there is sufficient demand to warrant investment of more funds in production and research.

4.2.2 Impact on innovation and research

There have already been noticeable changes within the metal degreasing industry as a result of concerns related to trichloroethylene and other solvents through the SED and the voluntary industry agreement (Charter for the safe use of Trichloroethylene in metal cleaning). These include increased use of closed systems, as well as use of alternative solvents. As such, there has already been significant development of new production methods and technologies.

The average expenditure per firm on R&D in the treatment and coatings of metals sector (NACE code v1.1 - DJ28.5) based on data from Eurostat, is less than €1000 per



year with the overall number of employees working in R&D fairly low (1,539 out of a sector total of just over 1.1million).

Also, given that any changes required to comply with an OEL will most likely affect smaller companies (or at least those using smaller quantities of trichloroethylene), these companies are likely to adopt techniques that are already being applied within other parts of the industry, rather than investing time and resources in new alternative technologies.

4.2.3 Macroeconomic impact

The metal greasing industry is included within the treatment and coatings of metals sector (NACE code v1.1 - DJ28.5) but it is not known what proportion of the sector the metal greasing industry comprises. The treatment and coatings of metals sector spent approximately €63bn in 2006 on goods and services within the EU economy. This is small compared to the total value of goods and services in the manufacturing sector of €5trillion in 2006. Given this and also that users of trichloroethylene consuming more than 1 tpa should already be using a closed system and therefore largely unaffected, (especially if they already have to comply with monitoring, reporting and verification requirements for a national OEL), it is very unlikely that the costs of compliance would be large enough collectively to cause significant macroeconomic impacts. It is also possible that some firms will substitute trichloroethylene or use an alternative process for metal degreasing. Therefore, there may only be a small redistribution of goods and services bought (i.e. to those firms producing the alternative substance rather than trichloroethylene) rather than any significant change in overall gross output.

4.3 SOCIAL IMPACTS

4.3.1 Employment and labour markets

The treatment and coatings of metals sector (NACE code v1.1 - DJ28.5) employed around 1.1 million people in 2006. There was a steady growth in 2003-2006 of around 2% with the largest growth seen in Eastern Europe. The largest employment levels were in Italy (254,144), Germany (192,314), France (141,939) and the UK (117,992) in 2006. Eurostat EU-27 level data indicates that, in 2006, the sector was dominated by firms employing fewer than 10 people, accounting for 81% of all enterprises; firms employing fewer than 20 people accounted for 92% of the sector. This is shown in Table 4.10.

Table 4.10 Breakdown of enterprises by employee size (year: 2006)

| Size of Enterprise by number of employees: | EU 27 level employment (numbers) | Percentage (%) |
|---|-------------------------------------|---------------------------|
| Between 1 and 9 | 114,639 | 81% |
| Between 10 and 19 | 16,031 | 11% |
| Between 20 and 49 | 8,007 | 6% |
| Between 50 and 250 | 2,852 | 2% |
| Greater than 250 | 170 | 0% |
| Source: Eurostat classification of economic activities mechanical engineering. Number of Enterprises by S | | pating of metals; general |



The data indicate that the majority of the sector is made up of SMEs (firms with fewer than 50 employees make up 98% of total firms in the sector). It is not possible to make a direct correlation between the sizes of firms using less than 1 tpa of trichloroethylene and the likely size of firms, since it is likely that both large and small employers use less than 1 tpa of trichloroethylene. It would be reasonable to assume that given the majority of the wider sector (DJ28.5) is composed of firms with fewer than 20 workers, the metal degreasing firms that would incur compliance costs (i.e. those that use <1tpa and do not currently have closed systems) will have fewer than 20 workers. Table 4.7 showed that these smaller firms were most vulnerable to the capital cost of a closed system and may opt to close down or switch to an alternative substance or process (if it is technically feasible to do so). If they do decide to close down there is potential for some increased levels of unemployment in Italy, Germany, Poland and the UK in particular (these countries have the most employers with numbers of employees between 1 and 9). SMEs can comprise a variety of skilled, semi-skilled and unskilled labour and therefore the length of any unemployment may largely depend on current external macroeconomic conditions rather than the skills of affected workers.

The use of closed vapour degreasing systems should not affect the skills required by metal degreasing workers. Training costs are expected to be minimal. Maintenance could be undertaken by technicians of closed system manufacturers, otherwise training might be required to ensure risks of exposure are correctly managed. Depending on the frequency of use, maintenance is likely to be required once or twice a year (at a cost of 1.5 days for a technician) ³³. Since the closed system reduces risks of human exposure in a way that should not inhibit production, there should also be improvements in working conditions.

4.3.2 Changes in end products

There should not be any changes in end products since it would still be possible to use trichloroethylene and comply with an EU-wide OEL by using a closed system. There are alternatives available for some metal degreasing applications, which would be technically feasible, implying that there would not be any significant changes in end products.

4.4 ENVIRONMENTAL IMPACTS

The EU risk assessment for trichloroethylene³⁹ concluded that there was a need to limit the risks to the environment associated with use of the substance in metal cleaning. However, as detailed in the environmental risk reduction strategy, once the implications of the Solvent Emissions Directive are taken into account (as of 2007), it was concluded that there would be no need for further limiting the environmental risks in this area. Nonetheless, if certain companies are required to install closed systems when using trichloroethylene (i.e. a certain proportion of generally smaller consumers of the substance); there could be a reduction in overall emissions of trichloroethylene to the environment. Likewise, if introduction of an EU-wide OEL were to lead to substitution of trichloroethylene using alternative degreasing agents, there would be a



³⁹ EU Risk Assessment Report on Trichloroethylene. Vol 31, 2004. Publication EUR 21057 EN. Available at: http://ecb.jrc.ec.europa.eu/documents/Existing- Chemicals/RISK ASSESSMENT/REPORT/trichloroethylenereport018.pdf

reduction in emissions to the environment. This could potentially be offset, however, by increased emissions of the replacement substance(s).

5 COMPARISON OF OPTIONS

The main identified impacts of introducing an OEL of 10 or 50 ppm are shown in the tables below relative to the baseline scenario.



Table 5.1 Comparison of health impacts by option (Present Value – 2010 €m prices)

| Baseline scenario – National OELs | | Introduce EU wide OEL=50ppm | | Introduce EU wide OEL=10ppm | |
|---|---|--|--|--|---|
| Health costs | Health benefits | Health costs | Health benefits | Health costs | Health benefits |
| As set out in section 2.5, the costs of cancer (kidney, liver and NHL) over the period 2010-70 is estimated to be: | It is assumed that exposures fall by 7% per year in the future continuing the historical trend in reduced exposure. | There is not expected to be a reduction in health costs relative to the baseline scenario. | There are not expected to be any health benefits since the estimated geometric mean exposure is already 5.5ppm at an EU level and taking into consideration there is already declining exposure assumed under the baseline scenario. | There is expected to be a reduction in health costs relative to the baseline scenario. This is shown as a benefit (see right). | There is expected to be more significant health benefits of introducing an OEL at 10ppm, which is also the SCOEL recommended TWA, than at 50ppm due to the additional |
| - Females: €105m to €1,287m | Therefore there is expected to be avoided health costs going forward in the absence of further regulatory intervention. | | | | |
| - Males: €1,210 m to €4,370m | | | | | reduction in exposure. |
| - Total: €1,582m to €5,657m | | | | | The total health benefit is estimated to be between €118-430m |
| This range takes into consideration tangible costs (e.g. lost income, | | | | | (male and female) ove the whole period of 2010-2070. |
| lost output from reduced productivity, medical costs, life years lost) and intangible costs (e.g. emotional and physical suffering from having cancer). | | | | | Health benefits post 2070 is not included in the estimate. |

Note: Costs and benefits under the intervention options are relative to the baseline scenario (i.e. are not absolute impacts but differences)



Table 5.2 Comparison of economic impacts by option (Present Value – 2010 €m prices)

| Baseline scenario – National OELs | | Introduce EU wide OEL=50ppm | | Introduce EU wide OEL=10ppm | | |
|---|---|--|---|---|--|--|
| Economic costs | Economic benefits | Economic costs | Economic benefits | Economic costs | Economic benefits | |
| Industries affected (e.g. in particular the metal degreasing sectors) are estimated to incur costs of installing and using closed systems to achieve national OELs, the solvent emissions directive (SED) if use is above 1tpa and the voluntary industry agreement (Charter for the safe use of Trichloroethylene in metal cleaning) meaning any firms using trichloroethylene above 1tpa should already have closed systems in place. | Closed systems manufacturers should benefit from increased demand over time for closed systems. | There are not expected to be any significant costs relative to those already being incurred under the baseline scenario as firms are already investing in closed systems which will help to control exposure to below 50ppm. | There are not expected to be any significant benefits relative to those already being incurred under the baseline scenario as firms are already investing in closed systems which will help sales for closed systems manufacturers. | The GM exposure of 5.5ppm under the baseline means that the majority of the sector will comply with an OEL of 10ppm. There is insufficient data to estimate the number of firms that will require closed systems in order to meet an OEL of 10ppm. It is estimated that the cost of a small unit (when <1tpa is used) is €58-135k (annualised as €6k per year). For large sized firms this is not estimated to be a significant cost but for SMEs this could be more difficult to finance as it can represent a significant proportion of their operating surplus (see table 5.4), potentially leading to business closures. However it may be possible for firms to use an alternative substance to avoid the cost of a closed system or instead to pass through costs in terms of higher final good prices. Since the OEL will be applied at an EU level, there will be less competitive distortions within the EU if prices were increased. | Closed systems manufacturers should benefit from increased demand over time for closed systems. There may also be a sales redistribution benefit to manufacturers of alternative substances. | |

Note: Costs and benefits under the intervention options are relative to the baseline scenario (i.e. are not absolute impacts but differences)



Table 5.3 Comparison of social impacts by option (Present Value – 2010 €m prices)

| Baseline scenario – National OELs | | Introduce EU wide OEL=50ppm | | Introduce EU wide OEL=10ppm | | |
|---|--|---|-----------------|---|---|--|
| Social costs | Social benefits | Social costs | Social benefits | Social costs | Social benefits | |
| Under the baseline there is estimated to a greater number of firms installing | Since the closed system reduces risks of human exposure in a way that | There are not expected to be any significant changes relative to the baseline scenario. | | There are not expected to be any significant changes relative to the baseline scenario. | | |
| and using closed systems for metal degreasing. | · · | | | | Table 5.4 showed that smaller firms were most vulnerable to the capital | |
| The use of closed vapour degreasing systems should not affect the skills required by metal degreasing workers. Training costs are expected to be minimal. | also be improvements in working conditions. | | | cost of a closed sy | stem and may opt to ch to an alternative | |
| | There should not be any changes in end products | | | substance or process (if technically feasible to do so). If they do decide to | | |
| | since would still be possible to use trichloroethylene and comply with the EU-wide | | | , | s potential for some | |
| | | | | Poland and the Uk | (in particular), who | |
| | OEL by using a closed system. | | | have the most emplo numbers of emplo 9. | yees between 1 and | |

Note: Costs and benefits under the intervention options are relative to the baseline scenario (i.e. are not absolute impacts but differences)



Table 5.4 Comparison of macroeconomic impacts by option (Present Value – 2010 €m prices

| Baseline scenario – National OELs | | Introduce EU wide OEL=50ppm | | Introduce EU wide OEL=10ppm | |
|--|------------------------|--|------------------------|--|------------------------|
| Macroeconomic costs | Macroeconomic benefits | Macroeconomic costs | Macroeconomic benefits | Macroeconomic costs | Macroeconomic benefits |
| There is not expected to be any noticeable macroeconomic impacts under any scenario. | | There is not expected to be any noticeable macroeconomic impacts under any scenario. | | There is not expected to be any noticeable macroeconomic impacts under any scenario. | |

The treatment and coatings of metals sector spent approximately €63bn in 2006 on goods and services within the EU economy. This is not significant considering the total value of goods and services in the manufacturing sector was €5trillion in 2006 and that users of trichloroethylene above 1tpa per year should already be using a closed system and therefore largely unaffected, (especially if they already have to comply with monitoring, reporting and verification requirements for national OELs). Therefore, while much of the sector may (or may not) be using less than 1tpa, it is very unlikely that the costs would be high enough collectively to cause significant macroeconomic impacts. It is also possible that some firms will substitute trichloroethylene or use an alternative process for metal degreasing. Therefore, there may only be a small redistribution of goods and services bought (i.e. to those firms producing the alternative substance rather than trichloroethylene) rather than any significant change in overall gross output.



Table 5.5 Comparison of environmental impacts by option (Present Value – 2010 €m prices)

| Baseline scenario – National OELs | | Introduce EU wide OEL=50ppm | | Introduce EU wide OEL=10ppm | |
|--|------------------------|--|------------------------|--|------------------------|
| Environmental costs | Environmental benefits | Environmental costs | Environmental benefits | Environmental costs | Environmental benefits |
| There is not expected to be any noticeable change in environmental impacts | | There is not expected to be any noticeable change in environmental impacts | | There is not expected to be any noticeable change in environmental impacts | |

The EU risk assessment for trichloroethylene concluded that there was a need to limit the risks to the environment associated with use of the substance in metal cleaning. However, as detailed in the environmental risk reduction strategy, once the implications of the Solvent Emissions Directive are taken into account (as of 2007), it was concluded that there would be no need for further limiting the environmental risks in this area. Nonetheless, if certain companies are required to install closed systems when using trichloroethylene (i.e. a certain proportion of generally smaller consumers of the substance), there could be a reduction in overall emissions of trichloroethylene to the environment.



6 CONCLUSIONS

We estimate that in 2006 approximately 74,000 workers in the EU were potentially exposed to TCE with most exposed workers being involved in the manufacture of fabricated metal products including machinery and transport equipment or the manufacture of furniture. In these industries, about 28% of workers are exposed to more than 10 ppm and about 2% are exposed are to more than 50 ppm. The estimated overall weighted GM exposure across all countries and industries is 4.6 with a GSD of 3.7.

We estimate that in 2010 in the EU there will be about 34 deaths from liver cancer and a similar number of registrations that might be attributable to past exposure to TCE, which corresponds to about 0.071% of all liver cancer deaths amongst the exposed workers. There will also be about 13 deaths from kidney cancer and about 31 registrations, accounting for 0.046% of all kidney cancer deaths amongst the exposed workers. There will be about 12 deaths from NHL and 28 registrations accounting for 0.054% of all NHL deaths amongst exposed workers. If no specific actions are taken to reduce exposure to TCE, based on the assumption that current employment and exposure levels are maintained, the predicted numbers of cancer deaths in 2060 attributable to TCE would be 21, 15 and 7 for cancers of the liver and kidney and NHL respectively with the corresponding numbers of registrations between 18, 29 and 15. The predicted loss of life expectancy in 2010 attributable to these cancers is 866 YLLs and 904 DALYs falling to 515 YLLs and 544 DALYs in 2060.

The introduction of an OEL of 50 ppm is predicted to reduce the number of liver cancer deaths and registrations in 2060 attributable to TCE from current levels to 25 and 22 respectively, the number of kidney cancer deaths and registrations to 15 and 30 respectively and the number of NHL deaths and registrations to 11 and 21 respectively. The predicted loss of life expectancy attributable to these cancers in 2060 would be 603 YLLs and 636 DALYs.

The introduction of an OEL of 10 ppm is predicted to reduce the number of liver cancer deaths and registrations in 2060 attributable to TCE from current levels to 10 and 9 respectively, the number of kidney cancer deaths and registrations to 14 and 27 respectively and the number of NHL deaths and registrations to 4 and 8 respectively. The predicted loss of life expectancy attributable to these cancers in 2060 would be 328 YLLs and 353 DALYs.

The total net health benefits from setting an OEL at 10 ppm are estimated to be estimated between €1118m and €430m for the period of 2010-2070, whereas there would be no significant health benefit in setting an OEL of 50 ppm.

Given that the current GM exposure to TCE is 5.5 ppm, it is anticipated that the majority of employers will be able to comply with an OEL of 50ppm (with around 4% of workers potentially affected above this OEL). There may be more workers affected with an OEL of 10 ppm (with around 28% of workers potentially affected above this OEL).

However, since under the Solvents Emissions Directive (SED) those firms using solvents that are covered by the SED (i.e. not just TCE) above 1 tonnes per year (tpa)



are required to install and use a closed system. This is also reinforced by a voluntary industry agreement (Charter for the safe use of Trichloroethylene in metal cleaning) whereby TCE will not be sold to those without an installed closed system. Therefore it is possible that the main costs of compliance with an OEL (i.e. the use of closed systems) may already have been incurred by industries affected.

Given the interactions with the SED, it is difficult to provide a good estimate of the number of firms affected, but it is possible to examine costs per firm affected. The capital cost of installing closed systems (estimated to be between €58k-135k) per enterprise, which is appropriately €6k per year).

Therefore the cost to comply with an OEL of 10 ppm (or 50ppm) is unlikely to be significant for large businesses but for SMEs, the majority of affected enterprises, it could represent a substantial proportion of their operating surplus, which could potentially lead to some business closures. Many businesses, however, may be able to switch to use of an alternative substance or pass on the additional costs by charging more for their products. The macroeconomic, social and environmental impacts of introducing an OEL of 10 ppm are not predicted to be significant (relative to the baseline scenario).



7 REFERENCES

Alexander, D.D., Kelsh, M.A., Mink, P.J., *et al.* (2007) A Meta-Analysis of Occupational Trichloroethylene Exposure and Liver Cancer. *International Archives of Occupational and Environmental Health*, **81(2)**, 127-143.

Bakke B, Stewart PA and Waters MA (2007) Uses of and Exposure to Trichlorotheylene in US Industry: A Systematic Literature Review. *Journal of Occupational and Environmental Hygiene*; **4(5)**: 375-390.

Creely KS, Cowie H, van Tongeren M, Kromhout H, Tickner J and Cherrie JW (2007) Trends in Inhalation Exposure – A Review of the Data in the Published Scientific Literature. *Annals of Occupational Hygiene*; **51(8)**: 665-678.

Creely KS, Tickner J, Soutar AJ, Hughson GW, Pryde DE, Warren ND, Rae R, Money C, Phillips A and Cherrie JW (2005) Evaluation and Further Development of EASE Model 2.0. *Annals of Occupational Hygiene*; **49(2)**: 135-145.

Kauppinen, T. (2001) Finnish Occupational Exposure Databases. *Applied Occupational and Environmental Hygiene*; **16(2)**:154-158.

Mandel JH, Kelsh MA, Mink PJ, Alexander DD, Kalmes RM, Weingart M, Yost L, Goodman M (2006) Occupational trichloroethylene exposure and non-Hodgkins lymphoma: a meta-analysis and review. *Occup Environ Med*; **63**: 597-607.

Mirabelli, D and Kauppinen, T. (2005). Occupational Exposures to Carcinogens in Italy: An Update of CAREX Database. *Int J Occup Environ Health*; **11**:53-63.

Raaschou-Nielsen O, Hansen J, Thomsen BL, Johansen I, Lipworth L, McLaughlin JK and Olsen JH (2002) *Applied Occupational and Environmental Hygiene*; **17(10)**: 693-703.

Ruder AM, Ward EM, Brown DP (2001) Mortality in dry cleaning workers: an update. *Amer J Indust Med*; **39**: 121-132.

Siemiatycki, J., Richardson, L., Straif, K., Latreille, B., Lakhani, R., Campbell, S., Rousseau, M-C. and Boffetta, P., 2004. Listing Occupational Carcinogens. *Environmental Health Perspectives*; **112**: 1447 – 1460.

Von Grote (2003) Reduction of occupational exposure to perchloroethylene and trichloroethylene in metal degreasing over the last 30 years: influences of technology innovation and legislation. *Journal of Exposure Analysis and Environmental Epidemiology*; **13**: 325-340.

Wartenberg D, Reyner D, Siegel Scott C (2000) Trichloroethylene and cancer: epidemiologic evidence. *Environmental Health Perspectives Supplements;* **108**: 161-176.



8 APPENDIX

8.1 ESTIMATED NUMBER OF EMPLOYEES IN EACH INDUSTRY GROUP – MEMBER STATE BREAKDOWN – MALES AND FEMALES

Table 8.1.1 Number of workers exposed to beryllium by Member State and NACE code – males and females

| | NACE | code | | | | | | | | | | | | | |
|----------------|-------|-----------|--------|-------|-----------|--------|-------|-----------|--------|-------|-----------|--------|-------|-----------|--------|
| | | 21 | | | 22 | | | 24 | | | 25 | | | 28 | |
| | Total | Male | Female |
| Austria | 5 | 4 | 1 | 5 | 4 | 1 | 48 | 39 | 9 | 53 | 43 | 10 | 215 | 174 | 41 |
| Belgium | 4 | 3 | 1 | 7 | 6 | 1 | 124 | 101 | 24 | 51 | 42 | 10 | 204 | 165 | 39 |
| Bulgaria | 3 | 2 | 2 | 3 | 2 | 2 | 46 | 24 | 22 | 45 | 24 | 22 | 125 | 65 | 60 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 1 | 2 | 2 | 1 | 11 | 9 | 3 |
| Czech Republic | 6 | 4 | 2 | 9 | 6 | 3 | 74 | 48 | 26 | 161 | 105 | 56 | 501 | 326 | 175 |
| Denmark | 2 | 2 | 1 | 7 | 5 | 2 | 53 | 39 | 14 | 39 | 29 | 11 | 142 | 104 | 38 |
| Estonia | 1 | 0 | 0 | 1 | 1 | 1 | 5 | 3 | 2 | 10 | 5 | 4 | 39 | 21 | 17 |
| Finland | 32 | 24 | 8 | 6 | 4 | 1 | 32 | 23 | 8 | 29 | 22 | 8 | 138 | 102 | 36 |
| France | 24 | 18 | 5 | 38 | 29 | 9 | 489 | 376 | 112 | 439 | 338 | 101 | 1288 | 992 | 296 |
| Germany | 43 | 34 | 9 | 73 | 57 | 16 | 814 | 635 | 179 | 720 | 561 | 158 | 2367 | 1846 | 521 |
| Greece | 2 | 2 | 1 | 6 | 4 | 1 | 32 | 25 | 8 | 22 | 17 | 5 | 121 | 92 | 29 |
| Hungary | 5 | 3 | 2 | 7 | 4 | 3 | 57 | 36 | 21 | 78 | 49 | 29 | 224 | 141 | 83 |
| Ireland | 1 | 1 | 0 | 3 | 2 | 1 | 44 | 33 | 11 | 19 | 14 | 5 | 39 | 29 | 10 |
| Italy | 0 | 0 | 0 | 33 | 25 | 8 | 355 | 266 | 89 | 382 | 286 | 95 | 2123 | 1592 | 531 |
| Latvia | 0 | 0 | 0 | 2 | 1 | 1 | 8 | 5 | 3 | 9 | 5 | 4 | 29 | 17 | 12 |
| Lithuania | 1 | 0 | 0 | 2 | 1 | 1 | 11 | 6 | 5 | 18 | 9 | 9 | 55 | 29 | 27 |
| Luxembourg | N | ot Avail | able | N | lot avail | able | 2 | 2 | 0 | 12 | 10 | 2 | 13 | 11 | 2 |
| Malta | N | lot avail | able | N | ot availa | able |
| Netherlands | 7 | 5 | 1 | 16 | 13 | 3 | 113 | 94 | 19 | 62 | 52 | 11 | 295 | 245 | 50 |
| Poland | 13 | 9 | 4 | 19 | 13 | 6 | 192 | 129 | 63 | 286 | 192 | 94 | 833 | 558 | 275 |
| Portugal | 4 | 2 | 1 | 7 | 4 | 3 | Ν | lot avail | able | 49 | 29 | 20 | 265 | 156 | 109 |
| Romania | 5 | 3 | 2 | 7 | 4 | 3 | 87 | 47 | 40 | 89 | 48 | 41 | 308 | 167 | 142 |



| | NACE | code | | | | | | | | | | | | | |
|----------------|-------|------|--------|-------|------|--------|-------|------|--------|-------|------|--------|-------|------|--------|
| | | 21 | | | 22 | | | 24 | | | 25 | | | 28 | |
| | Total | Male | Female |
| Slovakia | 2 | 1 | 1 | 2 | 1 | 1 | 23 | 15 | 8 | 40 | 25 | 14 | 104 | 66 | 37 |
| Slovenia | 2 | 1 | 1 | 2 | 1 | 1 | 25 | 16 | 8 | 26 | 17 | 9 | 102 | 67 | 35 |
| Spain | 0 | 0 | 0 | 31 | 24 | 7 | 248 | 193 | 55 | 228 | 178 | 50 | 1127 | 879 | 248 |
| Sweden | 12 | 10 | 3 | 10 | 8 | 2 | 77 | 60 | 17 | 54 | 42 | 12 | 255 | 199 | 56 |
| United Kingdom | 22 | 18 | 4 | 66 | 53 | 13 | 381 | 309 | 72 | 396 | 320 | 75 | 998 | 808 | 190 |
| Total | 196 | 146 | 50 | 364 | 275 | 89 | 3343 | 2524 | 818 | 3320 | 2465 | 855 | 11924 | 8863 | 3061 |

| | NACE | code | | | | | | | | | | | | | |
|----------------|-------|-----------|--------|-------|------------|--------|-------|-----------|--------|-------|-----------|--------|-------|-----------|--------|
| | | 29 | | | 30 | | | 31 | | | 34 | | | 35 | |
| | Total | Male | Female | Total | Male | Female | Total | Male | Female | Total | Male | Female | Total | Male | Female |
| Austria | 187 | 152 | 36 | 6 | 5 | 1 | 28 | 23 | 5 | 169 | 137 | 32 | 58 | 47 | 11 |
| Belgium | 101 | 81 | 19 | 5 | 4 | 1 | 18 | 15 | 3 | 240 | 194 | 46 | 48 | 39 | 9 |
| Bulgaria | 161 | 84 | 77 | 11 | 6 | 6 | 22 | 11 | 11 | 14 | 7 | 7 | 58 | 30 | 28 |
| Cyprus | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |
| Czech Republic | 376 | 244 | 131 | 57 | 37 | 20 | 116 | 75 | 40 | 574 | 373 | 201 | 111 | 72 | 39 |
| Denmark | 144 | 105 | 39 | 6 | 4 | 2 | 24 | 17 | 6 | 33 | 24 | 9 | 40 | 29 | 11 |
| Estonia | 13 | 7 | 6 | 2 | 1 | 1 | 6 | 3 | 3 | 11 | 6 | 5 | 15 | 8 | 7 |
| Finland | 134 | 99 | 35 | 2 | 1 | 0 | 18 | 13 | 5 | 34 | 25 | 9 | 55 | 40 | 14 |
| France | 703 | 542 | 162 | 43 | 33 | 10 | 151 | 116 | 35 | 1365 | 1051 | 314 | 757 | 583 | 174 |
| Germany | 2430 | 1895 | 535 | 216 | 168 | 47 | 519 | 405 | 114 | 4286 | 3343 | 943 | 711 | 555 | 156 |
| Greece | 52 | 40 | 13 | N | lot avail | able | 8 | 6 | 2 | 15 | 11 | 4 | 71 | 54 | 17 |
| Hungary | 158 | 99 | 58 | 49 | 31 | 18 | 69 | 44 | 26 | 261 | 165 | 97 | 41 | 26 | 15 |
| Ireland | 27 | 20 | 7 | 71 | 53 | 18 | 8 | 6 | 2 | 20 | 15 | 5 | 19 | 15 | 5 |
| Italy | 1305 | 979 | 326 | 81 | 61 | 20 | 185 | 139 | 46 | 847 | 635 | 212 | 553 | 415 | 138 |
| Latvia | 17 | 10 | 7 | 1 | 1 | 0 | 4 | 2 | 2 | 6 | 4 | 3 | 28 | 16 | 12 |
| Lithuania | 25 | 13 | 12 | 2 | 1 | 1 | 7 | 3 | 3 | 6 | 3 | 3 | 37 | 19 | 18 |
| Luxembourg | 5 | 5 | 1 | 0 | 0 | 0 | N | lot avail | able | N | ot availa | able | N | lot avail | able |
| Malta | N | lot avail | able | N | lot availa | able | ١ | lot avail | able | N | ot availa | able | N | lot avail | able |



| | NACE | code | | | | | | | | | | | | | |
|----------------|-------|------|--------|--------|---------|--------|-------|------|--------|-------|-----------|--------|-------|------|--------|
| | | 29 | | | 30 | | | 31 | | | 34 | | | 35 | |
| | Total | Male | Female | Total | Male | Female | Total | Male | Female | Total | Male | Female | Total | Male | Female |
| Netherlands | 206 | 171 | 35 | 29 | 24 | 5 | 17 | 14 | 3 | 115 | 95 | 20 | 128 | 107 | 22 |
| Poland | 477 | 320 | 157 | 35 | 24 | 12 | 107 | 72 | 35 | 613 | 411 | 202 | 363 | 243 | 120 |
| Portugal | 110 | 65 | 45 | Not av | ailable | | 25 | 15 | 10 | N | ot availa | able | 54 | 32 | 22 |
| Romania | 238 | 128 | 109 | 24 | 13 | 11 | 84 | 45 | 39 | 319 | 172 | 147 | 308 | 166 | 142 |
| Slovakia | 104 | 67 | 38 | 8 | 5 | 3 | 46 | 29 | 17 | 148 | 95 | 53 | 37 | 24 | 13 |
| Slovenia | 62 | 41 | 21 | 4 | 3 | 1 | 15 | 10 | 5 | 45 | 30 | 15 | 14 | 9 | 5 |
| Spain | 445 | 347 | 98 | 27 | 21 | 6 | 88 | 68 | 19 | 807 | 629 | 178 | 296 | 231 | 65 |
| Sweden | 270 | 210 | 59 | 24 | 18 | 5 | 25 | 19 | 5 | 438 | 341 | 96 | 113 | 88 | 25 |
| United Kingdom | 640 | 518 | 122 | 139 | 113 | 26 | 125 | 101 | 24 | 910 | 737 | 173 | 751 | 608 | 143 |
| Total | 8393 | 6245 | 2148 | 840 | 626 | 214 | 1713 | 1253 | 460 | 11277 | 8506 | 2772 | 4666 | 3456 | 1210 |

| | NACE | code | | | | | | | | | | | | | 1 |
|----------------|-------|------------|--------|-------|------|--------|-------|------|--------|-------|------|--------|-------|----------|--------|
| | | 36 | | | 73 | | | 80 | | | 0 | | | Grand To | tal |
| | Total | Male | Female | Total | Male | Female | Total | Male | Female | Total | Male | Female | Total | Male | Female |
| Austria | 506 | 410 | 96 | 5 | 3 | 2 | 22 | 6 | 15 | 125 | 59 | 66 | 1432 | 1105 | 326 |
| Belgium | 274 | 222 | 52 | 6 | 4 | 2 | 37 | 12 | 26 | 103 | 53 | 49 | 1222 | 940 | 281 |
| Bulgaria | 397 | 206 | 191 | 0 | 0 | 0 | 21 | 7 | 15 | 86 | 54 | 32 | 994 | 522 | 472 |
| Cyprus | 28 | 21 | 7 | 0 | 0 | 0 | 2 | 1 | 2 | 12 | 5 | 6 | 65 | 44 | 21 |
| Czech Republic | 775 | 504 | 271 | 6 | 3 | 2 | 28 | 7 | 21 | 110 | 54 | 56 | 2902 | 1857 | 1045 |
| Denmark | 298 | 217 | 80 | 6 | 4 | 2 | 21 | 9 | 12 | 109 | 59 | 50 | 925 | 647 | 277 |
| Estonia | 137 | 75 | 62 | 0 | 0 | 0 | 6 | 1 | 5 | 23 | 8 | 15 | 268 | 140 | 127 |
| Finland | 156 | 116 | 41 | 6 | 4 | 3 | 50 | 16 | 33 | 140 | 56 | 84 | 832 | 546 | 285 |
| France | 1637 | 1261 | 377 | 38 | 25 | 13 | 176 | 60 | 116 | 736 | 324 | 412 | 7884 | 5748 | 2136 |
| Germany | 2665 | 2079 | 586 | 85 | 54 | 30 | 206 | 41 | 164 | 1330 | 878 | 452 | 16463 | 12550 | 3912 |
| Greece | N | lot availa | ble | 8 | 5 | 3 | 30 | 11 | 19 | 87 | 39 | 48 | 455 | 306 | 149 |
| Hungary | 358 | 226 | 132 | 6 | 4 | 2 | 31 | 8 | 24 | 110 | 52 | 58 | 1454 | 887 | 568 |
| Ireland | N | lot availa | ble | 2 | 1 | 1 | 13 | 3 | 9 | 67 | 33 | 33 | 332 | 226 | 106 |
| Italy | 3336 | 2502 | 834 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9200 | 6900 | 2300 |



| | NACE | code | | | | | | | | | | | | | |
|----------------|-------|------------|--------|-------|----------|--------|-------|------|--------|-------|------|--------|-------|----------|--------|
| | | 36 | | | 73 | | | 80 | | | 0 | | | Grand To | tal |
| | Total | Male | Female | Total | Male | Female | Total | Male | Female | Total | Male | Female | Total | Male | Female |
| Latvia | 163 | 95 | 69 | 1 | 1 | 1 | 9 | 2 | 7 | 34 | 14 | 20 | 310 | 170 | 139 |
| Lithuania | 329 | 171 | 158 | 1 | 0 | 0 | 13 | 2 | 11 | 43 | 14 | 29 | 550 | 273 | 277 |
| Luxembourg | 3 | 3 | 0 | N | ot avail | able | 1 | 1 | 1 | 4 | 2 | 2 | 41 | 33 | 8 |
| Malta | N | lot availa | ble | N | ot avail | able | 1 | 0 | 1 | 4 | 2 | 2 | 5 | 2 | 3 |
| Netherlands | 424 | 352 | 72 | 30 | 22 | 9 | 53 | 21 | 32 | 198 | 87 | 111 | 1695 | 1303 | 392 |
| Poland | 2372 | 1589 | 783 | 4 | 2 | 1 | 112 | 27 | 85 | 359 | 190 | 169 | 5786 | 3778 | 2008 |
| Portugal | 663 | 391 | 272 | 1 | 1 | 0 | 31 | 8 | 22 | 98 | 42 | 56 | 1306 | 745 | 561 |
| Romania | 1225 | 662 | 564 | 21 | 13 | 7 | 41 | 11 | 30 | 163 | 98 | 65 | 2919 | 1577 | 1342 |
| Slovakia | 202 | 129 | 73 | 4 | 2 | 2 | 16 | 3 | 13 | 53 | 25 | 28 | 789 | 489 | 301 |
| Slovenia | 172 | 114 | 59 | 2 | 1 | 1 | 7 | 2 | 6 | 27 | 15 | 12 | 506 | 328 | 178 |
| Spain | 1975 | 1540 | 434 | 13 | 9 | 5 | 105 | 39 | 66 | 630 | 290 | 340 | 6021 | 4450 | 1571 |
| Sweden | 545 | 425 | 120 | N | ot avail | able | 48 | 12 | 36 | 154 | 72 | 81 | 2025 | 1507 | 519 |
| United Kingdom | 1935 | 1567 | 368 | 93 | 63 | 30 | 251 | 73 | 178 | 989 | 505 | 485 | 7695 | 5793 | 1901 |
| Total | 20577 | 14877 | 5700 | 337 | 222 | 115 | 1331 | 382 | 949 | 5791 | 3029 | 2762 | 74073 | 52868 | 21205 |



8.2 SUMMARY OF OCCUPATIONAL EXPOSURE DATA FOR TRICHLOROETHYLENE

 Table 8.2.1 Summary of occupational exposure data for trichloroethylene

| | | | | | | E | xposur | e (ppn | n) | |
|--------|--|------------------------------|---------|---------|-----|-------|--------|--------|-----|-----|
| NACE | Description | Source | Country | Year(s) | No. | Min | Max | AM | GM | GSD |
| 22 | Printing | Raaschou-Nielsen et al, 2002 | Denmark | 1980-89 | 12 | | | 6.3 | 3.5 | 2.9 |
| 24 | Manufacture of TCE | RAR, 2004 | UK | 1991-94 | 584 | | 49 | | 0.6 | |
| 24 | Manufacture of TCE | RAR, 2004 | UK | 1991-94 | 171 | | 128 | | 0.5 | |
| 24 | Manufacture of TCE | RAR, 2004 | UK | 1991-94 | 837 | | 128 | | 0.6 | |
| 24 | Manufacture of TCE | RAR, 2004 | UK | 1991-94 | 298 | | 1.3 | | 590 | |
| 24 | Use as an intermediate, manufacture of HCFC 133a | RAR, 2004 | UK | 1991-94 | 162 | | 11.5 | 0.2 | | |
| 24 | Use as an intermediate, manufacture of HCFC 133a | RAR, 2004 | UK | 1991-94 | 7 | | 1.5 | 0.3 | | |
| 24 | Use as an intermediate, manufacture of HFC 134a | RAR, 2004 | UK | 1991-94 | 57 | | 1.6 | 0.2 | | |
| 24 | Use as an intermediate, manufacture of HFC 134a | RAR, 2004 | UK | 1991-94 | 34 | | 2.7 | 0.2 | | |
| 28, 29 | Iron and metal | Raaschou-Nielsen et al, 2002 | Denmark | 1980-89 | 371 | | | 13.0 | 5.0 | 4.5 |
| 28 | Vapour degreasing | Selden <i>et al</i> , 1993 | UK | 1988 | 29 | | | 5.1 | | |
| 29 | Degreasing | NIOSH, 1984 (140) | US | 1984 | 18 | 0.3 | 26 | 85 | 22 | 6.9 |
| 29 | Degreasing | NIOSH, 1984 (140) | US | 1984 | 12 | 2.2 | 274 | 86 | 30 | 8.4 |
| 29 | Degreasing | NIOSH, 1990 (141) | US | 1990 | 2 | 4.5 | 5.2 | 4.9 | | |
| 29 | Degreasing | NIOSH, 1986 (143) | US | 1986 | 3 | 107 | 137 | 120 | 120 | 1.1 |
| 29 | Degreasing | NIOSH, 1986 (143) | US | 1986 | 18 | 20 | 89 | 38 | 36 | 1.3 |
| 29 | Degreasing | NIOSH, 1980 (144) | US | 1980 | 1 | 0.6 | | | | |
| 30 | NA | NIOSH, 1980 (164) | US | 1980 | 28 | 0.1 | 27 | 2.7 | 0.7 | 4.6 |
| 30 | NA | NIOSH, 1980 (164) | US | 1980 | 49 | 0.038 | 40 | 2.5 | 0.7 | 4.6 |
| 30 | Lacquer | NIOSH, 1993 (165) | US | 1993 | 4 | 0.04 | 0.04 | | | |
| 31 | Degreasing | NIOSH, 1990 (145) | US | 1990 | 6 | 0.01 | 11 | 4.1 | 1 | 14 |
| 32 | Electronics | Raaschou-Nielsen et al, 2002 | Denmark | 1980-89 | 24 | | | 7.8 | 0.7 | 7.3 |
| 34 | Degreasing | NIOSH, 1982 (146) | US | 1982 | 2 | 0.3 | 1.1 | 0.7 | | |
| 35.3 | Degreasing | NIOSH, 1982 (147) | US | 1982 | 1 | 4.1 | | | | |
| 35.3 | Degreasing | NIOSH, 1982 (147) | US | 1982 | 29 | 0.2 | 39 | 5.7 | 2.2 | 4 |
| 36.2 | Degreasing | NIOSH, 1988 | US | 1988 | 8 | 15 | 33 | 25 | 24 | 1.3 |
| 93 | Dry-cleaning shops | Raaschou-Nielsen et al, 2002 | Denmark | 1980-89 | 2 | | | 4.1 | 2.0 | 6.2 |



| | | | | | | | Expo | sure (pp | om) | |
|---|---------|---------|-----|--------|-----|------|------|----------|-----------|-----------|
| Source | Country | Year(s) | No. | Min | Max | AM | GM | GSD | 90th %ile | 95th %ile |
| NIOSH, 1980 (144) | US | 1980 | 1 | 0.6 | | | | | | |
| NIOSH, 1982 (149) | US | 1981 | 2 | 8.0 | 1.7 | 1.2 | | | | |
| NIOSH, 1982 (146) | US | 1982 | 2 | 0.3 | 1.1 | 0.7 | | | | |
| NIOSH, 1982 (147) | US | 1982 | 1 | 4.1 | | | | | | |
| NIOSH, 1982 (147) | US | 1982 | 29 | 0.2 | 39 | 5.7 | 2.2 | 4 | | |
| NIOSH, 1983 | US | 1983 | 4 | <0.004 | 25 | 7.8 | 0.2 | 136 | | |
| NIOSH, 1983 | US | 1983 | 4 | <0.004 | 25 | 7.8 | 0.2 | 136 | | |
| NIOSH, 1984 (140) | US | 1984 | 18 | 0.3 | 26 | 85 | 22 | 6.9 | | |
| NIOSH, 1984 (140) | US | 1984 | 12 | 2.2 | 274 | 86 | 30 | 8.4 | | |
| NIOSH, 1986 (143) | US | 1986 | 3 | 107 | 137 | 120 | 120 | 1.1 | | |
| NIOSH, 1986 (143) | US | 1986 | 18 | 20 | 89 | 38 | 36 | 1.3 | | |
| Selden et al, 1993 | UK | 1988 | 29 | | | 5.1 | | | | |
| NIOSH, 1988 | US | 1988 | 8 | 15 | 33 | 25 | 24 | 1.3 | | |
| NIOSH, 1990 (141) | US | 1990 | 2 | 4.5 | 5.2 | 4.9 | | | | |
| NIOSH, 1990 (145) | US | 1990 | 6 | 0.01 | 11 | 4.1 | 1 | 14 | | |
| Raaschou-Nielsen <i>et al</i> , 2002 | Denmark | 1980-89 | 371 | | | 13.0 | 5.0 | 4.5 | | |
| Raaschou-Nielsen <i>et al</i> , 2002 | Denmark | 1980-89 | 24 | | | 7.8 | 0.7 | 7.3 | | |
| Raaschou-Nielsen <i>et al</i> , 2002 | Denmark | 1980-89 | 45 | | | 32.6 | 11.2 | 6.4 | | |
| Raaschou-Nielsen <i>et al</i> , 2002 | Denmark | 1980-89 | 23 | | | 0.9 | 0.6 | 2.4 | | |
| Raaschou-Nielsen <i>et al</i> , 2002 | Denmark | 1980-89 | 371 | | | 13 | | | | |
| Raaschou-Nielsen <i>et al</i> , 2002 | Denmark | 1980-89 | 45 | | | 32.6 | 11.2 | 6.4 | | |
| Raaschou-Nielsen <i>et al</i> , 2002 | Denmark | 1980-89 | 23 | | | 0.9 | 0.6 | 2.4 | | |
| Bock <i>et al</i> , 1999 | Germany | 1990-95 | 14 | | | 7.6 | | | 56.3 | 109.6 |
| Bock et al, 1999 | Germany | 1990-95 | 23 | | | 4.1 | | | 52.2 | 104.8 |



| | | | | | | | Expo | sure (pp | om) | |
|---------------------------|-----------|---------|-----|-----|-----|------|------|----------|-----------|-----------|
| Source | Country | Year(s) | No. | Min | Max | AM | GM | GSD | 90th %ile | 95th %ile |
| Bock <i>et al</i> , 1999 | Germany | 1990-95 | 159 | | | 10 | | | 44.3 | 67.4 |
| Bock <i>et al</i> , 1999 | Germany | 1990-95 | 30 | | | 44.6 | | | 131.7 | 168.9 |
| Negab <i>et al</i> , 1997 | Australia | 1997* | 5 | | | 8.8 | | | | |



8.3 ESTIMATED DEATHS AND REGISTRATIONS IN THE EU FROM KIDNEY AND LIVER CANCER AND NHL

Table 8.3.1 Forecast number of kidney and liver cancer in ages 25+ (ages 15+ registrations) and NHL cancers in ages 15-84 (males) and 15-79 (females) (ages 15+ for registrations), based on projected EU country populations

| Kidney cancer deaths | Men | | | | | | Women | | | | | |
|--|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| FTY | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Ages 25+ | | | | | | | | | | | | |
| Austria | 265 | 332 | 407 | 483 | 536 | 539 | 203 | 226 | 273 | 318 | 359 | 358 |
| Belgium | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | 217 | 224 | 238 | 249 | 252 | 245 | 97 | 102 | 107 | 109 | 109 | 107 |
| Cyprus | 9 | 12 | 17 | 22 | 26 | 32 | 3 | 4 | 5 | 7 | 8 | 9 |
| Czech Republic | 750 | 926 | 1,100 | 1,245 | 1,364 | 1,433 | 414 | 481 | 565 | 618 | 658 | 702 |
| Denmark | 209 | 251 | 297 | 316 | 334 | 341 | 131 | 152 | 176 | 189 | 195 | 199 |
| Estonia | 76 | 82 | 92 | 106 | 115 | 121 | 42 | 47 | 49 | 55 | 56 | 57 |
| Finland | 214 | 272 | 335 | 363 | 369 | 381 | 133 | 153 | 183 | 196 | 196 | 196 |
| France | 2,168 | 2,603 | 3,139 | 3,576 | 3,830 | 4,006 | 1,152 | 1,320 | 1,542 | 1,780 | 1,882 | 1,905 |
| Germany (including ex- GDR from 1991) | 3,143 | 3,832 | 4,343 | 4,867 | 4,997 | 4,756 | 2,118 | 2,401 | 2,636 | 2,935 | 3,052 | 2,868 |
| Greece | 344 | 395 | 451 | 526 | 591 | 614 | 169 | 199 | 221 | 251 | 275 | 280 |
| Hungary | 459 | 511 | 585 | 645 | 712 | 754 | 271 | 298 | 330 | 351 | 369 | 384 |
| Ireland | 110 | 146 | 191 | 239 | 281 | 322 | 89 | 115 | 149 | 190 | 231 | 265 |
| Italy | 2,219 | 2,628 | 3,037 | 3,489 | 3,838 | 3,849 | 1,212 | 1,390 | 1,564 | 1,771 | 1,961 | 1,966 |
| Latvia | 124 | 137 | 153 | 176 | 195 | 209 | 86 | 91 | 96 | 102 | 108 | 109 |
| Lithuania | 192 | 218 | 249 | 287 | 320 | 329 | 112 | 122 | 135 | 149 | 156 | 155 |
| Luxembourg | 11 | 14 | 18 | 22 | 25 | 27 | 4 | 5 | 6 | 9 | 10 | 11 |
| Malta | 21 | 26 | 31 | 35 | 37 | 40 | 11 | 15 | 16 | 17 | 19 | 19 |
| Netherlands | 616 | 791 | 966 | 1,074 | 1,104 | 1,089 | 357 | 424 | 517 | 587 | 618 | 602 |
| Poland | 1,683 | 2,017 | 2,396 | 2,715 | 2,914 | 3,036 | 952 | 1,112 | 1,315 | 1,465 | 1,523 | 1,586 |



| Kidney cancer deaths | Men | | | | | | Women | | | | | |
|-------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| FTY | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Ages 25+ | | | | | | | | | | | | |
| Portugal | 214 | 252 | 298 | 349 | 392 | 415 | 111 | 129 | 148 | 171 | 188 | 197 |
| Romania | 399 | 435 | 503 | 554 | 589 | 591 | 218 | 237 | 266 | 292 | 311 | 311 |
| Slovakia | 215 | 273 | 335 | 380 | 422 | 421 | 137 | 167 | 200 | 223 | 244 | 247 |
| Slovenia | 78 | 102 | 127 | 152 | 162 | 167 | 52 | 58 | 69 | 75 | 77 | 76 |
| Spain | 1,216 | 1,491 | 1,840 | 2,242 | 2,594 | 2,743 | 707 | 836 | 994 | 1,193 | 1,371 | 1,444 |
| Sweden | 341 | 411 | 478 | 517 | 557 | 588 | 264 | 299 | 349 | 380 | 405 | 428 |
| UK | 2,392 | 2,820 | 3,282 | 3,682 | 4,047 | 4,330 | 1,334 | 1,490 | 1,739 | 1,979 | 2,181 | 2,316 |
| European Union (27 countries) | 17,592 | 21,030 | 24,645 | 28,014 | 30,261 | 31,128 | 10,548 | 12,081 | 13,880 | 15,699 | 16,849 | 17,122 |

| Kidney cancer registrations | Men | | | | | | Women | | | | | |
|--------------------------------------|-------|--------|--------|--------|--------|--------|-------|-------|-------|-------|-------|-------|
| FTY | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Ages 15+ | | | | | | | | | | | | |
| Austria | 859 | 1,023 | 1,182 | 1,283 | 1,322 | 1,328 | 602 | 682 | 784 | 855 | 880 | 875 |
| Belgium | 904 | 1,061 | 1,205 | 1,297 | 1,344 | 1,383 | 552 | 620 | 696 | 753 | 776 | 791 |
| Bulgaria | 286 | 287 | 299 | 307 | 293 | 274 | 128 | 129 | 131 | 131 | 126 | 118 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | 1,762 | 2,099 | 2,371 | 2,599 | 2,739 | 2,722 | 1,087 | 1,245 | 1,366 | 1,463 | 1,523 | 1,517 |
| Denmark | 509 | 608 | 671 | 706 | 708 | 728 | 295 | 344 | 386 | 408 | 411 | 418 |
| Estonia | 155 | 165 | 182 | 200 | 212 | 216 | 105 | 109 | 113 | 117 | 117 | 114 |
| Finland | 496 | 608 | 665 | 677 | 686 | 700 | 392 | 461 | 504 | 513 | 508 | 509 |
| France | 5,082 | 5,918 | 6,580 | 7,011 | 7,242 | 7,501 | 2,536 | 2,894 | 3,201 | 3,422 | 3,478 | 3,508 |
| Germany (including ex-GDR from 1991) | 9,345 | 10,627 | 11,625 | 12,003 | 11,733 | 11,203 | 5,270 | 5,722 | 6,177 | 6,351 | 6,224 | 5,919 |
| Greece | 741 | 839 | 956 | 1,068 | 1,114 | 1,088 | 444 | 497 | 549 | 603 | 626 | 608 |
| Hungary | 1,024 | 1,117 | 1,230 | 1,335 | 1,406 | 1,422 | 680 | 728 | 768 | 804 | 824 | 819 |



| Kidney cancer registrat | tions | Men | | | | | | Women | | | | | |
|-------------------------------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | FTY | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Ages 15+ | | | | | | | | | | | | | |
| Ireland | | 245 | 320 | 404 | 495 | 561 | 596 | 135 | 174 | 220 | 271 | 312 | 336 |
| Italy | | 6,315 | 7,244 | 8,188 | 8,900 | 9,057 | 8,890 | 2,887 | 3,210 | 3,544 | 3,809 | 3,858 | 3,739 |
| Latvia | | 174 | 183 | 197 | 215 | 222 | 218 | 134 | 135 | 137 | 140 | 137 | 129 |
| Lithuania | | 331 | 355 | 391 | 426 | 446 | 443 | 305 | 322 | 348 | 367 | 367 | 360 |
| Luxembourg | | 33 | 42 | 51 | 58 | 63 | 67 | 21 | 25 | 30 | 34 | 38 | 40 |
| Malta | | 18 | 22 | 25 | 26 | 27 | 28 | 18 | 22 | 25 | 26 | 28 | 29 |
| Netherlands | | 1,340 | 1,654 | 1,875 | 1,961 | 1,944 | 1,953 | 772 | 925 | 1,060 | 1,128 | 1,119 | 1,109 |
| Poland | | 3,618 | 4,170 | 4,687 | 5,174 | 5,350 | 5,243 | 1,857 | 2,137 | 2,377 | 2,558 | 2,626 | 2,569 |
| Portugal | | 515 | 589 | 675 | 752 | 802 | 811 | 267 | 304 | 342 | 375 | 394 | 392 |
| Romania | | 801 | 871 | 969 | 1,062 | 1,093 | 1,070 | 484 | 517 | 553 | 591 | 603 | 591 |
| Slovakia | | 494 | 591 | 694 | 778 | 817 | 804 | 303 | 351 | 397 | 438 | 452 | 437 |
| Slovenia | | 141 | 171 | 197 | 211 | 211 | 201 | 87 | 98 | 109 | 115 | 115 | 110 |
| Spain | | 3,221 | 3,907 | 4,728 | 5,440 | 5,731 | 5,603 | 1,481 | 1,741 | 2,022 | 2,256 | 2,385 | 2,354 |
| Sweden | | 760 | 883 | 973 | 1,039 | 1,091 | 1,147 | 516 | 579 | 637 | 679 | 708 | 738 |
| UK | | 4,413 | 5,116 | 5,747 | 6,278 | 6,705 | 7,207 | 2,539 | 2,848 | 3,197 | 3,505 | 3,725 | 3,934 |
| European Union (27 countries) | | 43,210 | 50,025 | 56,333 | 60,925 | 62,887 | 63,056 | 23,829 | 26,806 | 29,752 | 31,955 | 32,744 | 32,495 |

| | Liver cancer deaths | MEN | | | | | | WOMEN | | | | | |
|----------------|---------------------|------|------|------|------|-------|-------|-------|------|------|------|------|------|
| | FTY | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Austria | | 586 | 724 | 875 | 986 | 1,071 | 1,075 | 301 | 340 | 402 | 467 | 507 | 505 |
| Belgium | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | | 580 | 599 | 644 | 683 | 704 | 704 | 369 | 395 | 417 | 435 | 447 | 443 |
| Cyprus | | 26 | 37 | 51 | 65 | 80 | 99 | 18 | 24 | 32 | 40 | 47 | 56 |
| Czech Republic | | 605 | 727 | 882 | 998 | 1,081 | 1,144 | 348 | 401 | 478 | 519 | 551 | 595 |



| Liver cancer deaths | MEN | | | | | | WOMEN | | | | | |
|--------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| FTY | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Denmark | 222 | 267 | 306 | 323 | 332 | 340 | 108 | 130 | 155 | 174 | 184 | 184 |
| Estonia | 41 | 44 | 50 | 55 | 60 | 66 | 42 | 46 | 48 | 52 | 55 | 54 |
| Finland | 272 | 349 | 421 | 442 | 446 | 465 | 189 | 222 | 267 | 291 | 291 | 290 |
| France | 5,892 | 7,093 | 8,343 | 9,202 | 9,655 | 10,044 | 2,057 | 2,352 | 2,784 | 3,204 | 3,382 | 3,415 |
| Germany (including ex-GDR from 1991) | 4,762 | 5,692 | 6,488 | 7,184 | 7,229 | 6,924 | 2,478 | 2,802 | 3,058 | 3,411 | 3,547 | 3,333 |
| Greece | 1,032 | 1,203 | 1,381 | 1,623 | 1,826 | 1,906 | 578 | 714 | 792 | 925 | 1,055 | 1,113 |
| Hungary | 443 | 496 | 560 | 617 | 676 | 705 | 304 | 334 | 375 | 402 | 417 | 446 |
| Ireland | 111 | 152 | 202 | 259 | 323 | 375 | 91 | 118 | 157 | 201 | 246 | 288 |
| Italy | 6,827 | 8,006 | 9,310 | 10,725 | 11,575 | 11,460 | 3,642 | 4,161 | 4,694 | 5,375 | 5,940 | 5,925 |
| Latvia | 87 | 93 | 104 | 118 | 127 | 133 | 56 | 56 | 58 | 61 | 60 | 59 |
| Lithuania | 91 | 99 | 117 | 134 | 145 | 154 | 68 | 73 | 81 | 93 | 97 | 99 |
| Luxembourg | 23 | 32 | 41 | 52 | 62 | 67 | 12 | 14 | 18 | 23 | 28 | 31 |
| Malta | 12 | 16 | 18 | 20 | 21 | 22 | 5 | 7 | 9 | 10 | 11 | 11 |
| Netherlands | 374 | 478 | 587 | 656 | 677 | 664 | 222 | 267 | 329 | 378 | 393 | 380 |
| Poland | 1,127 | 1,363 | 1,690 | 1,932 | 2,106 | 2,287 | 1,028 | 1,213 | 1,454 | 1,676 | 1,737 | 1,854 |
| Portugal | 523 | 610 | 713 | 817 | 905 | 951 | 215 | 253 | 290 | 331 | 368 | 388 |
| Romania | 1,656 | 1,828 | 2,104 | 2,378 | 2,570 | 2,593 | 909 | 1,003 | 1,134 | 1,268 | 1,378 | 1,425 |
| Slovakia | 232 | 301 | 364 | 424 | 476 | 486 | 166 | 197 | 243 | 297 | 321 | 354 |
| Slovenia | 108 | 138 | 164 | 181 | 187 | 181 | 67 | 79 | 91 | 106 | 111 | 112 |
| Spain | 3,203 | 3,905 | 4,837 | 5,929 | 6,818 | 7,022 | 1,632 | 1,914 | 2,298 | 2,832 | 3,336 | 3,529 |
| Sweden | 390 | 470 | 541 | 587 | 627 | 663 | 274 | 310 | 360 | 392 | 417 | 438 |
| United Kingdom | 2,023 | 2,404 | 2,800 | 3,166 | 3,447 | 3,726 | 1,238 | 1,383 | 1,616 | 1,842 | 2,032 | 2,151 |
| European Union (27 countries) | 31,134 | 37,187 | 43,707 | 49,614 | 53,264 | 54,636 | 16,461 | 18,866 | 21,831 | 24,929 | 26,918 | 27,464 |



| Liver cancer registrations | MEN | | | | | | WOMEN | | | | | |
|--------------------------------------|-------|--------|--------|--------|--------|--------|-------|-------|-------|-------|-------|-------|
| FTY | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Austria | 594 | 713 | 846 | 936 | 966 | 977 | 290 | 324 | 382 | 427 | 440 | 441 |
| Belgium | 392 | 464 | 538 | 584 | 607 | 627 | 254 | 289 | 332 | 363 | 376 | 384 |
| Bulgaria | 299 | 309 | 328 | 347 | 356 | 346 | 204 | 214 | 222 | 228 | 229 | 221 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | 620 | 758 | 863 | 963 | 1,036 | 1,033 | 319 | 380 | 418 | 450 | 482 | 488 |
| Denmark | 213 | 259 | 290 | 305 | 305 | 315 | 130 | 152 | 169 | 180 | 181 | 184 |
| Estonia | 39 | 43 | 48 | 53 | 58 | 60 | 32 | 33 | 35 | 36 | 36 | 35 |
| Finland | 167 | 213 | 235 | 240 | 244 | 250 | 95 | 116 | 128 | 131 | 130 | 131 |
| France | 5,537 | 6,574 | 7,413 | 7,947 | 8,223 | 8,526 | 1,420 | 1,653 | 1,858 | 2,006 | 2,041 | 2,058 |
| Germany (including ex-GDR from 1991) | 3,360 | 3,859 | 4,319 | 4,504 | 4,413 | 4,233 | 1,527 | 1,651 | 1,824 | 1,907 | 1,867 | 1,785 |
| Greece | 1,406 | 1,600 | 1,833 | 2,076 | 2,193 | 2,144 | 673 | 761 | 847 | 941 | 985 | 955 |
| Hungary | 712 | 795 | 876 | 975 | 1,067 | 1,095 | 463 | 506 | 533 | 559 | 585 | 589 |
| Ireland | 68 | 90 | 116 | 146 | 168 | 179 | 17 | 22 | 28 | 34 | 39 | 43 |
| Italy | 9,489 | 10,982 | 12,619 | 13,993 | 14,327 | 14,057 | 4,130 | 4,635 | 5,216 | 5,816 | 5,973 | 5,784 |
| Latvia | 59 | 63 | 70 | 78 | 84 | 85 | 52 | 52 | 54 | 56 | 56 | 56 |
| Lithuania | 76 | 83 | 95 | 106 | 114 | 117 | 69 | 73 | 80 | 85 | 86 | 85 |
| Luxembourg | 17 | 23 | 29 | 33 | 36 | 38 | 7 | 8 | 10 | 12 | 13 | 14 |
| Malta | 12 | 17 | 20 | 22 | 24 | 26 | 2 | 3 | 3 | 3 | 3 | 3 |
| Netherlands | 243 | 303 | 346 | 365 | 360 | 363 | 94 | 111 | 125 | 134 | 133 | 131 |
| Poland | 972 | 1,175 | 1,350 | 1,492 | 1,613 | 1,630 | 991 | 1,173 | 1,331 | 1,427 | 1,501 | 1,500 |
| Portugal | 477 | 550 | 638 | 719 | 770 | 780 | 201 | 228 | 258 | 285 | 302 | 301 |
| Romania | 1,602 | 1,758 | 1,994 | 2,257 | 2,396 | 2,370 | 815 | 888 | 977 | 1,081 | 1,135 | 1,120 |
| Slovakia | 239 | 297 | 356 | 407 | 443 | 445 | 145 | 175 | 206 | 230 | 248 | 249 |
| Slovenia | 89 | 111 | 131 | 143 | 146 | 140 | 36 | 41 | 46 | 49 | 50 | 48 |
| Spain | 3,516 | 4,319 | 5,344 | 6,326 | 6,817 | 6,667 | 1,514 | 1,800 | 2,173 | 2,571 | 2,815 | 2,769 |



| Liver cancer registration | s MEN | | | | | | WOMEN | | | | | |
|-------------------------------|-------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| FT | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Sweden | 336 | 397 | 440 | 473 | 496 | 528 | 205 | 232 | 256 | 275 | 285 | 301 |
| United Kingdom | 1,773 | 2,076 | 2,358 | 2,590 | 2,764 | 2,997 | 1,105 | 1,252 | 1,437 | 1,603 | 1,701 | 1,826 |
| European Union (27 countries) | 32,249 | 37,934 | 43,519 | 47,801 | 49,852 | 50,251 | 14,686 | 16,729 | 18,933 | 20,700 | 21,438 | 21,415 |

| NHL deaths | MEN | | | | | | WOMEN | | | | | |
|--------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| FTY | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Austria | 297 | 366 | 436 | 510 | 540 | 545 | 177 | 211 | 233 | 263 | 238 | 239 |
| Belgium | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | 162 | 164 | 172 | 179 | 181 | 175 | 114 | 115 | 115 | 111 | 109 | 95 |
| Cyprus | 21 | 28 | 37 | 45 | 55 | 65 | 12 | 16 | 20 | 23 | 26 | 28 |
| Czech Republic | 343 | 428 | 512 | 570 | 639 | 668 | 241 | 289 | 296 | 300 | 331 | 290 |
| Denmark | 201 | 250 | 283 | 305 | 311 | 311 | 108 | 131 | 137 | 142 | 135 | 130 |
| Estonia | 38 | 42 | 47 | 53 | 59 | 64 | 41 | 40 | 43 | 43 | 42 | 42 |
| Finland | 192 | 243 | 288 | 302 | 302 | 315 | 116 | 137 | 145 | 137 | 129 | 133 |
| France | 2,259 | 2,683 | 3,200 | 3,566 | 3,770 | 3,921 | 1,219 | 1,368 | 1,598 | 1,614 | 1,569 | 1,556 |
| Germany (including ex-GDR from 1991) | 3,135 | 3,685 | 4,177 | 4,666 | 4,572 | 4,411 | 1,982 | 2,096 | 2,310 | 2,379 | 1,976 | 1,971 |
| Greece | 370 | 413 | 474 | 545 | 602 | 610 | 215 | 216 | 242 | 257 | 254 | 231 |
| Hungary | 315 | 353 | 393 | 430 | 473 | 484 | 254 | 270 | 277 | 266 | 284 | 256 |
| Ireland | 152 | 204 | 269 | 338 | 414 | 478 | 76 | 99 | 124 | 146 | 165 | 175 |
| Italy | 2,461 | 2,848 | 3,256 | 3,714 | 3,976 | 3,916 | 1,548 | 1,647 | 1,825 | 2,016 | 1,908 | 1,675 |
| Latvia | 68 | 70 | 77 | 81 | 86 | 87 | 58 | 56 | 57 | 58 | 54 | 54 |
| Lithuania | 88 | 96 | 109 | 121 | 131 | 134 | 82 | 83 | 89 | 95 | 87 | 85 |
| Luxembourg | 15 | 18 | 23 | 27 | 29 | 31 | 13 | 15 | 19 | 22 | 22 | 24 |
| Malta | 14 | 19 | 23 | 25 | 27 | 29 | 7 | 8 | 8 | 8 | 8 | 8 |
| Netherlands | 581 | 735 | 878 | 959 | 958 | 951 | 336 | 404 | 450 | 460 | 417 | 409 |



| N | IHL deaths | MEN | | | | | | WOMEN | | | | | |
|-----------------------------|------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | FTY | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Poland | | 1,122 | 1,344 | 1,606 | 1,779 | 1,927 | 2,037 | 834 | 937 | 1,076 | 1,014 | 1,078 | 1,035 |
| Portugal | | 326 | 373 | 432 | 493 | 540 | 556 | 220 | 238 | 265 | 285 | 287 | 264 |
| Romania | | 490 | 534 | 599 | 653 | 691 | 681 | 356 | 367 | 405 | 407 | 413 | 371 |
| Slovakia | | 157 | 196 | 240 | 278 | 308 | 324 | 115 | 135 | 158 | 159 | 168 | 157 |
| Slovenia | | 71 | 91 | 114 | 132 | 141 | 143 | 49 | 53 | 62 | 62 | 59 | 55 |
| Spain | | 1,382 | 1,664 | 2,023 | 2,450 | 2,782 | 2,810 | 830 | 949 | 1,133 | 1,310 | 1,342 | 1,184 |
| Sweden | | 330 | 403 | 456 | 493 | 523 | 555 | 204 | 247 | 251 | 265 | 266 | 275 |
| United Kingdom | | 2,227 | 2,611 | 2,998 | 3,341 | 3,595 | 3,887 | 1,299 | 1,478 | 1,623 | 1,784 | 1,749 | 1,881 |
| European Union (27 countrie | es) | 17,041 | 20,049 | 23,319 | 26,240 | 27,911 | 28,515 | 10,815 | 11,930 | 13,368 | 13,979 | 13,546 | 13,044 |

| NHL registrations | MEN | | | | | | WOMEN | | | | | |
|--------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| FTY | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Austria | 721 | 829 | 951 | 1,036 | 1,061 | 1,070 | 588 | 651 | 741 | 806 | 827 | 822 |
| Belgium | 998 | 1,146 | 1,292 | 1,389 | 1,432 | 1,475 | 733 | 819 | 914 | 985 | 1,014 | 1,033 |
| Bulgaria | 191 | 190 | 196 | 202 | 198 | 185 | 151 | 152 | 154 | 155 | 151 | 140 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | 586 | 701 | 783 | 855 | 913 | 914 | 588 | 667 | 724 | 766 | 792 | 791 |
| Denmark | 435 | 506 | 551 | 573 | 577 | 591 | 350 | 397 | 433 | 452 | 457 | 463 |
| Estonia | 61 | 64 | 70 | 75 | 80 | 82 | 66 | 68 | 70 | 72 | 72 | 70 |
| Finland | 479 | 579 | 630 | 641 | 647 | 661 | 478 | 541 | 581 | 590 | 583 | 581 |
| France | 5,828 | 6,758 | 7,506 | 8,014 | 8,269 | 8,560 | 4,273 | 4,919 | 5,490 | 5,897 | 5,997 | 6,045 |
| Germany (including ex-GDR from 1991) | 6,696 | 7,431 | 8,139 | 8,448 | 8,225 | 7,884 | 6,228 | 6,637 | 7,148 | 7,378 | 7,198 | 6,858 |
| Greece | 345 | 381 | 421 | 457 | 472 | 462 | 294 | 321 | 345 | 370 | 380 | 369 |
| Hungary | 519 | 566 | 617 | 672 | 715 | 725 | 534 | 575 | 605 | 631 | 652 | 651 |
| Ireland | 290 | 371 | 459 | 542 | 615 | 656 | 226 | 285 | 351 | 422 | 476 | 509 |



| NI | HL registrations | MEN | | | | | | WOMEN | | | | | |
|-----------------------|------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | FTY | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 |
| Italy | | 6,287 | 7,093 | 7,842 | 8,388 | 8,493 | 8,334 | 5,085 | 5,629 | 6,183 | 6,644 | 6,731 | 6,523 |
| Latvia | | 61 | 64 | 73 | 81 | 87 | 92 | 58 | 58 | 62 | 64 | 66 | 67 |
| Lithuania | | 105 | 111 | 126 | 139 | 149 | 155 | 80 | 87 | 91 | 94 | 96 | 90 |
| Luxembourg | | 38 | 47 | 56 | 64 | 69 | 74 | 29 | 35 | 42 | 49 | 53 | 57 |
| Malta | | 30 | 34 | 36 | 38 | 39 | 39 | 31 | 36 | 40 | 41 | 43 | 44 |
| Netherlands | | 1,324 | 1,599 | 1,789 | 1,870 | 1,851 | 1,854 | 1,114 | 1,313 | 1,486 | 1,581 | 1,566 | 1,547 |
| Poland | | 1,704 | 1,920 | 2,120 | 2,287 | 2,353 | 2,311 | 1,190 | 1,324 | 1,434 | 1,508 | 1,526 | 1,483 |
| Portugal | | 659 | 742 | 837 | 925 | 976 | 984 | 574 | 640 | 705 | 755 | 783 | 777 |
| Romania | | 656 | 693 | 750 | 798 | 804 | 776 | 453 | 474 | 498 | 522 | 525 | 508 |
| Slovakia | | 232 | 274 | 319 | 354 | 374 | 371 | 227 | 261 | 295 | 320 | 330 | 323 |
| Slovenia | | 127 | 152 | 175 | 187 | 191 | 183 | 140 | 158 | 175 | 186 | 188 | 179 |
| Spain | | 3,506 | 4,161 | 4,895 | 5,485 | 5,700 | 5,575 | 2,793 | 3,278 | 3,830 | 4,323 | 4,584 | 4,513 |
| Sweden | | 856 | 992 | 1,089 | 1,165 | 1,216 | 1,283 | 699 | 784 | 859 | 920 | 952 | 998 |
| United Kingdom | | 5,479 | 6,268 | 6,988 | 7,604 | 8,084 | 8,658 | 4,687 | 5,224 | 5,828 | 6,373 | 6,749 | 7,116 |
| European Union (27 co | untries) | 37,809 | 43,088 | 48,058 | 51,738 | 53,288 | 53,464 | 31,507 | 35,178 | 38,877 | 41,683 | 42,676 | 42,387 |



8.4 SUPPLEMENTARY TABLES - COSTS UNDER THE BASELINE SCENARIO

Table 8.4.1 Health costs – baseline scenario – Member State breakdown - Based on a 4% discount rate

| Low | Female | Male | Total | High | Female | Male | Total |
|----------------|--------|---------|---------|----------------|---------|---------|---------|
| Austria | €5 | € 24 | € 30 | Austria | € 22 | € 90 | € 112 |
| Belgium | €0 | €2 | €2 | Belgium | € 13 | € 55 | € 69 |
| Bulgaria | €7 | €9 | € 17 | Bulgaria | € 13 | € 17 | € 30 |
| Czech Republic | € 23 | € 48 | € 71 | Czech Republic | € 94 | € 192 | € 286 |
| Cyprus | €0 | € 0 | € 1 | Cyprus | €0 | €0 | €0 |
| Denmark | €4 | € 10 | € 14 | Denmark | € 15 | € 40 | € 54 |
| Estonia | €2 | €2 | € 4 | Estonia | €7 | €9 | € 16 |
| Finland | €4 | €8 | € 12 | Finland | € 13 | € 28 | € 42 |
| France | € 37 | € 185 | € 221 | France | € 108 | € 549 | € 657 |
| Germany | € 65 | € 258 | € 322 | Germany | € 234 | € 912 | € 1,146 |
| Greece | €2 | €6 | €7 | Greece | €6 | € 21 | € 28 |
| Hungary | €9 | € 16 | € 25 | Hungary | € 39 | € 68 | € 107 |
| Ireland | €1 | €3 | € 4 | Ireland | €3 | €8 | € 11 |
| Italy | € 83 | € 298 | € 381 | Italy | € 306 | € 1,219 | € 1,525 |
| Latvia | €2 | € 3 | € 5 | Latvia | €6 | €7 | € 13 |
| Lithuania | €4 | € 4 | €8 | Lithuania | € 15 | € 14 | € 29 |
| Luxembourg | €0 | €0 | € 1 | Luxembourg | €0 | €2 | €2 |
| Malta | €0 | €0 | € 0 | Malta | €0 | € 0 | €0 |
| Netherlands | €4 | € 16 | € 20 | Netherlands | € 14 | € 60 | € 73 |
| Poland | € 33 | € 60 | € 92 | Poland | € 97 | € 208 | € 305 |
| Portugal | €6 | € 11 | € 17 | Portugal | € 19 | € 34 | € 54 |
| Romania | € 21 | € 31 | € 52 | Romania | € 55 | € 84 | € 139 |
| Slovakia | €5 | €9 | € 14 | Slovakia | € 17 | € 32 | € 48 |
| Slovenia | €3 | €6 | €9 | Slovenia | €9 | € 19 | € 28 |
| Spain | € 20 | € 79 | € 99 | Spain | € 68 | € 278 | € 346 |
| Sweden | €8 | € 24 | € 32 | Sweden | € 28 | € 89 | € 117 |
| United Kingdom | € 24 | € 100 | € 125 | United Kingdom | € 84 | € 335 | € 419 |
| TOTAL | € 372 | € 1,210 | € 1,582 | TOTAL | € 1,287 | € 4,370 | € 5,657 |

Table 8.4.2 Health costs – baseline scenario – Industry group breakdown - Based on a 4% discount rate

| Low | Female | Male | Total |
|--|--------|-------|-------|
| Manufacture of pulp, paper and paper products | € 0 | € 1 | € 1 |
| Publishing, printing and reproduction of recorded media | €1 | € 4 | €6 |
| Manufacture of chemicals and chemical products | € 11 | € 41 | € 52 |
| Manufacture of rubber and plastic products | € 12 | € 40 | € 52 |
| Manufacture of fabricated metal products, except machinery and equipment | € 73 | € 249 | € 322 |
| Manufacture of machinery and equipment n.e.c. | € 51 | € 175 | € 226 |
| Manufacture of office machinery and computers | € 3 | € 10 | € 13 |
| Manufacture of electrical machinery apparatus, appliances and supplies | €6 | € 20 | € 26 |
| Manufacture of transport equipment | € 65 | € 236 | € 302 |



| Low | Female | Male | Total |
|---|--------|---------|---------|
| Manufacture of motor vehicles, trailers and semi-trailers | € 29 | € 99 | € 128 |
| Research and Development | € 0 | € 1 | €1 |
| Education | € 3 | € 1 | € 4 |
| Other community, social and personal service activities | € 25 | € 36 | € 61 |
| TOTAL | € 361 | € 1,167 | € 1,529 |

| High | Female | Male | Total |
|--|---------|---------|---------|
| Manufacture of pulp, paper and paper products | €1 | €3 | € 4 |
| Publishing, printing and reproduction of recorded media | € 4 | € 15 | € 19 |
| Manufacture of chemicals and chemical products | € 36 | € 142 | € 178 |
| Manufacture of rubber and plastic products | € 38 | € 139 | € 177 |
| Manufacture of fabricated metal products, except machinery and equipment | € 253 | € 885 | € 1,139 |
| Manufacture of machinery and equipment n.e.c. | € 177 | € 621 | € 798 |
| Manufacture of office machinery and computers | € 10 | € 35 | € 45 |
| Manufacture of electrical machinery apparatus, appliances and supplies | € 20 | € 70 | € 91 |
| Manufacture of transport equipment | € 225 | € 838 | € 1,063 |
| Manufacture of motor vehicles, trailers and semi-trailers | € 100 | € 349 | € 449 |
| Research and Development | € 2 | € 4 | € 6 |
| Education | € 13 | €7 | € 20 |
| Other community, social and personal service activities | € 85 | € 133 | € 218 |
| TOTAL | € 1,233 | € 4,130 | € 5,363 |

Note: Industry breakdown results may not equate exactly to Member State breakdown due to differences in underlying health data.

Table 8.4.3 Health costs – baseline scenario – Member State breakdown - Based on a declining discount rate

| Low | Female | Male | Total | High | Female | Male | Total |
|----------------|--------|-------|-------|----------------|--------|---------|---------|
| Austria | €6 | € 29 | € 35 | Austria | € 26 | € 109 | € 135 |
| Belgium | €0 | €2 | €2 | Belgium | € 16 | € 66 | € 82 |
| Bulgaria | €9 | € 11 | € 20 | Bulgaria | € 16 | € 20 | € 36 |
| Czech Republic | € 28 | € 58 | € 87 | Czech Republic | € 115 | € 236 | € 351 |
| Cyprus | €0 | €0 | €1 | Cyprus | € 0 | €0 | €0 |
| Denmark | €4 | € 12 | € 16 | Denmark | € 18 | € 47 | € 65 |
| Estonia | €2 | €3 | € 5 | Estonia | €9 | € 11 | € 19 |
| Finland | €4 | €9 | € 14 | Finland | € 16 | € 33 | € 50 |
| France | € 43 | € 214 | € 257 | France | € 126 | € 640 | € 766 |
| Germany | € 77 | € 308 | € 385 | Germany | € 281 | € 1,097 | € 1,378 |
| Greece | €2 | €7 | €9 | Greece | €8 | € 25 | € 33 |
| Hungary | € 11 | € 19 | € 30 | Hungary | € 46 | € 82 | € 129 |
| Ireland | €1 | €3 | € 4 | Ireland | €3 | € 10 | € 13 |
| Italy | € 105 | € 376 | € 480 | Italy | € 387 | € 1,540 | € 1,926 |
| Latvia | €2 | €3 | €6 | Latvia | €7 | €9 | € 16 |
| Lithuania | €4 | €5 | €9 | Lithuania | € 19 | € 17 | € 36 |
| Luxembourg | €0 | €1 | €1 | Luxembourg | €0 | €2 | €2 |
| Malta | €0 | €0 | €0 | Malta | €0 | €0 | €0 |
| Netherlands | €4 | € 19 | € 23 | Netherlands | € 16 | € 71 | € 88 |
| Poland | € 39 | € 72 | € 112 | Poland | € 118 | € 255 | € 373 |



| Low | Female | Male | Total | High | Female | Male | Total |
|----------------|--------|---------|---------|----------------|---------|---------|---------|
| Portugal | €7 | € 13 | € 20 | Portugal | € 23 | € 41 | € 64 |
| Romania | € 25 | € 37 | € 62 | Romania | € 66 | € 102 | € 168 |
| Slovakia | €6 | € 11 | € 17 | Slovakia | € 20 | € 39 | € 59 |
| Slovenia | € 4 | €8 | € 11 | Slovenia | € 11 | € 23 | € 34 |
| Spain | € 26 | € 100 | € 126 | Spain | € 86 | € 354 | € 440 |
| Sweden | € 10 | € 28 | € 38 | Sweden | € 33 | € 105 | € 139 |
| United Kingdom | € 28 | € 114 | € 142 | United Kingdom | € 97 | € 382 | € 479 |
| TOTAL | € 449 | € 1,461 | € 1,910 | TOTAL | € 1,563 | € 5,317 | € 6,880 |

Table 8.4.4 Health costs – baseline scenario – Industry group breakdown - Based on a declining discount rate

| Low | Female | Male | Total |
|--|---------|---------|---------|
| Manufacture of pulp, paper and paper products | €0 | €1 | €1 |
| Publishing, printing and reproduction of recorded media | €1 | € 5 | €6 |
| Manufacture of chemicals and chemical products | € 13 | € 47 | € 60 |
| Manufacture of rubber and plastic products | € 14 | € 46 | € 60 |
| Manufacture of fabricated metal products, except machinery and equipment | € 89 | € 304 | € 394 |
| Manufacture of machinery and equipment n.e.c. | € 62 | € 213 | € 275 |
| Manufacture of office machinery and computers | €3 | € 12 | € 15 |
| Manufacture of electrical machinery apparatus, appliances and supplies | €7 | € 23 | € 31 |
| Manufacture of transport equipment | € 79 | € 287 | € 366 |
| Manufacture of motor vehicles, trailers and semi-trailers | € 35 | € 119 | € 155 |
| Manufacture of furniture: manufacturing nec | € 95 | € 298 | € 393 |
| Research and Development | €0 | €1 | €2 |
| Education | €4 | €2 | €6 |
| Other community, social and personal service activities | € 29 | € 43 | € 73 |
| TOTAL | € 434 | € 1,402 | € 1,835 |
| High | Female | Male | Total |
| Manufacture of pulp, paper and paper products | €1 | €4 | € 5 |
| Publishing, printing and reproduction of recorded media | €5 | € 18 | € 23 |
| Manufacture of chemicals and chemical products | € 43 | € 166 | € 209 |
| Manufacture of rubber and plastic products | € 45 | € 164 | € 209 |
| Manufacture of fabricated metal products, except machinery and equipment | € 309 | € 1,082 | € 1,391 |
| Manufacture of machinery and equipment n.e.c. | € 215 | € 757 | € 972 |
| Manufacture of office machinery and computers | € 11 | € 42 | € 53 |
| Manufacture of electrical machinery apparatus, appliances | € 24 | € 83 | € 107 |
| and supplies | C 070 | C 4 040 | C 4 000 |
| Manufacture of transport equipment | € 273 | € 1,018 | € 1,290 |
| Manufacture of motor vehicles, trailers and semi-trailers | € 122 | € 422 | € 544 |
| Manufacture of furniture: manufacturing nec | € 318 | € 1,055 | € 1,373 |
| Research and Development | €2 | €6 | €8 |
| Education | € 18 | € 10 | € 27 |
| Other community, social and personal service activities | € 102 | € 161 | € 263 |
| TOTAL | € 1,487 | € 4,987 | € 6,474 |

Note: Industry breakdown results may not equate exactly to Member State breakdown due to differences in underlying health data.



Table 8.4.5 Summary

| Costs by Gender (€m) | 2010-2019 | 2020-2029 | 2030- 2039 | 2040- 2049 | 2050- 2059 | 2060- 2069 |
|-------------------------|-------------|-------------|---------------|---------------|---------------|---------------|
| Female | 105 to 360 | 86 to 291 | 86 to 290 | 70 to 241 | 56 to 206 | 45 to 175 |
| Male | 337 to 1187 | 282 to 993 | 285 to | 230 to 836 | 182 to 703 | 145 to |
| | | | 1008 | | | 590 |
| Total | 442 to 1547 | 368 to 1284 | 371 to | 301 to | 239 to 909 | 189 to |
| | | | 1299 | 1076 | | 765 |

Table 8.4.6 Health costs – baseline scenario – Member State breakdown - Based on a no discounting

| Low | Female | Male | Total | High | Female | Male | Total |
|----------------|---------|---------|---------|----------------|---------|----------|----------|
| Austria | € 15 | € 69 | € 84 | Austria | € 64 | € 264 | € 328 |
| Belgium | €1 | € 4 | € 5 | Belgium | € 38 | € 155 | € 193 |
| Bulgaria | € 20 | € 25 | € 46 | Bulgaria | € 38 | € 49 | € 87 |
| Czech Republic | € 69 | € 145 | € 214 | Czech Republic | € 290 | € 604 | € 894 |
| Cyprus | €0 | €1 | € 1 | Cyprus | €0 | €0 | € 0 |
| Denmark | € 10 | € 28 | € 38 | Denmark | € 43 | € 113 | € 156 |
| Estonia | €6 | €7 | € 12 | Estonia | € 21 | € 28 | € 49 |
| Finland | €9 | € 21 | € 31 | Finland | € 39 | € 79 | € 118 |
| France | € 96 | € 473 | € 570 | France | € 285 | € 1,433 | € 1,719 |
| Germany | € 183 | € 735 | € 918 | Germany | € 680 | € 2,677 | € 3,357 |
| Greece | € 4 | € 15 | € 19 | Greece | € 18 | € 58 | € 75 |
| Hungary | € 25 | € 45 | € 70 | Hungary | € 112 | € 203 | € 315 |
| Ireland | € 4 | €7 | € 11 | Ireland | €8 | € 24 | € 32 |
| Italy | € 285 | € 1,025 | € 1,311 | Italy | € 1,062 | € 4,222 | € 5,284 |
| Latvia | €6 | €8 | € 14 | Latvia | € 17 | € 23 | € 40 |
| Lithuania | € 11 | € 13 | € 23 | Lithuania | € 49 | € 45 | € 94 |
| Luxembourg | €0 | € 1 | € 1 | Luxembourg | €1 | € 5 | €6 |
| Malta | €0 | € 0 | € 0 | Malta | €0 | € 0 | €0 |
| Netherlands | € 11 | € 44 | € 55 | Netherlands | € 41 | € 171 | € 212 |
| Poland | € 96 | € 180 | € 276 | Poland | € 298 | € 651 | € 949 |
| Portugal | € 16 | € 31 | € 46 | Portugal | € 55 | € 99 | € 153 |
| Romania | € 59 | € 86 | € 145 | Romania | € 161 | € 249 | € 410 |
| Slovakia | € 15 | € 26 | € 41 | Slovakia | € 51 | € 99 | € 150 |
| Slovenia | €9 | € 19 | € 28 | Slovenia | € 26 | € 57 | € 83 |
| Spain | € 69 | € 274 | € 343 | Spain | € 231 | € 986 | € 1,217 |
| Sweden | € 23 | € 65 | € 87 | Sweden | € 79 | € 248 | € 327 |
| United Kingdom | € 60 | € 239 | € 299 | United Kingdom | € 210 | € 812 | € 1,022 |
| TOTAL | € 1,102 | € 3,587 | € 4,690 | TOTAL | € 3,917 | € 13,352 | € 17,269 |



Table 8.4.7 Health costs – baseline scenario – Industry group breakdown - Based on a no discounting

| Low | Female | Male | Total |
|--|---------|----------|----------|
| Manufacture of pulp, paper and paper products | €1 | €2 | € 2 |
| Publishing, printing and reproduction of recorded media | €3 | € 11 | € 14 |
| Manufacture of chemicals and chemical products | € 28 | € 103 | € 131 |
| Manufacture of rubber and plastic products | € 30 | € 102 | € 132 |
| Manufacture of fabricated metal products, except machinery and equipment | € 225 | € 766 | € 991 |
| Manufacture of machinery and equipment n.e.c. | € 156 | € 533 | € 689 |
| Manufacture of office machinery and computers | €7 | € 26 | € 33 |
| Manufacture of electrical machinery apparatus, appliances and supplies | € 16 | € 52 | € 68 |
| Research and Development | €1 | €3 | € 5 |
| Education | € 12 | €6 | € 17 |
| Other community, social and personal service activities | € 68 | € 100 | € 168 |
| Manufacture of transport equipment | | | |
| Manufacture of motor vehicles, trailers and semi-trailers | | | |
| TOTAL | € 1,048 | € 3,386 | € 4,434 |
| High | Female | Male | Total |
| Manufacture of pulp, paper and paper products | €3 | € 10 | € 13 |
| Publishing, printing and reproduction of recorded media | € 11 | € 41 | € 51 |
| Manufacture of chemicals and chemical products | € 99 | € 382 | € 481 |
| Manufacture of rubber and plastic products | € 104 | € 377 | € 481 |
| Manufacture of fabricated metal products, except machinery and equipment | € 782 | € 2,740 | € 3,522 |
| Manufacture of machinery and equipment n.e.c. | € 541 | € 1,904 | € 2,445 |
| Manufacture of office machinery and computers | € 25 | € 94 | € 120 |
| Manufacture of electrical machinery apparatus, appliances and supplies | € 55 | € 192 | € 247 |
| Manufacture of transport equipment | € 678 | € 2,536 | € 3,214 |
| Manufacture of motor vehicles, trailers and semi-trailers | € 302 | € 1,044 | € 1,347 |
| Manufacture of furniture: manufacturing nec | € 747 | € 2,501 | € 3,248 |
| Research and Development | €7 | € 18 | € 25 |
| Education | € 55 | € 31 | € 86 |
| Other community, social and personal service activities | € 251 | € 399 | € 650 |
| TOTAL | € 3,659 | € 12,270 | € 15,928 |

Note: Industry breakdown results may not equate exactly to Member State breakdown due to differences in underlying health data.

Table 8.4.8 Summary

| Costs by Gender (€m) | 2010- 2019 | 2020- 2029 | 2030- 2039 | 2040- 2049 | 2050- 2059 | 2060- 2069 |
|-------------------------|---------------|---------------|---------------|---------------|---------------|---------------|
| Female | 128 to | 155 to | 180 to | 198 to | 213 to | 228 to |
| | 438 | 524 | 608 | 677 | 780 | 891 |
| Male | 410 to | 508 to | 597 to | 648 to | 690 to | 735 to |
| | 1444 | 1788 | 2111 | 2352 | 2659 | 2998 |
| Total | 537 to | 663 to | 777 to | 846 to | 903 to | 963 to |
| | 1882 | 2312 | 2719 | 3029 | 3439 | 3889 |



8.5 HEALTH BENEFITS – INTERVENTION SCENARIOS

 Table 8.5.1
 Proportions exposed above the exposure limits being tested by country, forecast scenario

| OEL | 50 | ppm | | | | | 10 | ppm | | | | |
|-------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| | 1971-80 | 1981-90 | 1991-00 | 2001-10 | 2011-20 | 2021-30 | 1971-80 | 1981-90 | 1991-00 | 2001-10 | 2011-20 | 2021-30 |
| Austria | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 5.00 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Belgium | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Bulgaria | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Cyprus | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Czech Republic | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Denmark | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Estonia | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Finland | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| France | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Germany | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Greece | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Hungary | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Ireland | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Italy | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Latvia | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Lithuania | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Luxembourg | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Malta | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Netherlands | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Poland | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Portugal | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Romania | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |



| OEL | 50 | ррт | | | | | 10 | ррт | | | | |
|-------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| | 1971-80 | 1981-90 | 1991-00 | 2001-10 | 2011-20 | 2021-30 | 1971-80 | 1981-90 | 1991-00 | 2001-10 | 2011-20 | 2021-30 |
| Slovakia | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Slovenia | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Spain | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| Sweden | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| United Kingdom | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |
| TOTAL | 0.44 | 0.24 | 0.10 | 0.03 | 0.01 | 0.00 | 0.86 | 0.70 | 0.48 | 0.28 | 0.13 | 0.04 |

Table 8.5.2 Numbers and proportions of the population ever exposed for baseline, forecast and intervention ⁽¹⁾ scenarios (1) to (4a), by country, men plus women (for kidney and liver cancer)

| Scenario | All Scenarios | | employme | ent and exp | nario (1) ^[2] - posure level constant tl | l trends | Intervention scenario (2) - Full compliance for OEL = 50 ppm (273 mg/m3) | | | | Intervention scenario (3) - Full compliance for OEL = 10 ppm (50 mg/m3) | | | |
|-------------------|----------------|--------|----------|-------------|---|----------|--|--------|--------|--------|---|--------|--------|--------|
| | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Number ever | exposed in the | REP | | | | | | | | | | | | |
| Austria | 5,094 | 5,305 | 5,577 | 5,717 | 5,817 | 5,879 | 5,577 | 5,717 | 5,817 | 5,879 | 5,577 | 5,717 | 5,817 | 5,879 |
| Belgium | 4,505 | 4,698 | 4,947 | 5,081 | 5,177 | 5,236 | 4,947 | 5,081 | 5,177 | 5,236 | 4,947 | 5,081 | 5,177 | 5,236 |
| Bulgaria | 4,186 | 4,348 | 4,555 | 4,650 | 4,719 | 4,761 | 4,555 | 4,650 | 4,719 | 4,761 | 4,555 | 4,650 | 4,719 | 4,761 |
| Cyprus | 241 | 255 | 274 | 287 | 296 | 302 | 274 | 287 | 296 | 302 | 274 | 287 | 296 | 302 |
| Czech Republic | 11,730 | 12,100 | 12,559 | 12,692 | 12,787 | 12,846 | 12,559 | 12,692 | 12,787 | 12,846 | 12,559 | 12,692 | 12,787 | 12,846 |
| Denmark | 3,515 | 3,676 | 3,887 | 4,010 | 4,098 | 4,152 | 3,887 | 4,010 | 4,098 | 4,152 | 3,887 | 4,010 | 4,098 | 4,152 |
| Estonia | 1,121 | 1,165 | 1,223 | 1,251 | 1,271 | 1,283 | 1,223 | 1,251 | 1,271 | 1,283 | 1,223 | 1,251 | 1,271 | 1,283 |
| Finland | 3,114 | 3,304 | 3,559 | 3,745 | 3,878 | 3,961 | 3,559 | 3,745 | 3,878 | 3,961 | 3,559 | 3,745 | 3,878 | 3,961 |
| France | 35,346 | 34,612 | 34,024 | 33,559 | 32,736 | 32,475 | 34,024 | 33,559 | 32,736 | 32,475 | 34,024 | 33,559 | 32,736 | 32,475 |
| Greece | 1,671 | 1,783 | 1,935 | 2,051 | 2,135 | 2,187 | 1,935 | 2,051 | 2,135 | 2,187 | 1,935 | 2,051 | 2,135 | 2,187 |
| Hungary | 5,866 | 6,094 | 6,386 | 6,524 | 6,622 | 6,683 | 6,386 | 6,524 | 6,622 | 6,683 | 6,386 | 6,524 | 6,622 | 6,683 |



| Scenario | All Scenario | s | Baseline (trend) scenario (1) ¹²¹ - Linear employment and exposure level trends assumed to 2021-30, constant thereafter. | | | | Intervention scenario (2) - Full compliance for OEL = 50 ppm (273 mg/m3) | | | | Intervention scenario (3) - Full compliance for OEL = 10 ppm (50 mg/m3) | | | |
|-------------------|----------------|---------|---|---------|---------|---------|--|---------|---------|---------|---|---------|---------|---------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Number ever | exposed in the | | • • | • | • • | • • | | • • | • • | • | | • • | 11 | |
| Ireland | 1,231 | 1,307 | 1,409 | 1,485 | 1,539 | 1,572 | 1,409 | 1,485 | 1,539 | 1,572 | 1,409 | 1,485 | 1,539 | 1,572 |
| Italy | 35,738 | 36,616 | 37,657 | 37,657 | 37,657 | 37,657 | 37,657 | 37,657 | 37,657 | 37,657 | 37,657 | 37,657 | 37,657 | 37,657 |
| Latvia | 1,268 | 1,325 | 1,399 | 1,440 | 1,470 | 1,488 | 1,399 | 1,440 | 1,470 | 1,488 | 1,399 | 1,440 | 1,470 | 1,488 |
| Lithuania | 2,336 | 2,428 | 2,545 | 2,601 | 2,641 | 2,666 | 2,545 | 2,601 | 2,641 | 2,666 | 2,545 | 2,601 | 2,641 | 2,666 |
| Luxembourg | 147 | 154 | 163 | 168 | 172 | 175 | 163 | 168 | 172 | 175 | 163 | 168 | 172 | 175 |
| Malta | 16 | 20 | 24 | 29 | 32 | 35 | 24 | 29 | 32 | 35 | 24 | 29 | 32 | 35 |
| Netherlands | 6,146 | 6,455 | 6,864 | 7,123 | 7,310 | 7,425 | 6,864 | 7,123 | 7,310 | 7,425 | 6,864 | 7,123 | 7,310 | 7,425 |
| Poland | 22,991 | 23,824 | 24,882 | 25,319 | 25,633 | 25,828 | 24,882 | 25,319 | 25,633 | 25,828 | 24,882 | 25,319 | 25,633 | 25,828 |
| Portugal | 5,372 | 5,579 | 5,844 | 5,967 | 6,055 | 6,110 | 5,844 | 5,967 | 6,055 | 6,110 | 5,844 | 5,967 | 6,055 | 6,110 |
| Romania | 12,305 | 12,731 | 13,269 | 13,470 | 13,615 | 13,704 | 13,269 | 13,470 | 13,615 | 13,704 | 13,269 | 13,470 | 13,615 | 13,704 |
| Slovakia | 3,177 | 3,297 | 3,450 | 3,519 | 3,568 | 3,598 | 3,450 | 3,519 | 3,568 | 3,598 | 3,450 | 3,519 | 3,568 | 3,598 |
| Slovenia | 2,022 | 2,092 | 2,181 | 2,214 | 2,238 | 2,252 | 2,181 | 2,214 | 2,238 | 2,252 | 2,181 | 2,214 | 2,238 | 2,252 |
| Spain | 13,998 | 17,554 | 22,485 | 27,426 | 31,121 | 33,593 | 22,485 | 27,426 | 31,121 | 33,593 | 22,485 | 27,426 | 31,121 | 33,593 |
| Sweden | 7,618 | 7,920 | 8,309 | 8,497 | 8,633 | 8,717 | 8,309 | 8,497 | 8,633 | 8,717 | 8,309 | 8,497 | 8,633 | 8,717 |
| United Kingdom | 39,514 | 37,300 | 34,156 | 30,957 | 28,653 | 27,215 | 34,156 | 30,957 | 28,653 | 27,215 | 34,156 | 30,957 | 28,653 | 27,215 |
| TOŤAL | 291,882 | 299,942 | 310,620 | 315,914 | 319,370 | 321,932 | 310,620 | 315,914 | 319,370 | 321,932 | 310,620 | 315,914 | 319,370 | 321,932 |



| Scenario | All Scer | narios | Linear e | employmore level to | scenario ent and ends ass tant there | sumed | | ince for (| nario (2) - F DEL = 50 pp | | | ion scenari ce for OEL | o (3) - Full = 10 ppm (| 50 |
|-------------------|----------|--------|----------|---------------------|---|-------|-------|------------|------------------------------|-------|-------|---------------------------|----------------------------|-------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Proportion of | | | | | | | | | | | | | | |
| Austria | 0.083 | 0.081 | 0.082 | 0.082 | 0.083 | 0.085 | 0.082 | 0.082 | 0.083 | 0.085 | 0.082 | 0.082 | 0.083 | 0.085 |
| Belgium | 0.059 | 0.058 | 0.058 | 0.058 | 0.058 | 0.058 | 0.058 | 0.058 | 0.058 | 0.058 | 0.058 | 0.058 | 0.058 | 0.058 |
| Bulgaria | 0.075 | 0.079 | 0.088 | 0.094 | 0.101 | 0.110 | 0.088 | 0.094 | 0.101 | 0.110 | 0.088 | 0.094 | 0.101 | 0.110 |
| Cyprus | 0.043 | 0.038 | 0.036 | 0.034 | 0.032 | 0.031 | 0.036 | 0.034 | 0.032 | 0.031 | 0.036 | 0.034 | 0.032 | 0.031 |
| Czech Republic | 0.154 | 0.151 | 0.157 | 0.159 | 0.164 | 0.172 | 0.157 | 0.159 | 0.164 | 0.172 | 0.157 | 0.159 | 0.164 | 0.172 |
| Denmark | 0.091 | 0.091 | 0.093 | 0.095 | 0.097 | 0.097 | 0.093 | 0.095 | 0.097 | 0.097 | 0.093 | 0.095 | 0.097 | 0.097 |
| Estonia | 0.119 | 0.121 | 0.132 | 0.136 | 0.142 | 0.150 | 0.132 | 0.136 | 0.142 | 0.150 | 0.132 | 0.136 | 0.142 | 0.150 |
| Finland | 0.082 | 0.083 | 0.088 | 0.093 | 0.097 | 0.100 | 0.088 | 0.093 | 0.097 | 0.100 | 0.088 | 0.093 | 0.097 | 0.100 |
| France | 0.082 | 0.075 | 0.071 | 0.067 | 0.064 | 0.063 | 0.071 | 0.067 | 0.064 | 0.063 | 0.071 | 0.067 | 0.064 | 0.063 |
| Germany | 0.100 | 0.101 | 0.107 | 0.112 | 0.119 | 0.127 | 0.107 | 0.112 | 0.119 | 0.127 | 0.107 | 0.112 | 0.119 | 0.127 |
| Greece | 0.020 | 0.020 | 0.022 | 0.023 | 0.024 | 0.025 | 0.022 | 0.023 | 0.024 | 0.025 | 0.022 | 0.023 | 0.024 | 0.025 |
| Hungary | 0.080 | 0.082 | 0.087 | 0.090 | 0.094 | 0.098 | 0.087 | 0.090 | 0.094 | 0.098 | 0.087 | 0.090 | 0.094 | 0.098 |
| Ireland | 0.041 | 0.036 | 0.035 | 0.034 | 0.033 | 0.033 | 0.035 | 0.034 | 0.033 | 0.033 | 0.035 | 0.034 | 0.033 | 0.033 |
| Italy | 0.078 | 0.077 | 0.078 | 0.077 | 0.078 | 0.080 | 0.078 | 0.077 | 0.078 | 0.080 | 0.078 | 0.077 | 0.078 | 0.080 |
| Latvia | 0.079 | 0.081 | 0.091 | 0.097 | 0.104 | 0.113 | 0.091 | 0.097 | 0.104 | 0.113 | 0.091 | 0.097 | 0.104 | 0.113 |
| Lithuania | 0.100 | 0.101 | 0.109 | 0.115 | 0.122 | 0.133 | 0.109 | 0.115 | 0.122 | 0.133 | 0.109 | 0.115 | 0.122 | 0.133 |
| Luxembourg | 0.042 | 0.039 | 0.037 | 0.036 | 0.034 | 0.033 | 0.037 | 0.036 | 0.034 | 0.033 | 0.037 | 0.036 | 0.034 | 0.033 |
| Malta | 0.006 | 0.006 | 0.007 | 0.009 | 0.010 | 0.011 | 0.007 | 0.009 | 0.010 | 0.011 | 0.007 | 0.009 | 0.010 | 0.011 |
| Netherlands | 0.053 | 0.053 | 0.054 | 0.056 | 0.058 | 0.060 | 0.054 | 0.056 | 0.058 | 0.060 | 0.054 | 0.056 | 0.058 | 0.060 |
| Poland | 0.085 | 0.084 | 0.088 | 0.091 | 0.096 | 0.103 | 0.088 | 0.091 | 0.096 | 0.103 | 0.088 | 0.091 | 0.096 | 0.103 |
| Portugal | 0.068 | 0.067 | 0.068 | 0.067 | 0.068 | 0.070 | 0.068 | 0.067 | 0.068 | 0.070 | 0.068 | 0.067 | 0.068 | 0.070 |
| Romania | 0.081 | 0.082 | 0.086 | 0.089 | 0.094 | 0.101 | 0.086 | 0.089 | 0.094 | 0.101 | 0.086 | 0.089 | 0.094 | 0.101 |
| Slovakia | 0.084 | 0.081 | 0.084 | 0.087 | 0.091 | 0.098 | 0.084 | 0.087 | 0.091 | 0.098 | 0.084 | 0.087 | 0.091 | 0.098 |
| Slovenia | 0.134 | 0.133 | 0.140 | 0.144 | 0.152 | 0.163 | 0.140 | 0.144 | 0.152 | 0.163 | 0.140 | 0.144 | 0.152 | 0.163 |



| Scenario | All Scer | narios | Linear e | employmere level to | scenario ent and rends ass tant there | sumed | | ince for (| nario (2) - F DEL = 50 pp | | | ion scenari ce for OEL | o (3) - Full = 10 ppm (| 50 |
|-------------------|------------|----------|----------|---------------------|--|-------|-------|------------|------------------------------|-------|-------|---------------------------|----------------------------|-------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Proportion of | the popula | tion exp | osed | | | | | | | | | | | |
| Spain | 0.040 | 0.046 | 0.057 | 0.066 | 0.075 | 0.084 | 0.057 | 0.066 | 0.075 | 0.084 | 0.057 | 0.066 | 0.075 | 0.084 |
| Sweden | 0.117 | 0.112 | 0.114 | 0.113 | 0.111 | 0.110 | 0.114 | 0.113 | 0.111 | 0.110 | 0.114 | 0.113 | 0.111 | 0.110 |
| United Kingdom | 0.092 | 0.080 | 0.070 | 0.060 | 0.053 | 0.049 | 0.070 | 0.060 | 0.053 | 0.049 | 0.070 | 0.060 | 0.053 | 0.049 |
| TOTAL | 0.081 | 0.079 | 0.080 | 0.080 | 0.081 | 0.084 | 0.080 | 0.080 | 0.081 | 0.084 | 0.080 | 0.080 | 0.081 | 0.084 |

Table 8.5.3 Numbers and proportions of the population ever exposed for baseline, forecast and intervention ⁽¹⁾ scenarios (1) to (4a), by country, men plus women (for Non-Hodgkins Lymphoma)

| Scenario | All Sce | narios | Baseline (tren- employment a assumed to 20 | nd exposu | ire level tr | ends | | ion scenar | | | | | rio (3) - Ful L = 10 ppm | |
|----------------|---------|-----------|--|-----------|--------------|-------|-------|------------|-------|-------|-------|-------|-----------------------------|-------|
| Country | _ | _ | _ | | _ | _ | _ | _ | _ | _ | _ | _ | | _ |
| | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Number | ever expo | sed in the REP | | | | | | | | | | | |
| Austria | 4,009 | 4,112 | 4,196 | 4,228 | 4,228 | 4,228 | 4,196 | 4,228 | 4,228 | 4,228 | 4,196 | 4,228 | 4,228 | 4,228 |
| Belgium | 3,422 | 3,522 | 3,602 | 3,633 | 3,633 | 3,633 | 3,602 | 3,633 | 3,633 | 3,633 | 3,602 | 3,633 | 3,633 | 3,633 |
| Bulgaria | 3,042 | 3,114 | 3,172 | 3,194 | 3,194 | 3,194 | 3,172 | 3,194 | 3,194 | 3,194 | 3,172 | 3,194 | 3,194 | 3,194 |
| Cyprus | 186 | 196 | 203 | 206 | 206 | 206 | 203 | 206 | 206 | 206 | 203 | 206 | 206 | 206 |
| Czech Republic | 8,545 | 8,643 | 8,723 | 8,753 | 8,753 | 8,753 | 8,723 | 8,753 | 8,753 | 8,753 | 8,723 | 8,753 | 8,753 | 8,753 |
| Denmark | 2,656 | 2,748 | 2,822 | 2,850 | 2,850 | 2,850 | 2,822 | 2,850 | 2,850 | 2,850 | 2,822 | 2,850 | 2,850 | 2,850 |



| Scenario | All Sce | enarios | Baseline (trendemployment a assumed to 20 | nd exposเ | ire level tr | ends | | | rio (2) - Fu L = 50 ppn | | | tion scena nce for OE | | |
|-------------|---------|---------|---|-----------|--------------|--------|--------|--------|----------------------------|--------|--------|--------------------------|--------|--------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | | | | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 70 |
| | | | sed in the REP | 004 | 201 | 004 | 054 | 004 | 204 | 004 | 054 | 204 | 224 | 004 |
| Estonia | 817 | 838 | 854 | 861 | 861 | 861 | 854 | 861 | 861 | 861 | 854 | 861 | 861 | 861 |
| Finland | 2,409 | 2,547 | 2,657 | 2,700 | 2,700 | 2,700 | 2,657 | 2,700 | 2,700 | 2,700 | 2,657 | 2,700 | 2,700 | 2,700 |
| France | 23,659 | 23,061 | 22,890 | 21,840 | 21,840 | 21,840 | 22,890 | 21,840 | 21,840 | 21,840 | 22,890 | 21,840 | 21,840 | 21,840 |
| Germany | 46,351 | 47,423 | 48,292 | 48,625 | 48,625 | 48,625 | 48,292 | 48,625 | 48,625 | 48,625 | 48,292 | 48,625 | 48,625 | 48,625 |
| Greece | 1,310 | 1,396 | 1,466 | 1,493 | 1,493 | 1,493 | 1,466 | 1,493 | 1,493 | 1,493 | 1,466 | 1,493 | 1,493 | 1,493 |
| Hungary | 4,317 | 4,419 | 4,501 | 4,533 | 4,533 | 4,533 | 4,501 | 4,533 | 4,533 | 4,533 | 4,501 | 4,533 | 4,533 | 4,533 |
| Ireland | 956 | 1,012 | 1,058 | 1,075 | 1,075 | 1,075 | 1,058 | 1,075 | 1,075 | 1,075 | 1,058 | 1,075 | 1,075 | 1,075 |
| Italy | 26,105 | 26,105 | 26,105 | 26,105 | 26,105 | 26,105 | 26,105 | 26,105 | 26,105 | 26,105 | 26,105 | 26,105 | 26,105 | 26,105 |
| Latvia | 937 | 967 | 992 | 1,001 | 1,001 | 1,001 | 992 | 1,001 | 1,001 | 1,001 | 992 | 1,001 | 1,001 | 1,001 |
| Lithuania | 1,696 | 1,736 | 1,769 | 1,782 | 1,782 | 1,782 | 1,769 | 1,782 | 1,782 | 1,782 | 1,769 | 1,782 | 1,782 | 1,782 |
| Luxembourg | 113 | 117 | 121 | 122 | 122 | 122 | 121 | 122 | 122 | 122 | 121 | 122 | 122 | 122 |
| Malta | 15 | 19 | 22 | 23 | 23 | 23 | 22 | 23 | 23 | 23 | 22 | 23 | 23 | 23 |
| Netherlands | 4,738 | 4,931 | 5,087 | 5,146 | 5,146 | 5,146 | 5,087 | 5,146 | 5,146 | 5,146 | 5,087 | 5,146 | 5,146 | 5,146 |
| Poland | 16,936 | 17,261 | 17,524 | 17,625 | 17,625 | 17,625 | 17,524 | 17,625 | 17,625 | 17,625 | 17,524 | 17,625 | 17,625 | 17,625 |
| Portugal | 3,930 | 4,021 | 4,094 | 4,122 | 4,122 | 4,122 | 4,094 | 4,122 | 4,122 | 4,122 | 4,094 | 4,122 | 4,122 | 4,122 |
| Romania | 8,892 | 9,043 | 9,165 | 9,212 | 9,212 | 9,212 | 9,165 | 9,212 | 9,212 | 9,212 | 9,165 | 9,212 | 9,212 | 9,212 |
| Slovakia | 2,336 | 2,387 | 2,428 | 2,444 | 2,444 | 2,444 | 2,428 | 2,444 | 2,444 | 2,444 | 2,428 | 2,444 | 2,444 | 2,444 |
| Slovenia | 1,484 | 1,508 | 1,528 | 1,536 | 1,536 | 1,536 | 1,528 | 1,536 | 1,536 | 1,536 | 1,528 | 1,536 | 1,536 | 1,536 |
| Spain | 15,151 | 18,624 | 22,000 | 24,058 | 24,058 | 24,058 | 22,000 | 24,058 | 24,058 | 24,058 | 22,000 | 24,058 | 24,058 | 24,058 |
| Sweden | 5,730 | 5,870 | 5,983 | 6,026 | 6,026 | 6,026 | 5,983 | 6,026 | 6,026 | 6,026 | 5,983 | 6,026 | 6,026 | 6,026 |



| Scenario | All Sce | narios | Baseline (trend employment a assumed to 20 | nd exposur | è level trer | nds d | ntervention compliance ng/m3) | | | | | tion scena nce for OE | | | _ |
|--|----------------------------|----------------------------|--|----------------------------|----------------------------|--------------------------------------|--------------------------------------|-------------------------|--------------------------------------|----------------------------|----------------------------|----------------------------------|----------------------------|-----------------------------|---|
| Country | | | | | | | | | | | | | | | |
| | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 2040 | | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | |
| | | | sed in the REP | | ., | | ., | | ., | .,, | | | | | _ |
| United Kingdom | 23,911 | 21,289 | 19,123 | 18,268 | 18,268 | 18,268 | 19,123 1 | 8,268 | 18,268 | 18,268 | 19,123 | 18,268 | 18,268 | 18,268 | |
| TOTAL | 213,655 | 216,910 | 220,378 | 221,459 | 221,459 | 221,459 2 | 220,378 22 | 21,459 2 | 221,459 | 221,459 | 220,378 | 221,459 | 221,459 | 221,459 | _ |
| Scenario | All Sce | narios | Baseline (trer employment a assumed to 2 | and exposu | ire level tre | ends | | | ario (2) - I EL = 50 p | | CC | tervention ompliance g/m3) | |) (3) - Full = 10 ppm (5 | 50 |
| Country | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | , | o | 0 | 0 |
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | | 2040 | 2050 | 2060 |
| Proportion of th | ne populatio | on exposed | d | | | | | | | | | | | - 1 | |
| Proportion of th | | | | 5040 7040 | 0.062% | | | 5040 70 70 | | | | | 0.059% | 0.062% | 0.063 |
| Proportion of th | ne populatio | on exposed | d | | | 0.063% | 0.059% | | % 0.06 | 2% 0.0 | 063% 0 | .059% (| | - 1 | 0.063 % 0.040 |
| Proportion of th Austria | ne populatio 0.059% | 0.059% | 0.059% | 0.059% | 0.062% | 0.063% 0.040% | 0.059% 0.040% | 0.059 | % 0.06 % 0.04 | 2% 0.0 0% 0.0 | 063% 0 040% 0 | .059% (| 0.059% | 0.062% | 0.063 % 0.040 % 0.077 |
| Proportion of th Austria Belgium | 0.059% 0.041% | 0.059% 0.040% | 0.059% 0.040% | 0.059% 0.040% | 0.062% 0.040% | 0.063% 0.040% 0.077% | 0.059% 0.040% 0.058% | 0.059 0.040 | % 0.06 % 0.04 % 0.06 | 2% 0.0 0% 0.0 9% 0.0 | 063% 0 040% 0 077% 0 | .059% (.040% (| 0.059% 0.040% | 0.062% | 0.063 % 0.040 % 0.077 % 0.020 |
| Proportion of the Austria Belgium Bulgaria | 0.059% 0.041% 0.049% | 0.059% 0.040% 0.053% | 0.059% 0.040% 0.058% | 0.059% 0.040% 0.063% | 0.062% 0.040% 0.069% | 0.063% 0.040% 0.077% 0.020% | 0.059% 0.040% 0.058% 0.024% | 0.059 0.040 0.063 | % 0.06 % 0.04 % 0.06 % 0.02 | 2% 0.0 0% 0.0 9% 0.0 | 063% 0 040% 0 077% 0 | .059% (.040% (.058% (| 0.059% 0.040% 0.063% | 0.062% 0.040% 0.069% | 0.063 % 0.040 % 0.077 % 0.020 |



| Scenario | All Sce | narios | Baseline (tren employment a assumed to 20 | ınd exposu | re level trei | nds | | on scenario ce for OEL | o (2) - Full = 50 ppm (2 | 273 | | on scenarione ce for OEL | o (3) - Full = 10 ppm (| 50 |
|---------------|----------------|------------|---|------------|---------------|--------|--------|---------------------------|-----------------------------|--------|--------|-----------------------------|----------------------------|-----------------|
| Country | | | 0 | 0 | 0 | | 0 | | 0 | | 0 | 0 | 0 | 0 |
| | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Proportion of | the population | on exposed | 1 | | | | | | | | | | | |
| Estonia | 0.076% | 0.082% | 0.085% | 0.090% | 0.095% | 0.101% | 0.085% | 0.090% | 0.095% | 0.101% | 0.085% | 0.090% | 0.095% | 0.101 |
| Finland | 0.057% | 0.060% | 0.063% | 0.066% | 0.067% | 0.068% | 0.063% | 0.066% | 0.067% | 0.068% | 0.063% | 0.066% | 0.067% | % 0.068 % |
| France | 0.050% | 0.046% | 0.045% | 0.042% | 0.042% | 0.042% | 0.045% | 0.042% | 0.042% | 0.042% | 0.045% | 0.042% | 0.042% | 0.042 % |
| Germany | 0.069% | 0.072% | 0.076% | 0.081% | 0.088% | 0.093% | 0.076% | 0.081% | 0.088% | 0.093% | 0.076% | 0.081% | 0.088% | 0.093 % |
| Greece | 0.014% | 0.015% | 0.016% | 0.016% | 0.017% | 0.018% | 0.016% | 0.016% | 0.017% | 0.018% | 0.016% | 0.016% | 0.017% | 0.018 % |
| Hungary | 0.053% | 0.056% | 0.058% | 0.062% | 0.064% | 0.070% | 0.058% | 0.062% | 0.064% | 0.070% | 0.058% | 0.062% | 0.064% | 0.070 % |
| Ireland | 0.027% | 0.025% | 0.023% | 0.022% | 0.022% | 0.022% | 0.023% | 0.022% | 0.022% | 0.022% | 0.023% | 0.022% | 0.022% | 0.022 % |
| Italy | 0.054% | 0.054% | 0.053% | 0.054% | 0.057% | 0.060% | 0.053% | 0.054% | 0.057% | 0.060% | 0.053% | 0.054% | 0.057% | 0.060 % |
| Latvia | 0.051% | 0.057% | 0.061% | 0.065% | 0.072% | 0.078% | 0.061% | 0.065% | 0.072% | 0.078% | 0.061% | 0.065% | 0.072% | 0.078 % |
| Lithuania | 0.062% | 0.067% | 0.071% | 0.076% | 0.084% | 0.092% | 0.071% | 0.076% | 0.084% | 0.092% | 0.071% | 0.076% | 0.084% | 0.092 % |
| Luxembourg | 0.029% | 0.027% | 0.025% | 0.024% | 0.023% | 0.022% | 0.025% | 0.024% | 0.023% | 0.022% | 0.025% | 0.024% | 0.023% | 0.022 % |
| Malta | 0.005% | 0.006% | 0.006% | 0.007% | 0.007% | 0.008% | 0.006% | 0.007% | 0.007% | 0.008% | 0.006% | 0.007% | 0.007% | 0.008 % |
| Netherlands | 0.037% | 0.037% | 0.038% | 0.040% | 0.041% | 0.042% | 0.038% | 0.040% | 0.041% | 0.042% | 0.038% | 0.040% | 0.041% | 0.042 % |



| Scenario | All Sce | narios | Baseline (trer employment a assumed to 2 | and exposu | re level tre | nds | | on scenario ce for OEL | ` ' | 273 | | ion scenari ce for OEL | ` ' | 50 |
|-------------------|------------------|------------|--|------------|--------------|--------|--------|---------------------------|--------|--------|--------|---------------------------|--------|------------|
| Country | | | | | | | | | | | | | | |
| | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Proportion of | f the population | on exposed | 1 | | | | | | | | | | | |
| Poland | 0.054% | 0.056% | 0.058% | 0.063% | 0.068% | 0.075% | 0.058% | 0.063% | 0.068% | 0.075% | 0.058% | 0.063% | 0.068% | 0.075 % |
| Portugal | 0.046% | 0.045% | 0.045% | 0.046% | 0.047% | 0.049% | 0.045% | 0.046% | 0.047% | 0.049% | 0.045% | 0.046% | 0.047% | 0.049 |
| Romania | 0.051% | 0.054% | 0.056% | 0.060% | 0.064% | 0.072% | 0.056% | 0.060% | 0.064% | 0.072% | 0.056% | 0.060% | 0.064% | 0.072 |
| Slovakia | 0.053% | 0.053% | 0.055% | 0.059% | 0.063% | 0.071% | 0.055% | 0.059% | 0.063% | 0.071% | 0.055% | 0.059% | 0.063% | 0.071 |
| Slovenia | 0.089% | 0.091% | 0.094% | 0.100% | 0.109% | 0.118% | 0.094% | 0.100% | 0.109% | 0.118% | 0.094% | 0.100% | 0.109% | 0.118 |
| Spain | 0.040% | 0.046% | 0.052% | 0.057% | 0.060% | 0.064% | 0.052% | 0.057% | 0.060% | 0.064% | 0.052% | 0.057% | 0.060% | 0.064 |
| Sweden | 0.079% | 0.077% | 0.078% | 0.076% | 0.076% | 0.075% | 0.078% | 0.076% | 0.076% | 0.075% | 0.078% | 0.076% | 0.076% | 0.075 |
| United Kingdom | 0.049% | 0.042% | 0.036% | 0.033% | 0.033% | 0.032% | 0.036% | 0.033% | 0.033% | 0.032% | 0.036% | 0.033% | 0.033% | 0.032 |
| TOTAL | 0.054% | 0.053% | 0.054% | 0.055% | 0.057% | 0.059% | 0.054% | 0.055% | 0.057% | 0.059% | 0.054% | 0.055% | 0.057% | 0.059 |



Table 8.5.4 Results for baseline, forecast and intervention (1) scenarios (1) to (4a) for kidney cancer, by country, men plus women

| Scenario | All Scenar | rios | Linear e level tre | mployme | scenario (nt and ex med to 20 er. | posure | | nce for O | ario (2) - EL = 50 p | | | | ario (3) - EL = 10 p | |
|-----------------------|------------|-------|-----------------------|---------|---|--------|-------|-----------|-------------------------|-------|-------|-------|-------------------------|-------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Fraction | | -,, | - ' ' | - ' ' | - ' ' | | - ' ' | - ' ' | ., | | | - ' ' | - ' ' | -,, |
| Austria | 0.045 | 0.042 | 0.038 | 0.034 | 0.032 | 0.031 | 0.038 | 0.034 | 0.032 | 0.032 | 0.038 | 0.034 | 0.030 | 0.028 |
| Belgium | 0.034 | 0.031 | 0.027 | 0.024 | 0.022 | 0.021 | 0.027 | 0.024 | 0.022 | 0.021 | 0.027 | 0.024 | 0.021 | 0.019 |
| Bulgaria | 0.034 | 0.034 | 0.034 | 0.033 | 0.033 | 0.034 | 0.034 | 0.033 | 0.033 | 0.035 | 0.034 | 0.032 | 0.031 | 0.032 |
| Cyprus | 0.022 | 0.018 | 0.015 | 0.013 | 0.011 | 0.011 | 0.015 | 0.013 | 0.012 | 0.011 | 0.015 | 0.013 | 0.011 | 0.010 |
| Czech Republic | 0.084 | 0.078 | 0.073 | 0.066 | 0.061 | 0.060 | 0.073 | 0.065 | 0.061 | 0.062 | 0.072 | 0.064 | 0.057 | 0.055 |
| Denmark | 0.047 | 0.044 | 0.040 | 0.037 | 0.035 | 0.033 | 0.040 | 0.037 | 0.035 | 0.034 | 0.040 | 0.036 | 0.033 | 0.031 |
| Estonia | 0.054 | 0.052 | 0.052 | 0.049 | 0.047 | 0.046 | 0.052 | 0.048 | 0.046 | 0.047 | 0.052 | 0.048 | 0.044 | 0.043 |
| Finland | 0.043 | 0.039 | 0.036 | 0.033 | 0.032 | 0.032 | 0.036 | 0.033 | 0.032 | 0.032 | 0.036 | 0.033 | 0.031 | 0.031 |
| France | 0.051 | 0.044 | 0.035 | 0.029 | 0.025 | 0.023 | 0.035 | 0.029 | 0.025 | 0.023 | 0.035 | 0.029 | 0.024 | 0.021 |
| Germany | 0.059 | 0.057 | 0.053 | 0.049 | 0.046 | 0.046 | 0.053 | 0.049 | 0.047 | 0.048 | 0.053 | 0.048 | 0.044 | 0.042 |
| Greece | 0.011 | 0.011 | 0.010 | 0.009 | 0.008 | 0.008 | 0.010 | 0.009 | 0.008 | 0.008 | 0.010 | 0.009 | 0.008 | 0.008 |
| Hungary | 0.042 | 0.040 | 0.038 | 0.035 | 0.033 | 0.032 | 0.038 | 0.035 | 0.033 | 0.033 | 0.038 | 0.034 | 0.031 | 0.030 |
| Ireland | 0.019 | 0.016 | 0.014 | 0.012 | 0.011 | 0.010 | 0.014 | 0.012 | 0.011 | 0.011 | 0.014 | 0.012 | 0.011 | 0.010 |
| Italy | 0.046 | 0.044 | 0.040 | 0.037 | 0.036 | 0.037 | 0.040 | 0.037 | 0.036 | 0.037 | 0.040 | 0.037 | 0.035 | 0.036 |
| Latvia | 0.036 | 0.035 | 0.036 | 0.035 | 0.034 | 0.035 | 0.036 | 0.035 | 0.034 | 0.036 | 0.036 | 0.034 | 0.033 | 0.033 |
| Lithuania | 0.043 | 0.041 | 0.041 | 0.040 | 0.039 | 0.040 | 0.041 | 0.040 | 0.039 | 0.041 | 0.041 | 0.039 | 0.037 | 0.037 |
| Luxembourg | 0.027 | 0.023 | 0.020 | 0.016 | 0.014 | 0.013 | 0.020 | 0.016 | 0.014 | 0.013 | 0.020 | 0.016 | 0.013 | 0.012 |
| Malta | 0.002 | 0.002 | 0.002 | 0.002 | 0.003 | 0.003 | 0.002 | 0.002 | 0.003 | 0.003 | 0.002 | 0.002 | 0.003 | 0.003 |
| Netherlands | 0.030 | 0.028 | 0.025 | 0.023 | 0.022 | 0.021 | 0.025 | 0.023 | 0.022 | 0.022 | 0.025 | 0.022 | 0.021 | 0.020 |
| Poland | 0.044 | 0.041 | 0.039 | 0.036 | 0.035 | 0.036 | 0.039 | 0.036 | 0.035 | 0.036 | 0.039 | 0.035 | 0.033 | 0.033 |
| Portugal | 0.032 | 0.030 | 0.027 | 0.025 | 0.023 | 0.022 | 0.027 | 0.024 | 0.023 | 0.023 | 0.027 | 0.024 | 0.022 | 0.021 |
| Romania | 0.039 | 0.037 | 0.035 | 0.033 | 0.032 | 0.032 | 0.035 | 0.032 | 0.032 | 0.033 | 0.035 | 0.032 | 0.030 | 0.030 |
| Slovakia | 0.044 | 0.040 | 0.037 | 0.034 | 0.032 | 0.033 | 0.037 | 0.034 | 0.032 | 0.033 | 0.037 | 0.033 | 0.030 | 0.030 |
| Slovenia | 0.069 | 0.065 | 0.061 | 0.057 | 0.055 | 0.056 | 0.061 | 0.057 | 0.055 | 0.057 | 0.061 | 0.056 | 0.052 | 0.052 |



| Scenario | All Scenar | rios | Linear e level tre | e (trend) s mployme nds assu t thereaft | nt and ex med to 20 | posure | | ntion scen nce for O /m3) | ٠, | | | tion scen nce for O | | |
|-----------------------|------------|-------|-----------------------|--|------------------------|--------|-------|---------------------------------|-------|-------|-------|------------------------|-------|-------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Fraction | | | | | | | | | | | | | | |
| Spain | 0.018 | 0.020 | 0.023 | 0.025 | 0.028 | 0.030 | 0.023 | 0.025 | 0.028 | 0.031 | 0.023 | 0.024 | 0.026 | 0.028 |
| Sweden | 0.065 | 0.058 | 0.052 | 0.045 | 0.041 | 0.038 | 0.052 | 0.045 | 0.041 | 0.039 | 0.052 | 0.044 | 0.038 | 0.035 |
| United Kingdom | 0.057 | 0.047 | 0.036 | 0.027 | 0.020 | 0.017 | 0.036 | 0.027 | 0.021 | 0.017 | 0.036 | 0.026 | 0.020 | 0.016 |
| TOTAL | 0.046 | 0.042 | 0.038 | 0.034 | 0.031 | 0.030 | 0.038 | 0.034 | 0.031 | 0.031 | 0.038 | 0.033 | 0.030 | 0.028 |

| Scenario | All S | cenario | | Baseline Linear em level tren- constant | iploymen ds assum | t and exp ned to 20 | oosure | | nce for O | ario (2) - I EL = 50 p _l | | | ntion scen | | |
|---------------------|-------|---------|---|--|----------------------|------------------------|--------|------|-----------|--|------|------|------------|------|------|
| Country | 2010 | 0000 | | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Deaths | | | | | | | | | | | | | | | |
| Austria | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Belgium | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cyprus | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Denmark | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Estonia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Finland | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| France | | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 |
| Germany | | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
| Greece | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hungary | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ireland | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |



| Scenario | All Sc | enari | os | Linear en level trer | (trend) s mploymer nds assur thereafte | nt and exp ned to 20 | osure | Interven complia mg/m3) | nce for O | ario (2) - F EL = 50 pp | Full om (273 | | ition scen | | |
|---------------------|--------|-------|------|-------------------------|---|-------------------------|-------|-------------------------------|-----------|----------------------------|-----------------|------|------------|------|------|
| Country | 2010 | | 7070 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Deaths | | | | | | | | | | | | | | | |
| Italy | | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Latvia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lithuania | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Luxembourg | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Poland | | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 2 |
| Portugal | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Romania | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Slovakia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Slovenia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Spain | | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Sweden | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| United Kingdom | | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 |
| TOTAL | • | 13 | 14 | 14 | 15 | 15 | 15 | 14 | 15 | 15 | 15 | 14 | 14 | 14 | 14 |



| Scenario | All Scenario | s | Linear exposu | employ re level ed to 202 |) scenar ment an trends 21-30, co | ıd | | ntion sce ance for g/m3) | | | | ance for | enario (3 OEL = 1 | |
|----------------------------|--------------|------|---------------------------------------|---------------------------------|--|------|------|--------------------------------|------|------|------|----------|----------------------|------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Registrations | 1, | | | | | | | | | | | | | |
| Austria | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Belgium | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Bulgaria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 |
| Denmark | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Estonia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Finland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| France | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 |
| Germany | 9 | 9 | 10 | 9 | 9 | 8 | 10 | 9 | 9 | 8 | 10 | 9 | 8 | 7 |
| Greece | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hungary | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Ireland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Italy | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Latvia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lithuania | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Luxembourg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Poland | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Portugal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Romania | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Slovakia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Slovenia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |



| Scenario | All Sce | All Scenarios | | | Baseline (trend) scenario (1) ¹² - Linear employment and exposure level trends assumed to 2021-30, constant thereafter. | | | | ntion sco ance for g/m3) | | | Intervention scenario (3) - Full compliance for OEL = 10 ppm (50 mg/m3) | | | |
|----------------------------|---------|---------------|------|------|--|------|------|------|--------------------------------|------|------|---|------|------|------|
| | 2010 | | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Registrations | | | | | | | | | | | | | | | |
| Spain | | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 |
| Sweden | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| United Kingdom | | 4 | 4 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 2 |
| TOTAL | | 31 | 32 | 33 | 32 | 30 | 29 | 33 | 31 | 30 | 30 | 33 | 31 | 29 | 27 |

| Scenario | All Scenar | (1) ^[2] - l and ex assum | Linear e | | ent | Full co | | cenario (ce for OE n3) | | Intervention scenario (3) - Full compliance for OEL = 10 ppm (50 mg/m3) | | | | |
|--|------------|---|----------|------|------|---------|------|-------------------------------|------|---|------|------|------|------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Years of Life Lost (YLLs) | | | | | | | | | | | | | | |
| Austria | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Belgium | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | 14 | 14 | 15 | 14 | 14 | 13 | 15 | 14 | 14 | 13 | 15 | 14 | 13 | 12 |
| Denmark | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Estonia | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Finland | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| France | 25 | 25 | 22 | 20 | 18 | 17 | 22 | 20 | 18 | 17 | 22 | 20 | 17 | 16 |
| Germany | 44 | 47 | 48 | 46 | 43 | 40 | 48 | 46 | 43 | 42 | 48 | 45 | 40 | 37 |
| Greece | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Hungary | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |



| Scenario | All Scenari | Baseline (trend) scenario (1) ^[2] - Linear employment and exposure level trends assumed to 2021-30, constant thereafter. | | | | Full co | | cenario (ce for OE n3) | | Intervention scenario (3) - Full compliance for OEL = 10 ppm (50 mg/m3) | | | | |
|--|-------------|---|------|------|------|---------|------|-------------------------------|------|---|------|------|------|------|
| | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Years of Life Lost (YLLs) | | | | | 7.7 | | | | | | | | | |
| Ireland | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Italy | 22 | 24 | 25 | 25 | 25 | 24 | 25 | 25 | 25 | 25 | 25 | 24 | 24 | 24 |
| Latvia | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Lithuania | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Luxembourg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | 4 | 5 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 |
| Poland | 17 | 18 | 19 | 19 | 19 | 18 | 19 | 19 | 19 | 19 | 19 | 19 | 18 | 17 |
| Portugal | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| Romania | 4 | 4 | 4 | 4 | 3 | 3 | 4 | 4 | 3 | 3 | 4 | 4 | 3 | 3 |
| Slovakia | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 2 |
| Slovenia | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Spain | 5 | 7 | 10 | 12 | 14 | 15 | 10 | 12 | 14 | 16 | 10 | 11 | 13 | 14 |
| Sweden | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| United Kingdom | 32 | 29 | 25 | 20 | 16 | 14 | 25 | 20 | 16 | 15 | 25 | 20 | 16 | 14 |
| TOTAL | 189 | 196 | 196 | 188 | 179 | 174 | 196 | 187 | 180 | 178 | 196 | 184 | 170 | 162 |



| Scenario | All Scena | arios | | scena emplo expos assur | oyment sure leve ned to | ^[2] - Lin | nds 0, | (2) - F | ull cor 50 pp | scena npliand om (273 | e for | (3) - F | ull cor = 10 pp | scena npliano om (50 | |
|---|-----------|-------|----|----------------------------------|-------------------------------|----------------------|-----------|---------|------------------|-----------------------------|-------|---------|--------------------|----------------------------|------|
| Country | 2010 | 2020 | | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Years of Life Lived with Dis | | | | | - ' ' | | | | -,, | - ' ' | -,, | -,, | -,, | | |
| Austria | | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
| Belgium | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| Cyprus | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | | 16 | 17 | 17 | 17 | 16 | 15 | 17 | 17 | 16 | 16 | 17 | 16 | 15 | 14 |
| Denmark | | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 2 |
| Estonia | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Finland | | 2 | 3 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 2 |
| France | | 29 | 28 | 25 | 23 | 20 | 19 | 25 | 23 | 20 | 19 | 25 | 22 | 19 | 18 |
| Germany | | 52 | 55 | 56 | 53 | 50 | 47 | 56 | 53 | 50 | 49 | 56 | 52 | 47 | 43 |
| Greece | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Hungary | | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| Ireland | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Italy | | 26 | 28 | 29 | 29 | 29 | 28 | 29 | 29 | 29 | 29 | 29 | 28 | 28 | 28 |
| Latvia | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Lithuania | | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Luxembourg | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 |
| Poland | | 19 | 20 | 21 | 22 | 21 | 21 | 21 | 22 | 21 | 21 | 21 | 21 | 20 | 19 |
| Portugal | | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Romania | | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
| Slovakia | | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 |



| Scenario | All Sc | enarios | | scer emp expo assu | eline (tro ario (1) loyment sure le med to stant the | ^[2] - Lin t and vel trer 2021-3 | nds 60, | (2) - F | ull cor = 50 pp | scena npliand om (273 | e for | (3) - F | vention Full cor = 10 pp 13) | npliand | |
|---|-----------------|---------|------|-----------------------------|---|---|------------|---------|--------------------|-----------------------------|-------|---------|---------------------------------------|---------|------|
| Country | 2010 | | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Years of Life Lived with Dis | ability (DALYs) | | | | | | | | | | | | | | |
| Slovenia | | 1 | | 2 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| Spain | | 6 | | 3 11 | 13 | 16 | 17 | 11 | 13 | 16 | 18 | 11 | 13 | 15 | 16 |
| Sweden | | 6 | | 6 | 6 | 5 | 5 | 6 | 6 | 5 | 5 | 6 | 6 | 5 | 5 |
| United Kingdom | | 35 | 3 | 2 27 | 22 | 18 | 16 | 27 | 22 | 18 | 16 | 27 | 22 | 17 | 15 |
| TOTAL | | 216 | 22 | 223 | 215 | 205 | 198 | 223 | 214 | 205 | 203 | 223 | 210 | 194 | 185 |

Table 8.5.5 Results for baseline, forecast and intervention (1) scenarios (1) to (4a) for liver cancer, by country, men plus women

| Scenario | All Scenari | ios | Linear e level trei | mploymen | cenario (1) It and exp ned to 202 r. | osure | | tion scena nce for OE | | | | tion scena nce for OE | | |
|----------------|--------------|------------|------------------------|----------|---|-------|-------|--------------------------|-------|-------|-------|--------------------------|-------|-------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable | e Fraction | 1 | | | | | | · | | | | | |
| Austria | 0.076 | 0.071 | 0.063 | 0.050 | 0.035 | 0.023 | 0.063 | 0.049 | 0.037 | 0.031 | 0.063 | 0.044 | 0.021 | 0.006 |
| Belgium | 0.050 | 0.046 | 0.039 | 0.028 | 0.018 | 0.011 | 0.039 | 0.028 | 0.019 | 0.014 | 0.039 | 0.026 | 0.011 | 0.002 |
| Bulgaria | 0.056 | 0.056 | 0.055 | 0.045 | 0.033 | 0.022 | 0.054 | 0.044 | 0.031 | 0.023 | 0.054 | 0.040 | 0.019 | 0.004 |
| Cyprus | 0.034 | 0.027 | 0.022 | 0.015 | 0.009 | 0.005 | 0.022 | 0.015 | 0.009 | 0.007 | 0.022 | 0.014 | 0.006 | 0.001 |
| Czech Republic | 0.127 | 0.121 | 0.114 | 0.094 | 0.071 | 0.050 | 0.114 | 0.092 | 0.070 | 0.058 | 0.113 | 0.084 | 0.042 | 0.013 |
| Denmark | 0.077 | 0.072 | 0.062 | 0.048 | 0.031 | 0.019 | 0.062 | 0.047 | 0.032 | 0.024 | 0.062 | 0.043 | 0.019 | 0.004 |
| Estonia | 0.091 | 0.088 | 0.084 | 0.067 | 0.047 | 0.031 | 0.083 | 0.064 | 0.042 | 0.031 | 0.083 | 0.060 | 0.027 | 0.006 |
| Finland | 0.060 | 0.053 | 0.042 | 0.028 | 0.015 | 0.007 | 0.042 | 0.028 | 0.016 | 0.011 | 0.042 | 0.026 | 0.010 | 0.001 |
| France | 0.081 | 0.069 | 0.055 | 0.039 | 0.024 | 0.014 | 0.055 | 0.039 | 0.026 | 0.019 | 0.054 | 0.035 | 0.015 | 0.003 |



| Scenario | All Scenari | os | Linear ei level trei | mploymen | cenario (1) t and expo ned to 202 r. | osure | | tion scena nce for OE | | | | | rio (3) - Fu EL = 10 pp | |
|----------------|--------------|----------|-------------------------|----------|---|-------|-------|--------------------------|-------|-------|-------|-------|----------------------------|-------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable | Fraction |) | | | | | | | | | | | |
| Germany | 0.091 | 0.088 | 0.082 | 0.068 | 0.049 | 0.034 | 0.082 | 0.067 | 0.051 | 0.044 | 0.082 | 0.060 | 0.030 | 0.009 |
| Greece | 0.016 | 0.014 | 0.012 | 0.008 | 0.004 | 0.002 | 0.012 | 0.008 | 0.005 | 0.003 | 0.011 | 0.007 | 0.003 | 0.000 |
| Hungary | 0.064 | 0.062 | 0.056 | 0.044 | 0.030 | 0.019 | 0.056 | 0.043 | 0.030 | 0.022 | 0.056 | 0.040 | 0.018 | 0.004 |
| Ireland | 0.031 | 0.025 | 0.020 | 0.014 | 0.008 | 0.004 | 0.020 | 0.014 | 0.008 | 0.006 | 0.020 | 0.013 | 0.005 | 0.001 |
| Italy | 0.072 | 0.072 | 0.071 | 0.069 | 0.069 | 0.070 | 0.071 | 0.069 | 0.069 | 0.071 | 0.071 | 0.068 | 0.065 | 0.063 |
| Latvia | 0.060 | 0.058 | 0.055 | 0.044 | 0.031 | 0.020 | 0.055 | 0.043 | 0.030 | 0.024 | 0.055 | 0.040 | 0.018 | 0.004 |
| Lithuania | 0.074 | 0.071 | 0.066 | 0.055 | 0.039 | 0.026 | 0.066 | 0.053 | 0.036 | 0.027 | 0.066 | 0.049 | 0.023 | 0.005 |
| Luxembourg | 0.039 | 0.034 | 0.028 | 0.019 | 0.012 | 0.007 | 0.028 | 0.019 | 0.013 | 0.010 | 0.028 | 0.017 | 0.007 | 0.002 |
| Malta | 0.003 | 0.002 | 0.002 | 0.001 | 0.001 | 0.000 | 0.002 | 0.001 | 0.001 | 0.000 | 0.002 | 0.001 | 0.000 | 0.000 |
| Netherlands | 0.045 | 0.041 | 0.034 | 0.025 | 0.015 | 0.009 | 0.034 | 0.025 | 0.016 | 0.013 | 0.034 | 0.022 | 0.010 | 0.002 |
| Poland | 0.068 | 0.063 | 0.059 | 0.048 | 0.035 | 0.024 | 0.059 | 0.046 | 0.033 | 0.027 | 0.058 | 0.042 | 0.020 | 0.005 |
| Portugal | 0.052 | 0.048 | 0.042 | 0.032 | 0.022 | 0.014 | 0.042 | 0.032 | 0.022 | 0.017 | 0.042 | 0.029 | 0.013 | 0.003 |
| Romania | 0.061 | 0.059 | 0.055 | 0.044 | 0.032 | 0.022 | 0.055 | 0.043 | 0.030 | 0.024 | 0.054 | 0.039 | 0.019 | 0.004 |
| Slovakia | 0.067 | 0.061 | 0.055 | 0.043 | 0.030 | 0.020 | 0.055 | 0.042 | 0.029 | 0.022 | 0.054 | 0.038 | 0.018 | 0.004 |
| Slovenia | 0.108 | 0.103 | 0.095 | 0.076 | 0.055 | 0.038 | 0.095 | 0.075 | 0.054 | 0.044 | 0.094 | 0.068 | 0.033 | 0.008 |
| Spain | 0.029 | 0.032 | 0.036 | 0.034 | 0.029 | 0.022 | 0.036 | 0.034 | 0.030 | 0.029 | 0.035 | 0.029 | 0.016 | 0.006 |
| Sweden | 0.098 | 0.089 | 0.077 | 0.058 | 0.037 | 0.023 | 0.077 | 0.057 | 0.038 | 0.029 | 0.077 | 0.052 | 0.023 | 0.005 |
| United Kingdom | 0.086 | 0.070 | 0.051 | 0.031 | 0.016 | 0.007 | 0.051 | 0.031 | 0.016 | 0.010 | 0.050 | 0.029 | 0.010 | 0.001 |
| TOTAL | 0.071 | 0.066 | 0.058 | 0.047 | 0.035 | 0.025 | 0.058 | 0.046 | 0.035 | 0.030 | 0.058 | 0.043 | 0.024 | 0.012 |



| Scenario | All Scenario | os | Linear e | mployme | cenario (nt and ex med to 20 er. | posure | | nce for O | nario (2) - EL = 50 p | | | nce for O | nario (3) - EL = 10 p | |
|----------------|----------------|--------|----------|---------|--|--------|------|-----------|--------------------------|------|------|-----------|--------------------------|------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable I | Deaths | | | | | | | | | | | | |
| Austria | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Belgium | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 0 |
| Denmark | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Estonia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Finland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| France | 6 | 7 | 6 | 5 | 3 | 2 | 6 | 5 | 3 | 3 | 6 | 4 | 2 | 0 |
| Germany | 7 | 7 | 8 | 7 | 5 | 3 | 8 | 7 | 6 | 5 | 8 | 6 | 3 | 1 |
| Greece | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hungary | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Ireland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Italy | 8 | 9 | 10 | 11 | 12 | 12 | 10 | 11 | 12 | 12 | 10 | 11 | 11 | 11 |
| Latvia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lithuania | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Luxembourg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Poland | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 0 |
| Portugal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Romania | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 0 |
| Slovakia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Slovenia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Spain | 1 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 1 |



| Scenario | All Scenari | os | Linear en level trer | trend) somployments assument thereafte | t and exp ned to 202 | osure | | ntion scen | | | | ntion scen ince for O | | |
|----------------|--------------|--------|-------------------------|--|-------------------------|-------|------|------------|------|------|------|--------------------------|------|------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable | Deaths | | | | | | | | | | | | |
| Sweden | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| United Kingdom | 3 | 3 | 2 | 2 | 1 | 0 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 0 |
| TOTAL | 34 | 37 | 38 | 35 | 28 | 21 | 38 | 35 | 28 | 25 | 38 | 32 | 19 | 10 |

| Scenario | All S | cenar | ios | Linear o | e (trend) employm re level t -30, cons | ent and rends as | sumed | | ance for | enario (2) OEL = 50 | | | ance for | enario (3) OEL = 10 | |
|----------------------------|-------|-------|------|----------|---|---------------------|-------|------|----------|------------------------|------|------|----------|------------------------|------|
| Country | 2010 | | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Registrations | | | | | | | | | | | | | | | |
| Austria | | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Belgium | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cyprus | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Denmark | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Estonia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Finland | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| France | | 6 | 6 | 5 | 4 | 3 | 2 | 5 | 4 | 3 | 2 | 5 | 4 | 2 | 0 |
| Germany | | 5 | 5 | 5 | 4 | 3 | 2 | 5 | 4 | 3 | 3 | 5 | 4 | 2 | 1 |
| Greece | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hungary | | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Ireland | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Italy | | 10 | 11 | 13 | 14 | 14 | 14 | 13 | 14 | 14 | 14 | 13 | 14 | 13 | 13 |



| Scenario | All S | cenar | ios | Linear exposu | employm re level t | scenarion scent and rends as tant there | sumed | | ntion sce ance for (g/m3) | | | | ance for (| nario (3) DEL = 10 | |
|----------------------------|-------|-------|------|---------------|-----------------------|---|-------|------|----------------------------------|------|------|------|------------|-----------------------|------|
| Country | 2010 | | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Registrations | | | | | | | | | | | | | | | |
| Latvia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lithuania | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Luxembourg | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Poland | | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 0 |
| Portugal | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Romania | | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 0 |
| Slovakia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Slovenia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Spain | | 2 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 1 |
| Sweden | | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| United Kingdom | | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 0 | 0 |
| TOTAL | | 34 | 36 | 37 | 33 | 25 | 18 | 37 | 32 | 26 | 22 | 37 | 30 | 17 | 9 |



| Scenario | All Scenarios | | (1) ^[2] - I and ex assum | _inear e | | ent | Full co | | cenario (ce for OE n3) | | Full co | | cenario (e for OE 3) | |
|------------------------------------|---------------|-----|---|----------|------|------|---------|------|-------------------------------|------|---------|------|-----------------------------|------|
| Country | 2010 | | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Years of Life Lost () | | | | | | | | - 11 | | | | | | |
| Austria | 10 | 11 | 11 | 9 | 7 | 4 | 11 | 9 | 7 | 6 | 11 | 8 | 4 | 1 |
| Belgium | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | 7 | 7 | 7 | 6 | 4 | 3 | 7 | 6 | 4 | 3 | 7 | 5 | 2 | 1 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | 17 | 18 | 19 | 17 | 13 | 9 | 19 | 17 | 13 | 10 | 19 | 15 | 8 | 2 |
| Denmark | 4 | 4 | 4 | 3 | 2 | 1 | 4 | 3 | 2 | 2 | 4 | 3 | 1 | 0 |
| Estonia | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Finland | 4 | 4 | 3 | 2 | 1 | 1 | 3 | 2 | 1 | 1 | 3 | 2 | 1 | 0 |
| France | 99 | 98 | 86 | 66 | 42 | 25 | 86 | 66 | 45 | 35 | 86 | 59 | 26 | 6 |
| Germany | 94 | 102 | 102 | 87 | 62 | 40 | 102 | 87 | 64 | 53 | 102 | 78 | 37 | 10 |
| Greece | 3 | 3 | 3 | 2 | 1 | 1 | 3 | 2 | 1 | 1 | 3 | 2 | 1 | 0 |
| Hungary | 7 | 7 | 7 | 6 | 4 | 2 | 7 | 5 | 4 | 3 | 7 | 5 | 2 | 0 |
| Ireland | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Italy | 104 | 117 | 132 | 140 | 142 | 140 | 132 | 139 | 142 | 141 | 132 | 136 | 132 | 127 |
| Latvia | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Lithuania | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Luxembourg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | 4 | 4 | 4 | 3 | 2 | 1 | 4 | 3 | 2 | 1 | 4 | 3 | 1 | 0 |
| Poland | 20 | 22 | 23 | 20 | 15 | 10 | 23 | 20 | 14 | 11 | 23 | 18 | 9 | 2 |
| Portugal | 6 | 6 | 6 | 5 | 3 | 2 | 6 | 5 | 3 | 3 | 6 | 4 | 2 | 0 |
| Romania | 22 | 23 | 23 | 20 | 14 | 9 | 23 | 19 | 14 | 10 | 23 | 18 | 8 | 2 |
| Slovakia | 4 | 4 | 4 | 4 | 3 | 2 | 4 | 3 | 3 | 2 | 4 | 3 | 2 | 0 |
| Slovenia | 3 | 3 | 3 | 3 | 2 | 1 | 3 | 3 | 2 | 1 | 3 | 2 | 1 | 0 |



| Scenario | All Scenarios | | (1) ^[2] - I and ex assum | Linear e | , | ent | Full co | | cenario (e for OE n3) | | Full co | ntion so mplianc 0 mg/m | e for OE | |
|---------------------------------------|---------------|------|---|----------|------|------|---------|------|------------------------------|------|---------|-------------------------------|----------|------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Years of Life Lost (YLLs | | | | | | | | | | | | | | |
| Spain | 21 | 27 | 37 | 40 | 36 | 28 | 37 | 40 | 38 | 37 | 37 | 35 | 20 | 7 |
| Sweden | 9 | 9 | 9 | 7 | 5 | 3 | 9 | 7 | 5 | 4 | 9 | 6 | 3 | 1 |
| United KingdomK | 41 | 38 | 30 | 20 | 11 | 5 | 30 | 20 | 11 | 7 | 30 | 19 | 7 | 1 |
| TOTAL | 481 | 509 | 506 | 437 | 331 | 243 | 506 | 433 | 338 | 288 | 504 | 397 | 227 | 112 |

| Scenario | All Scenari | os | (1) ^[2] - L and exp assume | e (trend) inear em oosure le ed to 202 nt therea | ployme vel trei 1-30, | ent | | ntion sce ance for (g/m3) | | | | ntion sce ance for (m3) | | |
|----------------------------|--------------------------|-------|---|--|-----------------------------|------|------|----------------------------------|------|------|------|--------------------------------|------|------|
| Country | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Years of Life | Lived with Disability (D | ALYs) | | | | | | | | | | | | |
| Austria | 10 |) 11 | 11 | 9 | 7 | 4 | 11 | 9 | 7 | 6 | 11 | 8 | 4 | 1 |
| Belgium | (| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | - | 7 8 | 7 | 6 | 4 | 3 | 7 | 6 | 4 | 3 | 7 | 5 | 3 | 1 |
| Cyprus | (| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | 17 | 7 18 | 19 | 17 | 13 | 9 | 19 | 17 | 13 | 10 | 19 | 15 | 8 | 2 |
| Denmark | 4 | 1 4 | 4 | 3 | 2 | 1 | 4 | 3 | 2 | 2 | 4 | 3 | 1 | 0 |
| Estonia | • | 1 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Finland | 4 | 4 | 3 | 2 | 1 | 1 | 3 | 2 | 1 | 1 | 3 | 2 | 1 | 0 |
| France | 10 ⁻ | 1 100 | 88 | 67 | 43 | 26 | 88 | 67 | 45 | 35 | 87 | 60 | 26 | 6 |
| Germany | 95 | 5 103 | 104 | 88 | 62 | 41 | 104 | 88 | 65 | 53 | 103 | 79 | 38 | 10 |
| Greece | (| 3 | 3 | 2 | 1 | 1 | 3 | 2 | 1 | 1 | 3 | 2 | 1 | 0 |
| Hungary | - | 7 7 | 7 | 6 | 4 | 3 | 7 | 6 | 4 | 3 | 7 | 5 | 2 | 0 |



| Scenario | All Scenarios | | (1) ^[2] - Li and exp assume | e (trend) inear em osure le d to 202 it thereat | ployme vel trei 1-30, | ent | | ntion sce ance for (g/m3) | | | | ntion sce ance for (m3) | | |
|------------------------------|-----------------------------|-----|--|---|-----------------------------|------|------|----------------------------------|------|------|------|--------------------------------|------|------|
| Country | 2010 | | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Years of Life L | ived with Disability (DALYs | ;) | | | | | | | | | | | | |
| Ireland | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Italy | 107 | 120 | 135 | 143 | 145 | 144 | 135 | 143 | 145 | 145 | 135 | 140 | 136 | 130 |
| Latvia | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Lithuania | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 0 |
| Luxembourg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | 4 | 4 | 4 | 3 | 2 | 1 | 4 | 3 | 2 | 2 | 4 | 3 | 1 | 0 |
| Poland | 21 | 22 | 23 | 21 | 15 | 10 | 23 | 20 | 15 | 11 | 23 | 18 | 9 | 2 |
| Portugal | 6 | 6 | 6 | 5 | 4 | 2 | 6 | 5 | 4 | 3 | 6 | 4 | 2 | 0 |
| Romania | 22 | 23 | 24 | 20 | 15 | 9 | 24 | 20 | 14 | 10 | 23 | 18 | 9 | 2 |
| Slovakia | 4 | 4 | 4 | 4 | 3 | 2 | 4 | 4 | 3 | 2 | 4 | 3 | 2 | 0 |
| Slovenia | 3 | 3 | 3 | 3 | 2 | 1 | 3 | 3 | 2 | 1 | 3 | 2 | 1 | 0 |
| Spain | 21 | 28 | 38 | 41 | 37 | 28 | 38 | 41 | 39 | 37 | 37 | 36 | 21 | 7 |
| Sweden | 9 | 10 | 9 | 7 | 5 | 3 | 9 | 7 | 5 | 4 | 9 | 7 | 3 | 1 |
| United Kingdom | 41 | 38 | 30 | 20 | 11 | 5 | 30 | 20 | 11 | 7 | 30 | 19 | 7 | 1 |
| TOTAL | 490 | 519 | 516 | 445 | 338 | 247 | 515 | 441 | 345 | 294 | 514 | 405 | 232 | 114 |



Table 8.5.6 Results for baseline, forecast and intervention (1) scenarios (1) to (4a) for NHL, by country, men plus women

| Scenario | All Sce | narios | employme | (trend) scer ent and exp to 2021-30, | osure leve | l trends | | on scenari ce for OEL | o (2) - Full = 50 ppm (| 273 | | on scenarion ce for OEL | o (3) - Full = 10 ppm (| 50 |
|----------------|--------------|----------|----------|--|------------|----------|--------|--------------------------|----------------------------|--------|--------|----------------------------|----------------------------|--------|
| Country | | | | | | | | | | | | | | |
| | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable | Fraction | | | | | | | | | | | | |
| Austria | 0.048% | 0.036% | 0.023% | 0.013% | 0.014% | 0.014% | 0.024% | 0.024% | 0.026% | 0.026% | 0.004% | 0.004% | 0.005% | 0.005% |
| Belgium | 0.029% | 0.020% | 0.011% | 0.006% | 0.006% | 0.006% | 0.011% | 0.011% | 0.011% | 0.011% | 0.002% | 0.002% | 0.002% | 0.002% |
| Bulgaria | 0.034% | 0.027% | 0.018% | 0.011% | 0.012% | 0.013% | 0.014% | 0.016% | 0.017% | 0.020% | 0.003% | 0.003% | 0.003% | 0.004% |
| Cyprus | 0.020% | 0.013% | 0.007% | 0.003% | 0.003% | 0.003% | 0.007% | 0.006% | 0.006% | 0.006% | 0.001% | 0.001% | 0.001% | 0.001% |
| Czech Republic | 0.080% | 0.064% | 0.045% | 0.029% | 0.030% | 0.033% | 0.041% | 0.043% | 0.045% | 0.051% | 0.009% | 0.010% | 0.010% | 0.012% |
| Denmark | 0.046% | 0.033% | 0.020% | 0.011% | 0.011% | 0.011% | 0.020% | 0.020% | 0.021% | 0.021% | 0.003% | 0.003% | 0.003% | 0.003% |
| Estonia | 0.053% | 0.042% | 0.027% | 0.016% | 0.017% | 0.018% | 0.020% | 0.022% | 0.024% | 0.026% | 0.004% | 0.004% | 0.004% | 0.005% |
| Finland | 0.029% | 0.018% | 0.009% | 0.004% | 0.004% | 0.004% | 0.009% | 0.009% | 0.010% | 0.010% | 0.001% | 0.001% | 0.001% | 0.001% |
| France | 0.040% | 0.026% | 0.015% | 0.008% | 0.008% | 0.008% | 0.015% | 0.014% | 0.015% | 0.014% | 0.003% | 0.002% | 0.002% | 0.002% |
| Germany | 0.057% | 0.045% | 0.030% | 0.019% | 0.021% | 0.022% | 0.030% | 0.032% | 0.037% | 0.038% | 0.006% | 0.006% | 0.007% | 0.008% |
| Greece | 0.008% | 0.005% | 0.003% | 0.001% | 0.001% | 0.001% | 0.003% | 0.003% | 0.003% | 0.003% | 0.000% | 0.000% | 0.000% | 0.000% |
| Hungary | 0.037% | 0.028% | 0.018% | 0.010% | 0.011% | 0.012% | 0.016% | 0.017% | 0.017% | 0.019% | 0.003% | 0.003% | 0.003% | 0.003% |
| Ireland | 0.018% | 0.011% | 0.006% | 0.003% | 0.003% | 0.003% | 0.006% | 0.006% | 0.005% | 0.006% | 0.001% | 0.001% | 0.001% | 0.001% |
| Italy | 0.055% | 0.054% | 0.053% | 0.053% | 0.057% | 0.061% | 0.053% | 0.054% | 0.058% | 0.062% | 0.048% | 0.049% | 0.052% | 0.056% |
| Latvia | 0.034% | 0.027% | 0.017% | 0.010% | 0.011% | 0.012% | 0.014% | 0.015% | 0.017% | 0.018% | 0.002% | 0.002% | 0.003% | 0.003% |
| Lithuania | 0.043% | 0.034% | 0.022% | 0.013% | 0.014% | 0.016% | 0.017% | 0.018% | 0.020% | 0.022% | 0.003% | 0.003% | 0.004% | 0.004% |
| Luxembourg | 0.020% | 0.013% | 0.007% | 0.004% | 0.003% | 0.003% | 0.007% | 0.007% | 0.007% | 0.007% | 0.001% | 0.001% | 0.001% | 0.001% |
| Malta | 0.001% | 0.001% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% |
| Netherlands | 0.025% | 0.017% | 0.009% | 0.005% | 0.005% | 0.005% | 0.010% | 0.010% | 0.011% | 0.011% | 0.001% | 0.001% | 0.001% | 0.001% |
| Poland | 0.041% | 0.032% | 0.021% | 0.013% | 0.014% | 0.016% | 0.019% | 0.021% | 0.022% | 0.025% | 0.004% | 0.004% | 0.004% | 0.005% |



| Scenario | All Sce | narios | employme | ent and exp | nario (1) ^[2] - posure leve , constant t | l trends | | on scenarion ce for OEL | o (2) - Full = 50 ppm (2 | 273 | | on scenarion ce for OEL | o (3) - Full = 10 ppm (| 50 |
|----------------|--------------|------------|----------|-------------|---|----------|--------|----------------------------|-----------------------------|--------|--------|----------------------------|----------------------------|--------|
| Country | | | | | | | | | | | | | | |
| | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable | e Fraction | | | | | | | | | | | | |
| Portugal | 0.032% | 0.023% | 0.014% | 0.008% | 0.008% | 0.008% | 0.012% | 0.012% | 0.013% | 0.014% | 0.002% | 0.002% | 0.002% | 0.002% |
| Romania | 0.036% | 0.028% | 0.018% | 0.011% | 0.012% | 0.014% | 0.015% | 0.016% | 0.018% | 0.020% | 0.003% | 0.003% | 0.003% | 0.004% |
| Slovakia | 0.037% | 0.028% | 0.017% | 0.010% | 0.011% | 0.012% | 0.015% | 0.017% | 0.018% | 0.021% | 0.003% | 0.003% | 0.003% | 0.004% |
| Slovenia | 0.066% | 0.051% | 0.033% | 0.021% | 0.022% | 0.025% | 0.031% | 0.034% | 0.037% | 0.041% | 0.006% | 0.006% | 0.007% | 0.008% |
| Spain | 0.031% | 0.027% | 0.020% | 0.014% | 0.015% | 0.016% | 0.020% | 0.024% | 0.025% | 0.028% | 0.004% | 0.005% | 0.005% | 0.006% |
| Sweden | 0.060% | 0.042% | 0.026% | 0.014% | 0.014% | 0.014% | 0.026% | 0.025% | 0.026% | 0.026% | 0.004% | 0.004% | 0.004% | 0.004% |
| United Kingdom | 0.036% | 0.021% | 0.009% | 0.004% | 0.004% | 0.004% | 0.009% | 0.008% | 0.008% | 0.008% | 0.001% | 0.001% | 0.001% | 0.001% |
| TOTAL | 0.042% | 0.033% | 0.023% | 0.016% | 0.017% | 0.017% | 0.022% | 0.023% | 0.024% | 0.025% | 0.009% | 0.009% | 0.009% | 0.010% |



| Scenario | | All Scenarios | | - Linea | ne (trend or employ ure level ed to 202 fter. | ment an trends | d | | ention sca ance for g/m3) | | | | ntion sco ance for /m3) | | |
|---------------------|------|---------------|------|---------|---|-------------------|------|------|---------------------------------|------|------|------|-------------------------------|------|------|
| Country | | | | | | | | | | | | | | | |
| | 2010 | | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Deaths | | | ., | - ' ' | | | | | | | | | | | |
| Austria | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Belgium | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cyprus | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Denmark | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Estonia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Finland | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| France | | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Germany | | 3 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Greece | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hungary | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ireland | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Italy | | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 |
| Latvia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lithuania | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Luxembourg | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |



| Scenario | | All Scenarios | | Linea exposi | ne (trend r employ ire level ed to 202 ter. | ment an trends | d | | ntion sce ance for (g/m3) | | | | ance for | enario (3) OEL = 10 | |
|---------------------|------|---------------|------|---|---|-------------------|------|------|----------------------------------|------|------|------|----------|------------------------|------|
| Country | 2010 | | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Deaths | | | | | | | | | | | | | | | |
| Poland | | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Portugal | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Romania | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Slovakia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Slovenia | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Spain | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Sweden | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| United Kingdom | | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TOTAL | | 12 | 10 | 8 | 6 | 7 | 7 | 8 | 9 | 10 | 11 | 3 | 4 | 4 | 4 |



| Scenario | All Scenarios | | (1) ^[2] - and ex assum | Linear e | | ent | Full co | ention so ompliand 273 mg/n | e for OE | | Full co | ention so empliance 50 mg/m | e for O | |
|----------------|----------------------------|------|---|----------|------|------|---------|-----------------------------------|----------|------|---------|-----------------------------------|---------|------|
| Country | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable Registrations | | | | | | | | | | | | | |
| Austria | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Belgium | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Denmark | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Estonia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Finland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| France | 4 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Germany | 7 | 6 | 4 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 1 | 1 | 1 | 1 |
| Greece | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hungary | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ireland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Italy | 6 | 7 | 7 | 8 | 8 | 8 | 7 | 8 | 8 | 8 | 6 | 7 | 7 | 7 |
| Latvia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lithuania | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Luxembourg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |



| Scenario | All Scenarios | | (1) ^[2] - I and ex assum | ne (trend Linear en posure I ed to 20 Int there | mploymore treated to the second treated treate | ent | Full co | ntion sc mplianc 73 mg/m | e for OE | | Full co | ntion so mplianc 0 mg/m | e for OE | |
|----------------|----------------------------|---|---|---|--|------|---------|--------------------------------|----------|------|---------|-------------------------------|----------|------|
| Country | 0 | 0. | 9 | 2040 | 2050 | 2060 | 0 | 9 | 0 | 0 | 0 | 9 | 0 | 0 |
| | 2010 | 0 0 0 0 0 0 7 ributable Registrations | | | | | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable Registrations | | | | | | | | | | | | | |
| Poland | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Portugal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Romania | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Slovakia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Slovenia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Spain | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Sweden | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| United Kingdom | 3 | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| TOTAL | 28 | 24 | 19 | 14 | 15 | 15 | 18 | 19 | 20 | 21 | 7 | 8 | 8 | 8 |



| Scenario | All Scenarios | | (1) ^[2] and e assu | line (tre - Linear exposur med to 2 tant the | employ e level t 2021-30 | /ment trends | Full c | ompliar | scenarion nce for (mg/m3) | OÈL = | Full c | ompliar | scenarion nce for (mg/m3 | OEL |
|----------------|--|------|----------------------------------|--|--------------------------------|-----------------|--------|---------|----------------------------------|-------|--------|---------|---------------------------------|------|
| Country | 0 | | 0 | 0 | | | | 0 | • | | | • | 0 | 0 |
| | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable Years of Life Lost (YLLs) | | | | - 11 | | - ' ' | | | - ' ' | - ' ' | | | |
| Austria | 4 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 0 | 0 | 0 | 0 |
| Belgium | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | 7 | 6 | 5 | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 1 | 1 | 1 | 1 |
| Denmark | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Estonia | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Finland | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| France | 23 | 17 | 11 | 6 | 6 | 6 | 11 | 10 | 11 | 11 | 2 | 2 | 2 | 2 |
| Germany | 46 | 39 | 28 | 18 | 18 | 18 | 27 | 29 | 30 | 30 | 5 | 6 | 6 | 6 |
| Greece | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hungary | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Ireland | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Italy | 37 | 39 | 42 | 45 | 46 | 46 | 42 | 45 | 47 | 47 | 37 | 40 | 42 | 42 |
| Latvia | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lithuania | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Luxembourg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | 4 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |



| Scenario | All Scenarios | | (1) ^[2] - and ea assun | Linear xposure | nd) sce employ e level t 2021-30 reafter. | ment rends | Full co | omplian | scenarion nce for (ng/m3) | DÉL = | Full c | ompliar | scenari nce for mg/m3 | OEL |
|----------------|--|------|---|-------------------|---|---------------|---------|---------|----------------------------------|-------|--------|---------|-----------------------------|------|
| Country | | | | | | | | | | | | | | |
| | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable Years of Life Lost (YLLs) | | | | | | | | | | -,, | | | |
| Poland | 13 | 12 | 8 | 5 | 6 | 6 | 7 | 8 | 9 | 9 | 1 | 1 | 2 | 2 |
| Portugal | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 |
| Romania | 5 | 4 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 0 | 0 | 0 | 1 |
| Slovakia | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Slovenia | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Spain | 12 | 12 | 11 | 8 | 9 | 9 | 10 | 13 | 14 | 15 | 2 | 3 | 3 | 3 |
| Sweden | 5 | 4 | 3 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 0 | 0 | 0 | 0 |
| United Kingdom | 21 | 13 | 6 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 1 | 1 | 1 | 1 |
| TOTAL | 196 | 167 | 127 | 92 | 96 | 98 | 120 | 128 | 134 | 137 | 47 | 50 | 53 | 54 |



| Scenario | All Scenarios | | | Base scena Linea and e trend 2021- there | ario (1 ir emp exposi s assi 30, co | l) ^[2] - bloym ure le umed | ent vel to | (2) - F | ention full con = 50 pp 3) | npliand | e for | scei | plian = 10 | on (3) - F ce for ppm (| • |
|---------------------------------------|---------------|----|------|--|---|--|------------------|---------|-------------------------------------|---------|-------|------|---------------|----------------------------------|------|
| Country | 0 | | 0 | | 0 | | 0 | | 0 | | | | | | |
| | 2010 | | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Years of Life Lived with | | | | | | | | - ' ' | | | | | | | |
| Austria | | 4 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 0 | 0 | 0 | 0 |
| Belgium | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Cyprus | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Czech Republic | | 7 | 7 | 5 | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 1 | 1 | 1 | 1 |
| Denmark | | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Estonia | | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Finland | | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| France | | 24 | 18 | 11 | 6 | 6 | 6 | 11 | 11 | 11 | 11 | 2 | 2 | 2 | 2 |
| Germany | | 46 | 40 | 28 | 18 | 18 | 18 | 28 | 30 | 31 | 31 | 5 | 6 | 6 | 6 |
| Greece | | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hungary | | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Ireland | | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Italy | | 37 | 40 | 43 | 45 | 47 | 47 | 42 | 46 | 48 | 48 | 38 | 41 | 43 | 43 |
| Latvia | | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lithuania | | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Luxembourg | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | | 4 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |



| Scenario | All Scenarios | | | Basel scena Linea and e trends 2021- therea | ario (1 r emp xposi s assi 30, co |) ^[2] - loyma ure lev umed | vel to | (2) - F | ull con 50 pp | scenai nplianc m (273 | e for | scer | rventi nario pliano . = 10 m3) | (3) - F ce for | |
|--|------------------|----|------|---|---|--|-----------|---------|------------------|-----------------------------|-------|------|--|-------------------|------|
| Country 070 | | | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| Attributable Years of Life Lived with Di | sability (DALYs) | | | | | | | | | | | | | | 11 |
| Poland | | 13 | 12 | 8 | 5 | 6 | 6 | 7 | 8 | 9 | 9 | 1 | 1 | 2 | 2 |
| Portugal | | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 |
| Romania | | 5 | 4 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 0 | 0 | 0 | 1 |
| Slovakia | | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Slovenia | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Spain | | 12 | 13 | 11 | 8 | 9 | 9 | 10 | 13 | 15 | 15 | 2 | 3 | 3 | 3 |
| Sweden | | 5 | 4 | 3 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 0 | 0 | 0 | 0 |
| United Kingdom | : | 22 | 14 | 7 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 1 | 1 | 1 | 1 |
| TOTAL | 19 | 98 | 169 | 129 | 94 | 97 | 99 | 122 | 130 | 136 | 139 | 48 | 51 | 53 | 54 |

^[1] Intervention scenarios have been estimated assuming baseline exposure and employment levels [2] Change from 2010 in baseline scenario is due to trends in 'historic' (pre 2005) part of REP

Note: numbers and proportions ever exposed remain constant across the baseline and intervention scenarios



 Table 8.5.7
 Numbers and proportions of the EU population ever exposed, by industry, men plus women (for kidney and lung cancers)

| Scenario | All Scena | rios | employm | ent and ex to 2021-30 | enario (1) ^[2] posure lev), constant | el trends | | on scenario ce for OEL | | 273 | | | io (3) - Full . = 10 ppm | |
|--|-----------|------------|-------------|--------------------------|--|-----------|--------|---------------------------|--------|--------|--------|--------|-----------------------------|--------|
| Industry sector | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Number e | ever expos | ed in the R | EP | | | | | | | | | | |
| Manufacture of pulp, paper and paper products | 824 | 824 | 821 | 801 | 785 | 776 | 821 | 801 | 785 | 776 | 821 | 801 | 785 | 776 |
| Publishing, printing and reproduction of recorded media | 1,509 | 1,510 | 1,508 | 1,480 | 1,458 | 1,447 | 1,508 | 1,480 | 1,458 | 1,447 | 1,508 | 1,480 | 1,458 | 1,447 |
| Manufacture of chemicals and chemical products | 13,631 | 13,711 | 13,800 | 13,640 | 13,497 | 13,434 | 13,800 | 13,640 | 13,497 | 13,434 | 13,800 | 13,640 | 13,497 | 13,434 |
| Manufacture of rubber and plastic products | 13,448 | 13,519 | 13,594 | 13,418 | 13,266 | 13,195 | 13,594 | 13,418 | 13,266 | 13,195 | 13,594 | 13,418 | 13,266 | 13,195 |
| Manufacture of fabricated metal products, except machinery and equipment | 47,502 | 48,251 | 49,181 | 49,146 | 49,059 | 49,089 | 49,181 | 49,146 | 49,059 | 49,089 | 49,181 | 49,146 | 49,059 | 49,089 |
| Manufacture of machinery and equipment n.e.c. | 33,707 | 34,158 | 34,686 | 34,464 | 34,266 | 34,183 | 34,686 | 34,464 | 34,266 | 34,183 | 34,686 | 34,464 | 34,266 | 34,183 |
| Manufacture of office machinery and computers | 3,514 | 3,516 | 3,506 | 3,423 | 3,361 | 3,325 | 3,506 | 3,423 | 3,361 | 3,325 | 3,506 | 3,423 | 3,361 | 3,325 |
| Manufacture of electrical machinery apparatus, appliances and supplies | 6,924 | 7,017 | 7,126 | 7,080 | 7,039 | 7,022 | 7,126 | 7,080 | 7,039 | 7,022 | 7,126 | 7,080 | 7,039 | 7,022 |
| Manufacture of transport equipment | 45,155 | 45,707 | 46,379 | 46,131 | 45,878 | 45,797 | 46,379 | 46,131 | 45,878 | 45,797 | 46,379 | 46,131 | 45,878 | 45,797 |
| Manufacture of motor vehicles, trailers and semi-trailers | 19,699 | 19,642 | 19,539 | 19,108 | 18,753 | 18,569 | 19,539 | 19,108 | 18,753 | 18,569 | 19,539 | 19,108 | 18,753 | 18,569 |
| Manufacture of furniture: manufacturing nec | 82,680 | 84,055 | 85,727 | 85,655 | 85,540 | 85,594 | 85,727 | 85,655 | 85,540 | 85,594 | 85,727 | 85,655 | 85,540 | 85,594 |
| Research and Development | 991 | 1,194 | 1,480 | 1,770 | 1,978 | 2,106 | 1,480 | 1,770 | 1,978 | 2,106 | 1,480 | 1,770 | 1,978 | 2,106 |
| Education | 4,439 | 5,341 | 6,622 | 7,923 | 8,861 | 9,442 | 6,622 | 7,923 | 8,861 | 9,442 | 6,622 | 7,923 | 8,861 | 9,442 |
| Other community, social and personal service activities | 17,856 | 21,497 | 26,651 | 31,875 | 35,630 | 37,952 | 26,651 | 31,875 | 35,630 | 37,952 | 26,651 | 31,875 | 35,630 | 37,952 |



| Scenario | All Scena | rios | employm | (trend) sce ent and ex to 2021-30 r. | posure lev | el trends | | on scenario ce for OEL | | 273 | | ion scenari ce for OEL | | |
|--|-----------|-------------|------------|---|------------|-----------|-------|---------------------------|-------|-------|-------|---------------------------|-------|-------|
| Industry sector | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Proportio | n of the po | pulation e | xposed | | | | | | | | | | |
| Manufacture of pulp, paper and paper products | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Publishing, printing and reproduction of recorded media | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Manufacture of chemicals and chemical products | 0.004 | 0.004 | 0.004 | 0.003 | 0.003 | 0.003 | 0.004 | 0.003 | 0.003 | 0.003 | 0.004 | 0.003 | 0.003 | 0.003 |
| Manufacture of rubber and plastic products | 0.004 | 0.004 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
| Manufacture of fabricated metal products, except machinery and equipment | 0.013 | 0.013 | 0.013 | 0.012 | 0.013 | 0.013 | 0.013 | 0.012 | 0.013 | 0.013 | 0.013 | 0.012 | 0.013 | 0.013 |
| Manufacture of machinery and equipment n.e.c. | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 |
| Manufacture of office machinery and computers | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| Manufacture of electrical machinery apparatus, appliances and supplies | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
| Manufacture of transport equipment | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 |
| Manufacture of motor vehicles, trailers and semi-trailers | 0.004 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.005 | 0.005 | 0.005 | 0.005 | 0.005 | 0.005 | 0.005 | 0.005 |
| Manufacture of furniture: manufacturing nec | 0.023 | 0.022 | 0.022 | 0.022 | 0.022 | 0.022 | 0.022 | 0.022 | 0.022 | 0.022 | 0.022 | 0.022 | 0.022 | 0.022 |
| Research and Development | 0.000 | 0.000 | 0.000 | 0.000 | 0.001 | 0.001 | 0.000 | 0.000 | 0.001 | 0.001 | 0.000 | 0.000 | 0.001 | 0.001 |
| Education | 0.001 | 0.001 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
| Other community, social and personal service activities | 0.005 | 0.006 | 0.007 | 0.008 | 0.009 | 0.010 | 0.007 | 0.008 | 0.009 | 0.010 | 0.007 | 0.008 | 0.009 | 0.010 |



Table 8.5.8 Numbers and proportions of the EU population ever exposed, by industry, men plus women (for Non-Hodgkin's Lymphoma

| Scenario | All Scena | arios | employm | (trend) sce lent and ex to 2021-30 | posure lev | el trends | | on scenari ce for OEL | | 273 | | | io (3) - Full _ = 10 ppm | |
|--|-----------|------------|-------------|--|------------|-----------|--------|--------------------------|--------|--------|--------|--------|-----------------------------|--------|
| Industry sector | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Number | ever expos | ed in the R | PFP | | | | | | | | | | |
| Manufacture of pulp, paper and paper products | 571 | 554 | 542 | 534 | 534 | 534 | 542 | 534 | 534 | 534 | 542 | 534 | 534 | 534 |
| Publishing, printing and reproduction of recorded media | 1,050 | 1,024 | 1,008 | 1,000 | 1,000 | 1,000 | 1,008 | 1,000 | 1,000 | 1,000 | 1,008 | 1,000 | 1,000 | 1,000 |
| Manufacture of chemicals and chemical products | 9,602 | 9,441 | 9,357 | 9,290 | 9,290 | 9,290 | 9,357 | 9,290 | 9,290 | 9,290 | 9,357 | 9,290 | 9,290 | 9,290 |
| Manufacture of rubber and plastic products | 9,586 | 9,415 | 9,319 | 9,251 | 9,251 | 9,251 | 9,319 | 9,251 | 9,251 | 9,251 | 9,319 | 9,251 | 9,251 | 9,251 |
| Manufacture of fabricated metal products, except machinery and equipment | 34,100 | 33,946 | 33,994 | 33,989 | 33,989 | 33,989 | 33,994 | 33,989 | 33,989 | 33,989 | 33,994 | 33,989 | 33,989 | 33,989 |
| Manufacture of machinery and equipment n.e.c. | 24,062 | 23,830 | 23,717 | 23,636 | 23,636 | 23,636 | 23,717 | 23,636 | 23,636 | 23,636 | 23,717 | 23,636 | 23,636 | 23,636 |
| Manufacture of office machinery and computers | 2,437 | 2,367 | 2,315 | 2,292 | 2,292 | 2,292 | 2,315 | 2,292 | 2,292 | 2,292 | 2,315 | 2,292 | 2,292 | 2,292 |
| Manufacture of electrical machinery apparatus, appliances and supplies | 4,933 | 4,886 | 4,863 | 4,845 | 4,845 | 4,845 | 4,863 | 4,845 | 4,845 | 4,845 | 4,863 | 4,845 | 4,845 | 4,845 |
| Manufacture of transport equipment | 32,232 | 31,933 | 31,833 | 31,714 | 31,714 | 31,714 | 31,833 | 31,714 | 31,714 | 31,714 | 31,833 | 31,714 | 31,714 | 31,714 |
| Manufacture of motor vehicles, trailers and semi-trailers | 13,582 | 13,195 | 12,942 | 12,778 | 12,778 | 12,778 | 12,942 | 12,778 | 12,778 | 12,778 | 12,942 | 12,778 | 12,778 | 12,778 |
| Manufacture of furniture: manufacturing nec | 59,240 | 58,978 | 59,039 | 59,109 | 59,109 | 59,109 | 59,039 | 59,109 | 59,109 | 59,109 | 59,039 | 59,109 | 59,109 | 59,109 |
| Research and Development | 963 | 1,183 | 1,361 | 1,430 | 1,430 | 1,430 | 1,361 | 1,430 | 1,430 | 1,430 | 1,361 | 1,430 | 1,430 | 1,430 |
| Education | 4,173 | 5,125 | 5,892 | 6,184 | 6,184 | 6,184 | 5,892 | 6,184 | 6,184 | 6,184 | 5,892 | 6,184 | 6,184 | 6,184 |
| Other community, social and personal service activities | 17,124 | 21,032 | 24,196 | 25,406 | 25,406 | 25,406 | 24,196 | 25,406 | 25,406 | 25,406 | 24,196 | 25,406 | 25,406 | 25,406 |



| Scenario | All Scena | arios | employm | (trend) sce ent and ex to 2021-30 | posure lev | el trends | | on scenario ce for OEL | ` ' | 273 | | ion scenar ice for OEL | ` ' | |
|--|-----------|--------------|-------------|---|------------|-----------|--------|---------------------------|--------|--------|--------|---------------------------|--------|--------------|
| Industry sector | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Proportio | on of the po | opulation e | xposed | | | | | | | | | | - |
| Manufacture of pulp, paper and paper products | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% |
| Publishing, printing and reproduction of recorded media | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% |
| Manufacture of chemicals and chemical products | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% |
| Manufacture of rubber and plastic products | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% |
| Manufacture of fabricated metal products, except machinery and equipment | 0.009% | 0.008% | 0.008% | 0.008% | 0.009% | 0.009% | 0.008% | 0.008% | 0.009% | 0.009% | 0.008% | 0.008% | 0.009% | 0.009% |
| Manufacture of machinery and equipment n.e.c. | 0.006% | 0.006% | 0.006% | 0.006% | 0.006% | 0.006% | 0.006% | 0.006% | 0.006% | 0.006% | 0.006% | 0.006% | 0.006% | 0.006% |
| Manufacture of office machinery and computers | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% |
| Manufacture of electrical machinery apparatus, appliances and supplies | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% | 0.001% |
| Manufacture of transport equipment | 0.008% | 0.008% | 0.008% | 0.008% | 0.008% | 0.008% | 0.008% | 0.008% | 0.008% | 0.008% | 0.008% | 0.008% | 0.008% | 0.008% |
| Manufacture of motor vehicles, trailers and semi-trailers | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.002% | 0.003% | 0.003% | 0.003% | 0.003% | 0.003% | 0.003% | 0.003% | 0.003% |
| Manufacture of furniture: manufacturing nec | 0.015% | 0.015% | 0.014% | 0.015% | 0.015% | 0.016% | 0.014% | 0.015% | 0.015% | 0.016% | 0.014% | 0.015% | 0.015% | 0.016% |
| Research and Development | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% |
| Education | 0.001% | 0.001% | 0.001% | 0.002% | 0.002% | 0.002% | 0.001% | 0.002% | 0.002% | 0.002% | 0.001% | 0.002% | 0.002% | 0.002% |
| Other community, social and personal service activities | 0.004% | 0.005% | 0.006% | 0.006% | 0.007% | 0.007% | 0.006% | 0.006% | 0.007% | 0.007% | 0.006% | 0.006% | 0.007% | 0.007% |



Table 8.5.9 Occupation attributable fractions, deaths, registrations, YLLs and DALYs for kidney cancer by industry, men plus women

| Scenario | All Scena | rios | Baseline (tre employmen assumed to | t and expos | surè level ti | rends | Interventi complian mg/m3) | | ` ' | | | ance for (| nario (3) - DEL = 10 բ | |
|--|------------|--------------|--|-------------|---------------|-------|----------------------------------|-------|-------|-------|-------|------------|---------------------------|-------|
| Industry sector | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributal | ole Fraction | | | | | | | | | | | | |
| Manufacture of pulp, paper and paper products | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Publishing, printing and reproduction of recorded media | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Manufacture of chemicals and chemical products | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Manufacture of rubber and plastic products | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Manufacture of fabricated metal products, except machinery and equipment | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% |
| Manufacture of machinery and equipment n.e.c. | 0.01% | 0.01% | 0.01% | 0.00% | 0.00% | 0.00% | 0.01% | 0.00% | 0.00% | 0.00% | 0.01% | 0.00% | 0.00% | 0.00% |
| Manufacture of office machinery and computers | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Manufacture of electrical machinery apparatus, appliances and supplies | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Manufacture of transport equipment | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% | 0.00% |
| Manufacture of motor vehicles, trailers and semi-trailers | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Manufacture of furniture: manufacturing nec | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Research and Development | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Education | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other community, social and personal service activities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |



| Scenario | All Scenarios | emp | eline (trend) s loyment and umed to 2021 | exposure l | evel trend | s co | tervention mpliance g/m3) | | | (273 | | tion scenar | | |
|--|----------------|-------|--|------------|------------|------|---------------------------------|---|---|------|------|-------------|----|------|
| Industry sector | 2010 | 2030 | 2040 | 2050 | 2060 | 2030 | 9 | | | 7000 | 2030 | 2040 | | 7000 |
| | Attributable D | eaths | | | | | | | | | | | | · |
| Manufacture of pulp, paper and | | | | | | | | | | | | | | |
| paper products Publishing, printing and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| reproduction of recorded media Manufacture of chemicals and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| chemical products Manufacture of rubber and plastic | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| products Manufacture of fabricated metal | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| products, except machinery and equipment Manufacture of machinery and | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 |
| equipment n.e.c. Manufacture of office machinery | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| and computers Manufacture of electrical machinery apparatus, appliances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| and supplies Manufacture of transport | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| equipment Manufacture of motor vehicles, | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 2 |
| trailers and semi-trailers Manufacture of furniture: | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| manufacturing nec | 3 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 4 |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Education Other community, social and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| personal service activities | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 1 | 1 | 11 | 1_ |



| Scenario | All Scenarios | empl | line (trend) s oyment and med to 2021 | exposure l | evel trends | СО | tervention mpliance g/m3) | | | | | ntion scena nce for Ol | | |
|--|-----------------|--------------|---|------------|-------------|------|---------------------------------|---|------|------|------|---------------------------|------|------|
| Industry sector | 2010 | 2030 | 2040 | 2050 | 2060 | 2030 | 070 | | 0007 | 0907 | 2030 | 2040 | 2050 | 2060 |
| | Attributable Re | egistrations | | | | | | | | | | | | |
| Manufacture of pulp, paper and | | | | | | | | | | | | | | |
| paper products Publishing, printing and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| reproduction of recorded media Manufacture of chemicals and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| chemical products Manufacture of rubber and plastic | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| products Manufacture of fabricated metal products, except machinery and | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| equipment Manufacture of machinery and | 6 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 5 | 5 | 6 | 6 | 5 | 4 |
| equipment n.e.c. Manufacture of office machinery | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
| and computers Manufacture of electrical machinery apparatus, appliances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| and supplies Manufacture of transport | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| equipment Manufacture of motor vehicles, | 6 | 6 | 6 | 5 | 5 | 5 | 6 | 5 | 5 | 5 | 6 | 5 | 5 | 4 |
| trailers and semi-trailers Manufacture of furniture: | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| manufacturing nec | 7 | 7 | 8 | 8 | 7 | 7 | 8 | 8 | 7 | 7 | 8 | 8 | 7 | 7 |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Education Other community, social and | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| personal service activities | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 3 |



| Scenario | All Scenarios | em | seline (trend) ployment and sumed to 202 | d exposure | è level trer | nds | Interventic compliant mg/m3) | | | | | ntion scer ance for O | | |
|--|----------------|----------------|--|------------|--------------|------|------------------------------------|------|------|------|------|--------------------------|------|------|
| Industry sector | 2010 | 2030 | 2040 | 2050 | | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable Y | ears of Life L | ost (YLLs) | | | | | | | | | | | |
| Manufacture of pulp, paper and paper products | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Publishing, printing and reproduction of recorded media Manufacture of chemicals and | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| chemical products Manufacture of rubber and plastic | 7 | 7 | 8 | 7 | 7 | 7 | 8 | 7 | 7 | 7 | 8 | 7 | 7 | 7 |
| products Manufacture of fabricated metal | 7 | 7 | 8 | 7 | 7 | 7 | 8 | 7 | 7 | 7 | 8 | 7 | 7 | 7 |
| products, except machinery and equipment Manufacture of machinery and | 39 | 39 | 37 | 34 | 32 | 30 | 37 | 34 | 32 | 31 | 37 | 33 | 29 | 26 |
| equipment n.e.c. Manufacture of office machinery | 28 | 28 | 26 | 24 | 22 | 21 | 26 | 24 | 22 | 22 | 26 | 23 | 20 | 18 |
| and computers Manufacture of electrical | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| machinery apparatus, appliances and supplies Manufacture of transport | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
| equipment Manufacture of motor vehicles, | 37 | 37 | 35 | 32 | 30 | 28 | 35 | 32 | 30 | 29 | 35 | 31 | 27 | 24 |
| trailers and semi-trailers Manufacture of furniture: | 16 | 16 | 15 | 13 | 12 | 11 | 15 | 13 | 12 | 12 | 15 | 13 | 11 | 10 |
| manufacturing nec | 41 | 44 | 47 | 46 | 44 | 44 | 47 | 46 | 44 | 44 | 47 | 46 | 44 | 43 |
| Research and Development | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Education Other community, social and | 1 | 1 | 2 | 3 | 3 | 4 | 2 | 3 | 3 | 4 | 2 | 3 | 3 | 4 |
| personal service activities | 7 | 9 | 11 | 13 | 15 | 16 | 11 | 13 | 15 | 16 | 11 | 13 | 15 | 16 |



| Scenario | All Scenarios | em | seline (trend ployment an sumed to 202 | d exposure | e level tren | nds | Intervention compliant mg/m3) | | | | | ntion scer ance for C | | |
|--|----------------|----------------|--|--------------|--------------|------|-------------------------------|------|------|------|------|--------------------------|------|------|
| Industry sector | 2010 | 2030 | 2040 | 2 | | 7060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable Y | ears of Life L | ived with Dis | sability (DA | LYs | | | | | | | | | |
| Manufacture of pulp, paper and paper products Publishing, printing and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| reproduction of recorded media Manufacture of chemicals and | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| chemical products Manufacture of rubber and plastic | 8 | 8 | 9 | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 9 | 8 | 8 | 8 |
| products Manufacture of fabricated metal products, except machinery and | 8 | 8 | 9 | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 9 | 8 | 8 | 8 |
| equipment Manufacture of machinery and | 44 | 44 | 42 | 39 | 36 | 34 | 42 | 39 | 36 | 36 | 42 | 38 | 33 | 30 |
| equipment n.e.c. Manufacture of office machinery | 32 | 32 | 30 | 27 | 25 | 24 | 30 | 27 | 25 | 25 | 30 | 27 | 23 | 21 |
| and computers Manufacture of electrical machinery apparatus, appliances | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| and supplies Manufacture of transport | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| equipment Manufacture of motor vehicles. | 43 | 43 | 40 | 37 | 34 | 32 | 40 | 37 | 34 | 33 | 40 | 36 | 31 | 28 |
| trailers and semi-trailers Manufacture of furniture: | 19 | 18 | 17 | 15 | 14 | 13 | 17 | 15 | 14 | 13 | 17 | 15 | 13 | 11 |
| manufacturing nec | 46 | 51 | 54 | 53 | 50 | 50 | 54 | 53 | 50 | 50 | 54 | 52 | 50 | 49 |
| Research and Development | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Education Other community, social and | 1 | 2 | 2 | 3 | 4 | 4 | 2 | 3 | 4 | 4 | 2 | 3 | 4 | 4 |
| personal service activities | 8 | 10 | 12 | 15 | 17 | 19 | 12 | 15 | 17 | 19 | 12 | 15 | 17 | 19 |



 Table 8.5.10 Occupation attributable fractions, deaths, registrations, YLLs and DALYs for liver cancer by industry, men plus women

| Scenario | All Scena | rios | Baseline (tre employmen assumed to | t and expos | sure level tr | ends | Interventi compliand mg/m3) | | | | | nce for C | nario (3) - DEL = 10 p | |
|--|------------|-------------|--|-------------|---------------|-------|-----------------------------------|-------|-------|-------|-------|-----------|---------------------------|-------|
| Industry sector | 2010 | 2020 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributab | le Fraction | | | | | | | | | | | | |
| Manufacture of pulp, paper and paper products Publishing, printing and | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| reproduction of recorded media Manufacture of chemicals and | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| chemical products Manufacture of rubber and plastic | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| products Manufacture of fabricated metal | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| products, except machinery and equipment | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% |
| Manufacture of machinery and equipment n.e.c. Manufacture of office machinery | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% | 0.00% |
| and computers Manufacture of electrical | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| machinery apparatus, appliances and supplies Manufacture of transport | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| equipment Manufacture of motor vehicles, | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% |
| trailers and semi-trailers Manufacture of furniture: | 0.01% | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| manufacturing nec | 0.02% | 0.02% | 0.01% | 0.01% | 0.00% | 0.00% | 0.01% | 0.01% | 0.00% | 0.00% | 0.01% | 0.01% | 0.00% | 0.00% |
| Research and Development | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Education Other community, social and | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| personal service activities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |



| Scenario | All Scenarios | emį | eline (trend) s ployment and umed to 2021 | exposure l | evel trend | s co | tervention ompliance g/m3) | | | | | tion scena nce for OE | | |
|---|----------------|-------|---|------------|------------|------|----------------------------------|-----|------|------|------|--------------------------|------|------|
| Industry sector | 2010 | 2030 | 2040 | 2050 | 2060 | 2030 | 9 | 040 | 7020 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable D | eaths | | | | | | | | | | | | |
| Manufacture of pulp, paper and | | | | | | | | | | | | | | |
| paper products Publishing, printing and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| reproduction of recorded media Manufacture of chemicals and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| chemical products | 2 | 2 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Manufacture of rubber and plastic | | | | | • | • | | | • | • | _ | _ | • | • |
| products Manufacture of fabricated metal | 2 | 2 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| products, except machinery and | | | | | | | | | | | | | | |
| equipment | 6 | 7 | 8 | 8 | 7 | 6 | 8 | 8 | 8 | 7 | 8 | 7 | 5 | 3 |
| Manufacture of machinery and equipment n.e.c. | 4 | 5 | 5 | 6 | 5 | 4 | 5 | 6 | 5 | 5 | 5 | 5 | 3 | 2 |
| Manufacture of office machinery | 7 | J | J | U | J | 7 | J | J | J | J | J | J | J | _ |
| and computers | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Manufacture of electrical | | | | | | | | | | | | | | |
| machinery apparatus, appliances | 4 | 4 | 4 | 0 | • | • | _ | • | • | • | | • | • | • |
| and supplies Manufacture of transport | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| equipment | 6 | 7 | 7 | 8 | 7 | 5 | 7 | 8 | 7 | 6 | 7 | 7 | 4 | 2 |
| Manufacture of motor vehicles, | ŭ | • | • | Ü | • | Ŭ | • | Ū | • | Ü | • | • | • | _ |
| trailers and semi-trailers | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 1 |
| Manufacture of furniture: | | | | | | | | | | | | | | |
| manufacturing nec | 9 | 10 | 9 | 6 | 4 | 3 | 9 | 7 | 4 | 3 | 9 | 6 | 3 | 2 |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Education | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other community, social and | | | | | | | | | | | | | | |
| personal service activities | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 2 | 1 | 0 | 0 |



| Scenario | All Scenarios | emp | eline (trend) s loyment and imed to 2021 | exposure l | evel trends | c c | tervention ompliance g/m3) | | | | | nce for Ol | ario (3) - F EL = 10 pp | |
|---|----------------|--------------|--|------------|-------------|------|----------------------------------|-----|------|------|------|------------|----------------------------|------|
| Industry sector | 2010 | 2030 | 2040 | 2050 | 2060 | 2030 | | 0 0 | 0007 | 7060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable R | egistrations | | | | | | | | | | | | |
| Manufacture of pulp, paper and | | | | | | | | | | | | | | |
| paper products Publishing, printing and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| reproduction of recorded media Manufacture of chemicals and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| chemical products Manufacture of rubber and plastic | 2 | 2 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| products Manufacture of fabricated metal | 2 | 2 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| products, except machinery and equipment Manufacture of machinery and | 6 | 7 | 7 | 8 | 7 | 5 | 7 | 8 | 7 | 6 | 7 | 7 | 4 | 2 |
| equipment n.e.c. Manufacture of office machinery | 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 4 | 5 | 5 | 3 | 2 |
| and computers Manufacture of electrical machinery apparatus, appliances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| and supplies Manufacture of transport | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| equipment Manufacture of motor vehicles, | 6 | 6 | 7 | 7 | 6 | 5 | 7 | 7 | 6 | 6 | 7 | 6 | 4 | 2 |
| trailers and semi-trailers Manufacture of furniture: | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 2 | 1 |
| manufacturing nec | 9 | 10 | 9 | 6 | 3 | 2 | 9 | 6 | 4 | 3 | 9 | 6 | 3 | 2 |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Education Other community, social and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| personal service activities | 1 | 2 | 2 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 2 | 1 | 0 | 0 |



| Scenario | All Scenarios | er | aseline (trend nployment a ssumed to 20 | nd exposu | re level tre | nds | Interventicomplianomg/m3) | | | | | ance for C | nario (3) - DEL = 10 p | |
|---|----------------|--------------|---|-----------|--------------|------|---------------------------|------|------|------|------|------------|---------------------------|------|
| Industry sector | 2010 | 2030 | | | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable \ | ears of Life | Lost (YLLs) | | | | | | | | | | | |
| Manufacture of pulp, paper and | | | | | | | | | | | | | | |
| paper products Publishing, printing and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| reproduction of recorded media Manufacture of chemicals and | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 0 | 0 |
| chemical products | 22 | 22 | 18 | 11 | 5 | 3 | 18 | 11 | 5 | 3 | 18 | 11 | 5 | 2 |
| Manufacture of rubber and plastic products Manufacture of fabricated metal | 22 | 22 | 18 | 11 | 6 | 3 | 18 | 11 | 6 | 4 | 18 | 11 | 5 | 3 |
| products, except machinery and equipment | 86 | 94 | 102 | 102 | 89 | 70 | 102 | 100 | 91 | 83 | 101 | 90 | 58 | 31 |
| Manufacture of machinery and | • | | | | | | | | | | | | | |
| equipment n.e.c. Manufacture of office machinery | 61 | 67 | 72 | 71 | 62 | 47 | 72 | 70 | 63 | 57 | 72 | 63 | 40 | 20 |
| and computers Manufacture of electrical | 6 | 6 | 5 | 3 | 1 | 1 | 5 | 3 | 1 | 1 | 5 | 3 | 1 | 1 |
| machinery apparatus, appliances and supplies Manufacture of transport | 11 | 11 | 9 | 6 | 3 | 2 | 9 | 6 | 3 | 2 | 9 | 6 | 3 | 1 |
| equipment Manufacture of motor vehicles, | 83 | 90 | 97 | 96 | 81 | 60 | 97 | 95 | 84 | 74 | 97 | 84 | 49 | 20 |
| trailers and semi-trailers Manufacture of furniture: | 36 | 39 | 41 | 40 | 34 | 25 | 41 | 39 | 34 | 30 | 41 | 35 | 21 | 10 |
| manufacturing nec | 130 | 133 | 119 | 82 | 46 | 30 | 119 | 82 | 46 | 33 | 119 | 80 | 40 | 23 |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Education Other community, social and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| personal service activities | 22 | 24 | 22 | 15 | 5 | 0 | 22 | 15 | 5 | 1 | 22 | 14 | 4 | 0 |



| Scenario | All Scenarios | er | aseline (tren nployment a ssumed to 20 | ınd exposur | è level trer | nds | Intervention compliant mg/m3) | | | | | ntion scer ance for C | | |
|---|----------------|--------------|--|---------------|--------------|------|-------------------------------|------|------|------|------|--------------------------|------|------|
| Industry sector | 2010 | 2030 | | 2040 | | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable \ | ears of Life | Lived with D | isability (DA | ALYs) | | | | | | | | | |
| Manufacture of pulp, paper and | | | | | | | | | | | | | | |
| paper products Publishing, printing and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| reproduction of recorded media Manufacture of chemicals and | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 0 | 0 |
| chemical products Manufacture of rubber and plastic | 22 | 22 | 19 | 11 | 5 | 3 | 19 | 11 | 5 | 3 | 19 | 11 | 5 | 3 |
| products Manufacture of fabricated metal | 22 | 22 | 19 | 12 | 6 | 3 | 19 | 12 | 6 | 4 | 19 | 11 | 5 | 3 |
| products, except machinery and equipment Manufacture of machinery and | 88 | 96 | 104 | 104 | 91 | 72 | 104 | 102 | 93 | 85 | 103 | 91 | 59 | 32 |
| equipment n.e.c. Manufacture of office machinery | 63 | 68 | 74 | 73 | 63 | 48 | 73 | 72 | 64 | 58 | 73 | 64 | 41 | 21 |
| and computers Manufacture of electrical | 6 | 6 | 5 | 3 | 1 | 1 | 5 | 3 | 1 | 1 | 5 | 3 | 1 | 1 |
| machinery apparatus, appliances and supplies Manufacture of transport | 11 | 11 | 10 | 6 | 3 | 2 | 10 | 6 | 3 | 2 | 10 | 6 | 3 | 1 |
| equipment Manufacture of motor vehicles, | 85 | 92 | 99 | 98 | 83 | 61 | 99 | 96 | 85 | 76 | 99 | 85 | 50 | 21 |
| trailers and semi-trailers Manufacture of furniture: | 37 | 40 | 42 | 40 | 34 | 26 | 42 | 40 | 35 | 31 | 42 | 36 | 21 | 10 |
| manufacturing nec | 132 | 135 | 121 | 83 | 47 | 31 | 121 | 83 | 47 | 33 | 121 | 81 | 41 | 24 |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Education Other community, social and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| personal service activities | 22 | 24 | 23 | 15 | 5 | 0 | 23 | 15 | 5 | 1 | 23 | 15 | 4 | 0 |



 Table 8.5.11 Occupation attributable fractions, deaths, registrations, YLLs and DALYs for NHL by industry, men plus women

| Scenario Industry sector | All Scenarios | emp | seline (trend) ployment and umed to 202 | CC | Intervention scenario (2) - Full compliance for OEL = 50 ppm (273 mg/m3) | | | | | Intervention scenario (3) - Full compliance for OEL = 10 ppm (50 mg/m3) | | | | |
|--|-----------------|-------|---|------|--|------|-----|---|------|---|------|------|---|-----|
| | 2010 | 2030 | 2040 | 2050 | 2060 | 2030 | 070 | 7 | 0602 | 2060 | 2030 | 2040 | | 000 |
| | Attributable De | eaths | | | | | | | | | | | | |
| Manufacture of pulp, paper and paper products Publishing, printing and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| reproduction of recorded media Manufacture of chemicals and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| chemical products Manufacture of rubber and plastic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| products Manufacture of fabricated metal products, except machinery and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| equipment Manufacture of machinery and | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 1 | 1 | 1 | 1 |
| equipment n.e.c. Manufacture of office machinery | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| and computers Manufacture of electrical machinery apparatus, appliances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| and supplies Manufacture of transport | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| equipment Manufacture of motor vehicles, | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 1 | 1 | 1 | 1 |
| trailers and semi-trailers Manufacture of furniture: | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| manufacturing nec | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Education Other community, social and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| personal service activities | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |



| Scenario Industry sector | All Scenarios | empl | Baseline (trend) scenario (1) ^[2] - Linear employment and exposure level trends assumed to 2021-30, constant thereafter. | | | | | Intervention scenario (2) - Full compliance for OEL = 50 ppm (273 mg/m3) | | | | | Intervention scenario (3) - Full compliance for OEL = 10 ppm (50 mg/m3) | | | | |
|---|-----------------|--------------|---|------|------|------|-----|--|---|------|------|------|---|------|--|--|--|
| | 2010 | 2030 | 2040 | 2050 | 2060 | 2030 | 070 | 2000 | | 7007 | 2030 | 2040 | 0007 | 7060 | | | |
| | Attributable Re | egistrations | | | | | | | | | | | | | | | |
| Manufacture of pulp, paper and | | | | | | | | | | | | | | | | | |
| paper products Publishing, printing and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | |
| reproduction of recorded media Manufacture of chemicals and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | |
| chemical products | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | |
| Manufacture of rubber and plastic products Manufacture of fabricated metal | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | |
| products, except machinery and equipment Manufacture of machinery and | 6 | 6 | 5 | 4 | 4 | 4 | 5 | 6 | 6 | 6 | 2 | 2 | 2 | 2 | | | |
| equipment n.e.c. Manufacture of office machinery | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 1 | 1 | 1 | 2 | | | |
| and computers Manufacture of electrical machinery apparatus, appliances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | |
| and supplies Manufacture of transport | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | |
| equipment Manufacture of motor vehicles, | 6 | 6 | 5 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 1 | 1 | 1 | 1 | | | |
| trailers and semi-trailers Manufacture of furniture: | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | | | |
| manufacturing nec | 6 | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | | | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | |
| Education Other community, social and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | |
| personal service activities | 11 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | |



| Scenario | All Scenarios | em | Baseline (trend) scenario (1) ^[2] - Linear employment and exposure level trends assumed to 2021-30, constant thereafter. | | | | | on scenar ce for OEL | | Intervention scenario (3) - Full compliance for OEL = 10 ppm (50 mg/m3) | | | | |
|--|----------------|----------------|---|------|----|------|------|-------------------------|------|---|------|------|------|------|
| Industry sector | 2010 | 2030 | 2040 | 2050 | | 2060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable Y | ears of Life L | ost (YLLs) | | | | | | | | | | | |
| Manufacture of pulp, paper and paper products | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Publishing, printing and reproduction of recorded media Manufacture of chemicals and | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| chemical products Manufacture of rubber and plastic | 7 | 3 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| products Manufacture of fabricated metal products, except machinery and | 7 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| equipment Manufacture of machinery and | 40 | 42 | 37 | 27 | 28 | 28 | 35 | 37 | 39 | 40 | 13 | 14 | 15 | 15 |
| equipment n.e.c. Manufacture of office machinery | 29 | 29 | 25 | 18 | 18 | 19 | 24 | 25 | 26 | 27 | 9 | 9 | 10 | 10 |
| and computers Manufacture of electrical | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| machinery apparatus, appliances and supplies Manufacture of transport | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| equipment Manufacture of motor vehicles, | 38 | 39 | 33 | 22 | 22 | 23 | 31 | 33 | 34 | 35 | 8 | 9 | 9 | 10 |
| trailers and semi-trailers Manufacture of furniture: | 16 | 16 | 14 | 9 | 10 | 10 | 13 | 13 | 14 | 14 | 4 | 4 | 5 | 5 |
| manufacturing nec | 44 | 26 | 14 | 13 | 14 | 14 | 14 | 15 | 15 | 16 | 10 | 10 | 11 | 11 |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Education Other community, social and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| personal service activities | 9 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |



| Scenario | All Scenarios | All Scenarios Baseline (trend) scenario (1) ¹² - Linear employment and exposure level trends assumed to 2021-30, constant thereafter. | | | nds | Intervention scenario (2) - Full compliance for OEL = 50 ppm (273 mg/m3) | | | | Intervention scenario (3) - Full compliance for OEL = 10 ppm (50 mg/m3) | | | | |
|---|----------------|--|----------------|------|-----|--|------|------|------|---|------|------|------|------|
| Industry sector | 2010 | 2030 | 2040 | 2050 | | 7060 | 2030 | 2040 | 2050 | 2060 | 2030 | 2040 | 2050 | 2060 |
| | Attributable Y | | ived with Disa | | | | | | | | | | | |
| Manufacture of pulp, paper and | | | | , , | , | | | | | | | | | |
| paper products Publishing, printing and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| reproduction of recorded media Manufacture of chemicals and | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| chemical products Manufacture of rubber and plastic | 7 | 3 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| products Manufacture of fabricated metal | 7 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| products, except machinery and equipment Manufacture of machinery and | 41 | 42 | 38 | 27 | 28 | 29 | 35 | 38 | 40 | 40 | 13 | 14 | 15 | 15 |
| equipment n.e.c. Manufacture of office machinery | 29 | 30 | 26 | 18 | 19 | 19 | 24 | 26 | 27 | 27 | 9 | 9 | 10 | 10 |
| and computers Manufacture of electrical machinery apparatus, appliances | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| and supplies Manufacture of transport | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| equipment Manufacture of motor vehicles, | 39 | 40 | 33 | 22 | 23 | 23 | 31 | 33 | 35 | 36 | 9 | 9 | 10 | 10 |
| trailers and semi-trailers Manufacture of furniture: | 16 | 16 | 14 | 9 | 10 | 10 | 13 | 14 | 14 | 15 | 4 | 4 | 5 | 5 |
| manufacturing nec | 45 | 27 | 14 | 13 | 14 | 14 | 14 | 15 | 16 | 16 | 10 | 11 | 11 | 11 |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Education Other community, social and | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| personal service activities | 9 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |



 ^[1] Intervention scenarios have been estimated assuming baseline exposure and employment levels
 [2] Change from 2010 in baseline scenario is due to trends in 'historic' (pre 2005) part of REP
 Note: numbers and proportions ever exposed remain constant across the baseline and intervention scenarios

8.6 VALUING HEALTH BENEFITS – INTERVENTION SCENARIOS




Figure 8.6.1 Total health benefits to females of introducing an EU wide OEL – By Member State – Low Scenario (Present Value – 2010 €m prices)



Total Health benefits (2010 - 2070) for Females of different OELs - By Member State - High cost scenario




Figure 8.6.2 Total health benefits for females of introducing an EU wide OEL – By Member State – High Scenario (Present Value – 2010 €m prices)






Figure 8.6.3 Total health benefits to males of introducing an EU wide OEL – By Member State – Low Scenario (Present Value – 2010 €m prices)



Total Health benefits (2010 - 2070) for Males of different OELs - By Member State - High cost scenario




Figure 8.6.4 Total health benefits for males of introducing an EU wide OEL – By Member State – High Scenario (Present Value – 2010 €m prices)







Figure 8.6.5 Total health benefits to females of introducing an EU wide OEL – By Industry Group – Low Scenario (Present Value – 2010 €m prices)








Figure 8.6.6 Total health benefits for females of introducing an EU wide OEL – By Industry Group – High Scenario (Present Value – 2010 €m prices)






Figure 8.6.7 Total health benefits to males of introducing an EU wide OEL – By Industry Group – Low Scenario (Present Value – 2010 €m prices)






Figure 8.6.8 Total health benefits for males of introducing an EU wide OEL – By Member State – High Scenario (Present Value – 2010 €m prices)



8.7 HEALTH BENEFITS USING DIFFERENT DISCOUNT RATES

COLOUR KEY

No discount

Using the EU IA guidance - 4%

Using a declining discount rate (4% going to 3%)

Table 8.7.1 Introducing an OEL of 50pmm

| | Gender | 2010-2019 | 2020-2029 | 2030-2039 | 2040-2049 | 2050-2059 | 2060-2069 |
|----------|---------|-----------|-----------|-----------|-----------|-----------|-----------|
| | Females | €0 | €0 | €0 | €0 | €0 | €0 |
| | Males | €0 | €0 | €0 | €0 | €0 | €0 |
| | Totals | €0 | €0 | €0 | €0 | €0 | € 0 |
| (€m) | Gender | 2010-2019 | 2020-2029 | 2030-2039 | 2040-2049 | 2050-2059 | 2060-2069 |
| of costs | Females | €0 | €0 | €0 | €0 | €0 | € 0 |
| o o e | Males | €0 | €0 | €0 | €0 | € 0 | € 0 |
| Range | Totals | €0 | €0 | €0 | €0 | € 0 | € 0 |
| Ľ | Gender | 2010-2019 | 2020-2029 | 2030-2039 | 2040-2049 | 2050-2059 | 2060-2069 |
| | Females | €0 | €0 | €0 | €0 | €0 | € 0 |
| | Males | €0 | €0 | €0 | €0 | €0 | €0 |
| | Totals | €0 | €0 | €0 | €0 | €0 | € 0 |

| Member State | Low cost | High cost | Low cost | High cost | Low cost | High cost |
|----------------|-------------|--------------|----------|-----------|----------|-----------|
| Austria | €0 | €0 | €0 | € 0 | €0 | €0 |
| Belgium | €0 | €0 | €0 | € 0 | €0 | €0 |
| Bulgaria | €0 | €0 | €0 | € 0 | €0 | €0 |
| Czech Republic | €0 | €0 | €0 | € 0 | €0 | €0 |
| Cyprus | €0 | €0 | €0 | €0 | €0 | €0 |
| Denmark | €0 | €0 | €0 | € 0 | €0 | €0 |
| Estonia | €0 | €0 | €0 | €0 | €0 | €0 |
| Finland | €0 | €0 | €0 | €0 | €0 | €0 |
| France | €0 | €0 | €0 | €0 | €0 | €0 |
| Germany | €0 | €0 | €0 | € 0 | €0 | €0 |
| Greece | €0 | €0 | €0 | € 0 | €0 | €0 |
| Hungary | €0 | €0 | €0 | €0 | € 0 | €0 |



SHEcan Report P937/3

| Member State | Low cost | High cost | Low cost | High cost | Low cost | High cost |
|----------------|-------------|--------------|----------|-----------|----------|-----------|
| Ireland | €0 | €0 | €0 | € 0 | € 0 | €0 |
| Italy | €0 | €0 | €0 | € 0 | €0 | €0 |
| Latvia | €0 | €0 | €0 | €0 | €0 | €0 |
| Lithuania | €0 | €0 | €0 | € 0 | €0 | €0 |
| Luxembourg | €0 | €0 | €0 | €0 | €0 | €0 |
| Malta | €0 | €0 | €0 | € 0 | €0 | €0 |
| Netherlands | €0 | €0 | €0 | €0 | €0 | €0 |
| Poland | €0 | €0 | €0 | €0 | €0 | €0 |
| Portugal | €0 | €0 | €0 | €0 | €0 | €0 |
| Romania | €0 | €0 | €0 | €0 | €0 | €0 |
| Slovakia | €0 | €0 | €0 | € 0 | €0 | €0 |
| Slovenia | €0 | €0 | €0 | €0 | €0 | €0 |
| Spain | €0 | €0 | €0 | € 0 | €0 | €0 |
| Sweden | €0 | €0 | €0 | € 0 | €0 | €0 |
| United Kingdom | €0 | €0 | €0 | € 0 | € 0 | €0 |

| Industry Group | Low | High cost | Low | High cost | Low | High cost |
|--|-------|--------------|-------|--------------|-------|--------------|
| Manufacture of pulp, paper and paper products | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Publishing, printing and reproduction of recorded media | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Manufacture of chemicals and chemical products | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Manufacture of rubber and plastic products | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Manufacture of fabricated metal products, except machinery and equipment | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Manufacture of machinery and equipment n.e.c. | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Manufacture of office machinery and computers | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Manufacture of electrical machinery apparatus, appliances and supplies | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Manufacture of transport equipment | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Manufacture of motor vehicles, trailers and semi-trailers | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Manufacture of furniture: manufacturing nec | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Research and Development | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Education | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |
| Other community, social and personal service activities | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 | € 0.0 |



Table 8.7.2 Introducing an OEL of 10 ppm

| | Gender | 2010-2019 | 2020-2029 | 2030-2039 | 2040-2049 | 2050-2059 | 2060-2069 |
|---------------------|---------|-----------|-----------|-----------|-----------|------------|------------|
| | Females | 0 to 0 | 3 to 12 | 18 to 83 | 20 to 75 | 44 to 143 | 63 to 201 |
| | Males | 0 to 0 | 7 to 30 | 53 to 239 | 66 to 235 | 148 to 475 | 213 to 676 |
| _ | Totals | 0 to 0 | 9 to 42 | 71 to 322 | 86 to 310 | 192 to 619 | 276 to 877 |
| Range of costs (€m) | Gender | 2010-2019 | 2020-2029 | 2030-2039 | 2040-2049 | 2050-2059 | 2060-2069 |
| costs | Females | 0 to 0 | 1 to 7 | 7 to 31 | 5 to 19 | 8 to 25 | 7 to 23 |
| e of c | Males | 0 to 0 | 4 to 16 | 20 to 90 | 17 to 60 | 25 to 81 | 25 to 78 |
| kango | Totals | 0 to 0 | 5 to 23 | 27 to 121 | 22 to 79 | 33 to 106 | 32 to 101 |
| Ľ | Gender | 2010-2019 | 2020-2029 | 2030-2039 | 2040-2049 | 2050-2059 | 2060-2069 |
| | Females | 0 to 0 | 1 to 7 | 9 to 40 | 7 to 27 | 12 to 38 | 12 to 40 |
| | Males | 0 to 0 | 4 to 16 | 25 to 114 | 23 to 84 | 39 to 126 | 42 to 133 |
| | Totals | 0 to 0 | 5 to 23 | 34 to 154 | 31 to 110 | 51 to 164 | 54 to 173 |

| Member State | Low cost | High cost | Low cost | High cost | Low cost | High cost |
|----------------|----------|-----------|----------|-----------|----------|-----------|
| Austria | € 16 | €7 | €3 | € 11 | € 4 | € 16 |
| Belgium | €1 | €0 | €0 | €7 | €0 | €9 |
| Bulgaria | €8 | €4 | €1 | €3 | €2 | €4 |
| Czech Republic | € 34 | € 15 | €6 | € 24 | €9 | € 35 |
| Cyprus | €0 | €0 | €0 | €0 | €0 | €0 |
| Denmark | €6 | €2 | €1 | €5 | €2 | €7 |
| Estonia | €2 | €1 | €0 | €1 | €1 | €2 |
| Finland | €3 | €1 | €1 | €2 | € 1 | €3 |
| France | € 88 | € 39 | € 16 | € 56 | € 24 | € 80 |
| Germany | € 167 | € 70 | € 32 | € 115 | € 47 | € 164 |
| Greece | €3 | €1 | €0 | €1 | €1 | €2 |
| Hungary | € 11 | €5 | €2 | €9 | €3 | € 13 |
| Ireland | €2 | €1 | €0 | €1 | €1 | €2 |
| Italy | € 48 | € 23 | €8 | € 35 | € 12 | € 52 |
| Latvia | €2 | €1 | €0 | €1 | €1 | €1 |
| Lithuania | €3 | €1 | €1 | €2 | €1 | €3 |
| Luxembourg | €0 | €0 | €0 | €0 | €0 | €0 |
| Malta | € 0 | €0 | €0 | €0 | € 0 | €0 |



SHEcan Report P937/3

| Member State | Low cost | High cost | Low cost | High cost | Low cost | High cost |
|----------------|----------|-----------|----------|-----------|----------|-----------|
| Netherlands | €7 | €3 | €2 | €7 | €2 | €9 |
| Poland | € 47 | € 20 | €9 | € 26 | € 13 | € 38 |
| Portugal | €9 | € 4 | €2 | €6 | €3 | €9 |
| Romania | € 28 | € 13 | €5 | € 13 | €7 | € 20 |
| Slovakia | €7 | €3 | €1 | €4 | €2 | €6 |
| Slovenia | € 5 | €2 | €1 | €3 | €1 | €5 |
| Spain | € 92 | € 42 | € 16 | € 61 | € 25 | € 89 |
| Sweden | € 14 | €6 | €3 | € 12 | € 4 | € 17 |
| United Kingdom | € 30 | € 12 | €6 | € 26 | €9 | € 36 |

| Industry Group | Low | High cost | Low | High cost | Low | High cost |
|--|---------|--------------|------|--------------|------|--------------|
| Manufacture of pulp, paper and paper products | € 0.0 | € 0 | €0 | €0 | € 0 | €0 |
| Publishing, printing and reproduction of recorded media | € 0.3 | € 1 | €0 | €0 | €0 | €0 |
| Manufacture of chemicals and chemical products | € 2.8 | € 10 | € 1 | €2 | € 1 | €3 |
| Manufacture of rubber and plastic products | € 3.2 | € 11 | € 1 | €2 | € 1 | €3 |
| Manufacture of fabricated metal products, except machinery and equipment | € 196.9 | € 690 | € 37 | € 136 | € 54 | € 197 |
| Manufacture of machinery and equipment n.e.c. | € 137.4 | € 481 | € 26 | € 95 | € 38 | € 138 |
| Manufacture of office machinery and computers | € 0.6 | €2 | €0 | €0 | €0 | €1 |
| Manufacture of electrical machinery apparatus, appliances and supplies | € 1.5 | € 5 | €0 | € 1 | €0 | €2 |
| Manufacture of transport equipment | € 200.4 | € 701 | € 37 | € 138 | € 55 | € 201 |
| Manufacture of motor vehicles, trailers and semi- trailers | € 78.3 | € 274 | € 15 | € 54 | € 22 | € 79 |
| Manufacture of furniture: manufacturing nec | € 29.1 | € 103 | € 5 | € 20 | €8 | € 29 |
| Research and Development | € 0.0 | € 0 | €0 | €0 | €0 | €0 |
| Education | € 0.0 | € 0 | €0 | €0 | €0 | €0 |
| Other community, social and personal service activities | € 1.1 | €3 | €0 | €1 | € 0 | €1 |



HEAD OFFICE:

Research Avenue North, Riccarton, Edinburgh, EHI4 4AP, United Kingdom Telephone: +44 (0)131 449 8000 Facsimile: +44 (0)131 449 8084

Tapton Park Innovation Centre, Brimington Road, Tapton, Chesterfield, Derbyshire, S4I 0TZ, United Kingdom

Telephone: +44 (0)1246 557866 Facsimile: +44 (0)1246 551212

Research House Business Centre, Fraser Road, Perivale, Middlesex, UB6 7AQ, United Kingdom

Telephone: +44 (0)208 537 3491/2 Facsimile: +44 (0)208 537 3493

Brookside Business Park, Cold Meece, Stone, Staffs, ST15 0RZ, United Kingdom Telephone: +44 (0)1785 764810 Facsimile: +44 (0)1785 764811

Email: iom@iom-world.org